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Due to the limited endogenous regenerative potential of the myocardium, 
therapeutic interventions are necessary to restore function following the 
occurrence of myocardial infarction. Cardiac tissue engineering offers the promise 
of restoring lost functionality. With the highly complex make-up of the myocardium, 
a multi-component/multi-stage approach to regeneration is essential. 
Cardiomyocytes are highly metabolic and require continuous amounts of oxygen 
and nutrients following transplantation onto the native myocardium. To address 
this, several groups have attempted to create pre-vascularized grafts, in which the 
engineered vasculature would be able to anastomose with the host blood vessels 
to promote survival of transplanted cells.  Hence, the culture of cardiomyocytes 
has been coupled with endothelial cell types. To stabilize endothelial cell-derived 
vascular networks, vascular mural cells are necessary. In an effort to improve 
vascular development, we investigate the use of an abundant clinically relevant 
cell source, the human adipose derived stem/stromal cells.  The objective of this 
thesis is to identify the cell-cell interactions of human adipose derived stem/stromal 
cells (hASCs) when cultured with cardiomyocytes and endothelial cells and to also 
develop a biomaterial platform for engineering aligned, contractile, vascularized 
myocardium that can be used to regenerate a fibrotic heart. 
This objective was achieved utilizing a multi-step approach which included 
first investigating the electrophysiological effects of co-culturing hASCs with 
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cardiomyocytes (CMs). After determining the concentration of hASCs that would 
not statistically impede the electrophysiological properties of CMs 
[NRVCM:hASC:HUVEC ~ 500:100:0 and 500:50:0 cells], we used these 
concentrations of hASCs with endothelial cells (ECs) to promote stabilized 
vasculature. After exploring the ratios of each co-culture, we combined the 
optimized ratios to develop tri-cultures for a vascularized cardiac system. The 
ultimate ratio of 250,000:25,000:12,500 cells/cm2  resulted in dense vessel network 
development with electrophysiological properties with an average conduction 
velocity of 20 ± 2 cm/s, APD80 and APD30 of 122 ± 5 ms and 59 ± 4 ms, respectively, 
and maximum captured rate of 7.4 ± 0.6 Hz.  
Following this, novel fibrin microfiber sheets were used in conjunction with 
these cell types to develop vascularized cardiac patches.  Initially, the fibrin 
microfibers were characterized for mechanical properties. NRVCMs were seeded 
onto fibrin microfibers at a concentration of 1.5  106 cells/cm2. NRVCMs were 
cultured for up until 56 days and achieved electrical conduction velocities of 22  
2.1 cm/s.  Using a tri-culture system, we engineered contractile cardiac patches 
with vascular network structures that were capable of being implanted into the 
ischemic myocardium. Ultimately cardiomyocytes were seeded for 14 days prior 
to adding hASCs and HUVECs. Upon the addition of the supporting cell types, we 
found that the electrophysiological properties at the ratio of 1500:37.5:150 were 
conduction velocity of  14 ± 0.6 cm/s, APD80 and APD30 of 152 ± 11 ms and 71 ± 
6 ms, respectively, and maximum capture rate of 3.9 ± 0.7 Hz. The values obtained 
at this ratio were not statistically significant different from the NRVCM only control 
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and appeared to match the closest compared to other tri-cultures. Lastly, we 
investigated the human interactions of development of a tri-culture system with 
completely translatable cell types which include human induced pluripotent stem 
cells differentiated towards the cardiomyocyte lineage and the endothelial cell 
lineage. This work will ultimately lead to the development of clinically translatable 
vascularized cardiac patches.    
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Chapter 1: Introduction 
 
1.  Introduction: 
 
Myocardial Infarction (MI) affects more than 1.3 million Americans each 
year1. MI, caused by thrombotic occlusion of coronary arteries, often results in 
heart failure, cardiac rupture, and death due to the limited regenerative capacity of 
human myocardium2. A lack of blood flow to the myocardium during MI results in 
necrosis of cardiac myocytes, which leads to the subsequent release of their 
intracellular contents, activating resident macrophages, and initiating an 
inflammatory cascade3,4. This inflammatory cascade further damages cardiac 
myocytes and leads to destruction of the extracellular matrix (ECM). Recent 
advances, which include stem cell transplantation, thrombolytic therapy, and 
stenting of coronary arteries, have improved myocardial salvage but therapies that 
directly induce regeneration of the ventricular wall and improvement in functionality 
are lacking. 
Cardiovascular tissue engineering has the potential to ameliorate the 
damage resulting from the limited endogenous repair mechanisms of the heart 
following MI5. Currently, there are no methods that completely repair the damaged 
myocardium post injury. Tissue engineering approaches aim to regenerate the 
myocardium by mimicking the tissue structure and cell composition. The native 
make-up of the myocardium includes a host of cells that are critical for survival, 
maturation, and repair.  These cell types include cardiomyocytes, fibroblasts, 
endothelial cells, vascular smooth muscle cells, and macrophages7 (Figure 1). The 
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myocardium is a highly metabolic, vascularized tissue characterized as having 
three endothelial cells to every one cardiomyocyte6 and an inter-capillary distance 
of 15 – 50 μm.6  Tissue engineering of the myocardium requires the development 
of adequate interconnected capillary networks that have the ability to anastomose 
quickly with the host vasculature to maintain cell viability. Engineered pre-
vasculature could expedite integration of the graft with host tissue and enhance 
regeneration. Vascular structures require perivascular cells for angiogenic growth 
factor release and stabilization. Thus, multiple cell types are required to form 
functional vasculature as well as a syncytium of cardiomyocytes. 
Through tissue engineering, there have been several strategies developed 
to enhance cardiac regeneration. These strategies include the injection of cells 
within hydrogels or preassembly of epicardial patches with cells, natural and 
synthetic materials, and growth factors. Tissue engineering strategies aim to 
recapitulate key structural elements of the myocardium. 
2. TISSUE ENGINEERED CARDIAC PATCHES: 
Cardiac patches are designed to be placed epicardially where they integrate 
with the healthy tissue surrounding the infarcted region shunting the electrical 
signals over the scar tissue and contributing to the contractile function of the heart 
(Figure 2). In vivo studies of engineered cardiac patches primarily rely on two 
types of assessments: functional characterization and tissue-level analysis. 
Functional studies include measurements of cardiovascular output, such as 
ventricular ejection fraction, and end-systolic and -diastolic volumes, all of which 
can be measured in living specimens using echocardiography. Also included under 
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the functional umbrella is the organ-level electrophysiology of the heart which can 
be assessed by electrocardiogram in live specimens and by whole-heart optical 
mapping post-mortem7. Tissue-level investigations of in vivo experiments involve 
assessing cell survival and morphology as well as tissue organization. For 
example, a surgically implanted engineered cardiac patch might be assessed for 
anastomosis of host vasculature with engrafted vasculature or for migration of cells 
between graft and host. Histology and immunohistochemistry are crucial tools for 
these measurements as they can be used to differentiate cell types and sources 
and can help characterize the composition and organization of the extracellular 
matrix. 
There are also several in vitro assessments performed on engineered 
cardiac tissues for which optimization is believed to correspond to improved clinical 
outcomes. Electrophysiological measurements are frequently treated as the gold 
standard for evaluating engineered cardiac tissues, with conduction velocities and 
action potential shapes seen in mature, adult tissues established as ideal. These 
measurements also allow engineers to evaluate the uniformity across the tissue 
and to gauge the maturity of stem cell-derived cardiomyocytes. However, full 
electrophysiological characterization of these tissues requires extensive facilities 
and expertise and as a result, much of the literature relies on stimulated contractile 
force measurements. Sometimes referred to in the literature as “twitch force”, this 
assessment is frequently used as a measure of tissue development and increased 
force is believed to correlate with improved tissue maturity and clinical outcomes. 
Cell and tissue-level analysis are also frequently performed on engineered tissue 
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in vitro as cellular morphology and tissue organization are important determinants 
of tissue function.  
3. CELL SOURCES: 
Approaches to engineer cardiac grafts employ the combination of multiple 
cell types, typically including cardiomyocytes (electrically excitable cells), 
endothelial cells (vessel development), and fibroblasts/mural cells (vasculature 
stabilization). Each of these phenotypes may be derived from various sources (see 
Table 1). 
3.1 Cardiomyocytes: 
Typically, cardiac tissue engineering strategies have been studied using 
neonatal rat ventricular myocytes (NRVCMs). NRVCMs are isolated from newborn 
(day 0 – 3) rat hearts that have been minced and digested with trypsin and 
collagenase. To enrich the cardiomyocyte population, cells are usually plated into 
flasks and incubated for short periods to allow for the selective adherence of 
fibroblasts in order to purify the NRVCM population. NRVCMs retain the ability to 
contract ex vivo, undergo a rapid dedifferentiaition-redifferentiation cycle, and can 
be easily plated into monolayers. NRVCMs are widely used to study 
morphological, electrophysiological, and biochemical characteristics of 
cardiomyocytes. Despite their advantages, NRVCMs have the main disadvantage 
of being rodent-derived. Electrophysiologically, NRVCMs have little to no plateau 
phase when cultured in vitro. In addition, NRVCMs differ in their excitation-coupling 
with a lack of T-tubule systems relative to adult myocytes and their ability to 
maintain cytosolic Ca2+ signaling independent of the sarcoplasmic reticulum 
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calcium release8. And while the adult rat myocardium has conduction velocities of 
69  6 cm/s in the longitudinal direction and 19  5 cm/s in the transverse direction, 
there is yet to be a report of tissue engineered grafts achieving these values9. 
These cells are also not able to be cultured for extended periods of time especially 
in monolayers10. 
 While healthy human cardiomyocytes isolated from adult hearts cannot be 
obtained ethically, the use of pluripotent stem cells has provided an avenue to 
obtain viable human cardiomyocytes. Human embryonic stem cells have been 
used to differentiate stem cells into functional human cardiomyocytes. hESC-CM 
have well documented electrophysiological properties, contract rhythmically, and 
are responsive to cardiac compounds. Similar to NRVCMs, hESC-CMs can be 
genetically manipulated but have the advantage of being maintained in vitro for 
longer periods. These cells can also be engrafted into the human myocardium11. 
While these cells are advantageous for studying human cardiomyocytes, there are 
ethical and regulatory concerns related to the accessibility to embryos as well the 
immune response that arises with transplantation12. Additionally, hESCs have 
been shown to have genetic instability and specifically, cardiomyocytes are 
immature in their development. In addition, due to the pluripotent state of the stem 
cells, they have the potential to form teratomas when transplanted in vivo. Recent 
work has established that purifying the culture and removing undifferentiated stem 
cells, should reduce the probability of uncontrolled cell proliferation.  
Human induced pluripotent stem cells (hiPSCs) have similar characteristics 
to hESCs and have the advantage that they can be used autologously. The hiPSC-
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derived cardiomyocytes (hiPSC-CMs) circumvent the ethical concerns associated 
with hESCs, but there is variability among cell lines derived from different patients. 
While these cell types are capable of spontaneously contracting, their functional 
and structural immaturity needs to be addressed. For example, hiPSC-CMs are 
polygonal in shape and mononucleated (while the adult myocytes are larger, rod-
like and binucleated) and they exhibit fetal-like sarcomeric organization, ion-
channel expression, force generation, and action potential shape. The sarcomeres 
in hiPSC-CMs are also shorter and more disorganized than in the adult myocyte13. 
The hiPSC-CMs also have reduced contractile machinery as compared to the adult 
myocyte and have not undergone isotype switch to a stiffer form of titin. Similar to 
neonatal rat cardiomyocytes, these cells exhibit immature calcium handling 
properties and no T-tubule formation14. Finally, gap junction proteins are located 
around the cardiomyocytes rather than located at the intercalated disk space in 
pluripotent stem cells, which yields slower conduction velocities compared to the 
native human adult heart13. In spite of these limitations, hiPSC-derived 
cardiomyocytes (hiPSC-CMs) are a suitable cell source for drug screens and 
disease modeling based on their electrophysiological characteristics. 
3.2 Endothelial Cells: 
Several sources of endothelial cells have been used for vessel 
development. These include human umbilical vein endothelial cells (HUVECs), 
endothelial colony forming cells (ECFCs) also termed blood outgrowth endothelial 
cells (BOECs) or endothelial progenitor cells (EPCs), human embryonic stem cell-
derived and human induced pluripotent stem cell-derived endothelial cells (hESC-
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ECs & hiPSC-ECs). HUVECs display a mature phenotype and have been shown 
to develop cord-like structures in monolayers and vascularized lumens in 3D 
microenvironments that can anastomose with host vasculature in vivo.  
 ECFCs are critical in wound healing/ischemic environments and are found 
circulating in peripheral blood. These endothelial progenitor cells are 
advantageous for patient-specific therapies and have the ability to mature and 
anastomose with host vasculature. While these cells can be patient-specific, there 
is a limited supply circulating in the peripheral blood, they are initially slow growing, 
and take many passages to acquire enough cells to perform experiments or use 
for therapies.  
More recently, hESC-EC, and hiPSC-EC have been used to make to 
vascular structures in vitro and can anastomose with host vasculature in vivo. 
hESC-ECs and hiPSC-ECs have the ability to make lumens in 3D (i.e. hydrogels) 
and are responsive to vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF) signaling15,16.  While phenotypically similar to both 
mature and immature endothelial cells, some studies indicate that the hESC-ECs 
and hiPSC-ECs may be less responsive to shear stress17 but retain the ability to 
be differentiated into arterial and venous endothelial cells18.  
3.3 Fibroblast (-like) cells: 
Developing stable, perfusable vascular networks that can anastomose with 
host vasculature to deliver nutrients provides the capacity to enhance the viability 
of engineered grafts. Vascular stabilization occurs through the activity of mural 
cells i.e. pericytes or smooth muscle cells and several mesenchymal phenotypes 
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(characterized as being positive for surface markers CD73, CD90, and CD105) 
have been used to perform this function19. In particular, fibroblasts from the skin, 
lung, and bladder have been widely used though their perivascular characteristics 
vary with the anatomical site of isolation. Dermal fibroblast are the most 
translatable due to the ability to be easily obtained from the skin and their potential 
to rapidly proliferate, and express limited perivascular potential. Chen et al. have 
demonstrated vessel development using normal human lung fibroblasts in co-
culture with HUVECs or EPCs. Vessel development was monitored over 7 days in 
the presence of low (0.2 million cells/mL) or high (2 million cells/mL) concentrations 
of fibroblasts. The higher concentration of normal lung fibroblasts co-cultured with 
HUVECs or EPCs resulted in longer vessels compared to the lower concentration 
of fibroblasts20. Costa-Almeida et al compared the vessel development of human 
dermal fibroblasts coupled with HUVECs or blood outgrowth endothelial cells 
(BOECs). Studies were completed at 2:1 ratio of EC:FB. Cells were co-cultured for 
up to 21 days. By day 21, the co-culture of BOECs and NHDF resulted in ~32 
capillary like structures/mm2, while HUVEC and NHDF co-cultures developed ~30 
capillary like structures/mm2. Average length of the capillary like structures 
decreased from day 14 to day 21 in both groups21.  
 Cardiac fibroblasts are specifically derived from the myocardium through 
biopsy. This, however, causes damage to the myocardium. Cardiac fibroblasts 
contribute to the myocardial structure and can potentially aid in signal transduction 
between cardiomyocytes.  They can be found in the wound healing environment 
post injury and provide paracrine signaling22,23. Cardiac fibroblasts have 
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perivascular potential and serve as a suitable source for cardiomyocyte co-culture. 
Twardowski et al focused on the role of vascular development with cardiac 
fibroblasts coupled with endothelial cells. The study specifically looked at using rat 
aortic endothelial cells (rAEC) coupled with neonatal cardiac fibroblasts (nCF) in 
fibrin hydrogels. As a positive control for pericyte-like cells, rat bone marrow-
derived mesenchymal stem cells (BM-MSCs) were used to compare vessel 
assembly. Seeding support cells and endothelial cells at 1:1 ratio, this study 
demonstrated that nCF:rAEC developed longer sprouting networks compared to 
when endothelial cells were co-cultured with BM-MSCs 24.  
 As indicated above, BM-MSCs have the potential to serve as pericyte-like 
cells/mural cells and stabilize vascular structures. While these cells have many 
potential benefits, there is high morbidity associated with their extraction and the 
cell yields are relatively low. In contrast, adipose-derived stem/stromal cells 
(ASCs) can be procured in high numbers from a minimally invasive liposuction 
procedure. In addition to acting as mural cells, ASCs secrete an abundance of pro-
angiogenic growth factors. ASCs are also capable of modulating inflammatory 
responses, reducing apoptosis, preventing fibrosis, stimulating endogenous repair 
and neovascularization, and can withstand temporary ischemia25–27. ASCs have 
also been shown to electrically couple with neonatal rat cardiomyocytes by forming 
gap junctions, which would indicate that these cells have the potential to behave 
as cardiac fibroblasts.28 There has not been a study to date that demonstrates the 
potential of hASCs to behave as both cardiac fibroblasts and perivascular cells 
within the same cultures.  
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Merfeld-Clauss et al have monitored vessel assembly of hASCs coupled 
with cord blood endothelial colony-forming cells (cbECFCs). In the monolayer 
culture, there was dense vessel network assembly which appeared to regress over 
time. When cbECFCs were cultured with coronary artery smooth muscle cells 
(SMCs), aortic SMCs, normal human dermal fibroblasts, or human ASCs, the 
hASCs had statistically higher tube lengths29. In a 2015 report, this group reported 
that Activin A expression directed hASC differentiation down the smooth muscle 
lineage when in direct contact with cbECFCs 30. Hutton et al found that 
heterogeneous hASCs contained a small amount of endothelial cells that have the 
ability to expand and form vessel networks. These cells cultured in high density 
(20,000 cells/cm2) monolayer resulted in the development of CD31+ vessel 
structures31. This study was followed up with 3D vascular development in fibrin 
hydrogels32. Freiman et al developed vessel networks with co-cultures of hASCs 
or normal human dermal fibroblasts and human adipose derived microvascular 
endothelial cells (HAMECs) or HUVECs. It was found that the co-culture of hASCs 
and HAMECs resulted in the greatest increase in vessel length by day 7 and 
maintained the vessel length up until day 1433.  
4. MULTICELLULAR STRATEGIES: 
Several strategies have been used to develop vascularized contractile 
grafts that recapitulate key characteristics of the native myocardium. A common 
feature of these approaches is the culture of the three essential cell types: (i) 
contractile, electrically excitable cardiomyocytes, (ii) endothelial cells to self-
assemble into vascular networks, and (iii) fibroblasts-like cells to stabilize cardiac 
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and vascular function (see Table 2).  The first such reported tri-culture system 
utilized hESC-CMs, hESC-ECs or HUVECs, and mouse embryonic fibroblasts 
(mFBs) combined in a cell ratio of 1:1:1 (hCM:mFB:hEC) and seeded into 1:1 
mixed poly L-lactic acid (PLLA) / polylactic glycolic acid (PLGA) scaffolds via 
Matrigel34,35 (Figure 3). Within this study, it was demonstrated that vascular 
structures were stabilized in the presence of fibroblasts and developed increased 
lumens and vessel density. Without the presence of fibroblasts, vessel structures 
were limited in development. In this tri-culture system, cardiomyocytes displayed 
chronotropic responses to compounds like isoproterenol and carbamylcholine34,35. 
While this approach was a landmark in the development of vascularized cardiac 
tissues, there was limited quantitative characterization of cardiomyocyte 
interconnectivity or electrophysiology.   
Fibrin hydrogels have also been used extensively as a scaffold for cardiac 
grafts36–38. Ye et al. co-cultured cardiomyocytes, smooth muscle cells, and 
endothelial cells all derived from hiPSCs at a ratio of 1:1:1.  These cells were 
directly injected into the infarct or directly injected into a fibrin hydrogel loaded with 
insulin-like growth factor (IGF). Groups that were tested included direct cell 
injection, fibrin patch only, and hEC plus hSMC encapsulated within the fibrin 
hydrogel. After 4 weeks in vivo, the cardiac patch resulted in ejection fraction 
increase near sham and the lowest infarct size compared to sham, MI with no 
treatment, patch only, and cells with patch.  In this study, cells were not cultivated 
before injection and subsequent characterization of the cardiomyocyte contractility 
or vessel development were not characterized. Schaefer et al co-cultured hiPSC-
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CMs, human pericytes, and human blood outgrowth endothelial cells (BOEC). 
Within this study, presence of vasculature structures improved the force of 
contraction over time. Increased presence of the mature form of troponin (cTnI) 
compared to the immature form (ssTnI). There was near 1 mN of force generated 
in these constructs by day 14. When the patch was implanted in vivo, the 
vasculature anastomosed with the host vasculature and also integrated with 
cardiomyocytes. There were nearly 150 vessels/mm2 in the tri-culture system. One 
limitation of these approaches is that hydrogel systems are isotropic with cells 
growing in several directions. The native myocardium is anisotropic. In addition, 
hydrogels do not allow for the highest level of homotypic cell-cell connections 
among cardiomyocytes when multiple cell types are encapsulated.   
Scaffold and hydrogel studies typically require all cells to be seeded 
simultaneously. Subsequent studies have demonstrated advantages associated 
with a sequential seeding strategy whereby cardiomyocytes were cultured for a 
period of time before supporting cells were added (Figure 3). In one such study, 
cells were seeded onto micropatterned polyethylene glycol (PEG) hydrogels that 
were coated with Matrigel™ to enhance cell attachment and the development of 
cardiac organoids39. NRVCMs were seeded with D4T endothelial cells and 
neonatal cardiac fibroblasts at three different CM:FB:EC ratios (40:13:47; 60:9:31; 
and 80:4:16). Cells were seeded simultaneously or sequentially. In sequential 
seeding, the cell ratios were maintained and D4T ECs and nCFs were seeded 2 
days prior to the addition of cardiomyocytes and evaluated for electrophysiological 
and contractile changes relative to NRVCM-only cultures. Simultaneously seeded 
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tri-cultures resulted in increased excitation threshold to 6 V/cm, compared to 
~3V/cm in NRVCM-only controls, and decreased maximum captured rates from 
~4.2 to 3 Hz. Upon sequential seeding however, the conditions containing the 
highest percentage of cardiomyocytes coupled with supporting cells types resulted 
in an excitation threshold closest to the NRVCM-only control of about 3 – 4 V/cm 
with statistically unchanged maximum captured rates. The data demonstrated that 
the greatest presence of CD31/PECAM-1 positively stained cells was found in the 
simultaneously-seeded cultures but electrophysiological and functional 
parameters were sacrificed relative to the sequentially-seeded cultures. Although 
the cells were positive for CD31, the development of cord-like structures was not 
uniformly seen throughout the constructs. Recent studies have also investigated 
the impact of using hASCs in lieu of human dermal fibroblasts together with 
NRVCMs and HUVECs. ASCs have been found to be beneficial in ischemic 
settings like myocardial infarction. Studies that have injected hASCs into rats and 
pigs have found paracrine secretion of multiple growth factors. From the 
echocardiogram, there was decrease in infarct size, increase in wall thickness, 
decrease in end systolic and diastolic volumes, and an increase in left ventricle 
ejection fraction and left ventricle fractional shortening40. Therefore, within a 
monolayer in vitro system, NRVCM:hASC and hASC:HUVEC co-cultures were first 
used to determine the appropriate tri-culture ratios. In the tri-culture system, an 
NRVCM:hASC:HUVEC ratio of 10:2:1 resulted in vessel development of 70 mm 
per 3,240 mm2 with an average of 454 junctions. The electrophysiological 
properties were reported as 20 ± 2 cm/s, APD80 and APD30 of 122 ± 5 ms and 59 
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± 4 ms, respectively, and maximum capture rate of 7.4 ± 0.6 Hz41. From these 
studies it could be seen that sequential seeding allowed for cardiomyocytes to 
develop cell-cell connections allow for improved electrophysiological outcomes for 
cardiomyocytes. Although this allowed for the development of close cell-cell 
connections, the cultures were 2D in nature.  
 Zhang et al developed the AngioChip that enabled the formation of 3D 
tissues with spatial and temporal control while seeding different cell populations 
(Figure 3). AngioChip was made from the micropatterned biodegradable 
elastomer poly(octamethylene maleate (anhydride) citrate) POMaC and cells were 
encapsulated into collagen hydrogels. The tri-culture system was developed from 
NRVCMs or hESC-CMs, hMSCs, and HUVECs. Uniquely these devices allowed 
for the development of channels to accommodate medium perfusion to provide 
adequate nutrient transfer to cardiomyocytes. After optical mapping the resulting 
conduction velocity was 4.8 cm/s. In this system the channels were coated with 
vascular cells to develop a channel for nutrient perfusion and ideal integration 
when implanted in vivo. The AngioChip was surgically implanted and 
demonstrated ‘artery to artery’ anastomosis with host vasculature42. Employing 
similar principles for spatial control, Gershlak et al developed a decellularized 
spinach leaf system, which served as an attractive biomaterial for cardiac tissue 
engineering. The native venous architecture of the leaves provided intrinsic 
vasculature networks. The spinach leaf was reseeded with a tri-culture system 
consisting of hESC-CMs, hMSCs, and HUVECs. After 10 days of culture, the tri-
culture system resulted in 10% contractile strain. Contractile strength peaked at 
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day 7 and was maintained until day 17. After day 17, there was a decrease in 
contractile strength. The endothelial cells (HUVECs) were reseeded through the 
cannula and appeared to line the spinach leaf to form vessel like structures within 
the inherent plant structure43. 
 Another promising strategy used cell clusters rather than individual cell 
suspensions (Figure 3). Stevens et al developed spheroid/cell cluster tri-culture 
systems which were seeded with hESC-CMs, hDF, and HUVECs. In this system, 
there was increased force of contraction over time as well as increased force-
length relationships in the presence of all three cell types. In addition, these 
clusters developed a similar percentage of contraction in the patches as the control 
group up to 3 Hz pacing. The vessel characterization showed increased CD31 
staining compared to cardiomyocyte only control and anastomosis with host 
vasculature when implanted in vivo44. Ong et al developed a 3D printed tri-culture 
system, in which cells are the matrix. This tri-culture consisted of hiPSC-CMs, 
hCFs, and HUVECs. The electrophysiological properties consisted of ventricular-
like action potentials and conduction velocity near 4.6 cm/s which appeared to 
decrease with increased fibroblast percentage. CD31 staining was found in the 
histology inside the cell cluster but vessel density was not calculated.  When the 
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5. BIOMATERIALS: 
Biomaterials are designed to provide structural support, alignment cues, 
and bioactive signaling to enhance cardiomyocyte function and maximize 
contractile and electrophysiological properties. In addition, incorporation of 
proangiogenic cues facilitates the development of dense vasculature46. 
Biomaterial choices for the development of vascularized cardiac grafts range from 
natural to synthetic biopolymers. For example, PLLA/PLGA (in a 1:1 ratio) has 
been used to create a sponge-like, biocompatible scaffold. PLGA has a high 
degradation rate while PLLA provides mechanical support to the 3D structure47. 
Alternatively, PEG and Poly (octamethylene maleate (anhydride) citrate) (POMaC) 
which degrades easily through hydrolysis are the materials to which hydrogels 
containing cells will be cultured39,48,49. These polymers were coated with Matrigel™ 
or the combination of Matrigel™ and collagen.  
Hydrogels are an attractive material because they are generally made from 
the natural materials and can be modified to tune their properties, encapsulate 
cells, and serve as an adhesive to maintain cells in desired location. While 
hydrogels are attractive sources for providing a scaffold for development, there are 
drawbacks. These include limited mechanical integrity, reduced flexibility in 
seeding procedures, and isotropy50. The native myocardium is composed of mostly 
collagen and collagen gels would facilitate a similar extracellular matrix 
composition.  
Despite collagen being one of the major extracellular matrix proteins of the 
native myocardium, many multi-cellular approaches utilize fibrin as a scaffold. 
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Fibrin is composed of fibrinogen and cross-linked with thrombin. Fibrin has the 
ability to recruit vasculature because it is proangiogenic 20. Fibrin is often used in 
cardiac patch systems because it has many attractive features and naturally 
occurs at wound sites51,52. Among the benefits of fibrin are its ability to promote 
angiogenesis, cell survival, and extracellular matrix secretion36. This matrix 
secretion in combination with the natural strain stiffening of fibrin mimic the 
mechanics of the cardiac microenvironment53,54. 
To provide mechanical integrity and facilitate the development of alignment 
and tension for cardiomyocyte contractility, researchers have developed casting 
methods like posts for fibrin hydrogels55–57.  Recently, fibrin has been electrospun 
into microfibers. Electrospun microfibers offer the added advantage of tunable 
mechanical properties and alignment cues, which is critical for myocardial tissue58. 
Also groups have initiated a bilayer scaffold approach which includes culturing 
cardiomyocyte gels and vascular gels both independently and in combination for 
therapy38. 
Decellularized matrices are also attractive for the development of tissues 
because they utilize nature’s platform. Most recently, there has been the 
development of vascularized cardiac tissue on a decellularized spinach leaf by the 
Gaudette group. The spinach leaf was specifically used because of the intrinsic 
network that it possesses that could be used for the development of dense vessel 
networks alongside contractile cardiomyocytes43. Other groups have 
decellularized rat, porcine, and human myocardium and reseeded with 
cardiomyocytes and endothelial cells59. The drawbacks currently to decellularized 
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matrix are the reseeding efficiency and the detergents used to decellularize can 
alter the stiffness of the matrix.  
6. BIOPHYSICAL CUES: 
Cellular behavior is strongly influenced by the properties of the cells’ 
microenvironment. Hence, tissue engineering strategies aim to tightly regulate the 
biochemical, mechanical and electrical cues experienced by cells to influence cell- 
and tissue-level behaviors. However, the ideal microenvironment for cardiac 
development is not necessarily conducive to angiogenesis and vice-versa. This 
discord presents a challenge in the engineering of tissues with both mature cardiac 
function and functional vasculature and necessitates a firm understanding of how 
environmental factors contribute to each process.  
6.1 Biochemical Cues: 
Embryological studies have proven that cardiac development relies heavily 
on the biochemical makeup of its surroundings, as small variations in localization, 
timing or concentration of certain signaling molecules can result in hugely 
consequential cardiac defects. The earliest stage of cardiogenesis, the formation 
of cardiac progenitor cells, relies on Nodal, a cytokine in the TGF- family60. Wnt/-
catenin and bone morphogenic protein (BMP) signaling also play critical roles in 
early differentiation and facilitate the proliferation of those progenitors, although 
evidence suggests that both factors can exert an inhibitory effect on terminal 
cardiac differentiation61–64. These embryological revelations have yielded a variety 
of approaches to promote myocardial differentiation in pluripotent cells, the most 
efficient of which rely on modulating Wnt, BMP, and Fibroblast growth factor (FGF) 
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signaling with small molecule regimens65. In a widely cited report, Burridge and 
colleagues found that L-ascorbic acid 2-phosphate and recombinant human 
albumin along with transient exposure to CHIR99021, a glycogen synthase kinase 
3 inhibitor, and IWR-1, an inhibitor of Wnt/-catenin signaling, are sufficient to 
induce cardiac differentiation in 11 hiPSC lines66. 
Dozens of factors have been identified as promoting angiogenesis, enacting 
their effects via a variety of mechanisms. Among the most relevant and researched 
in the context of vascularized cardiac tissues are vascular endothelial growth factor 
(VEGF), platelet-derived growth factor subunit B (PDGF-B), and angiopoietin-1 
(Ang-1). In tri-culture experiments combining hESC-derived cardiomyocytes with 
endothelial cells and fibroblasts, Caspi et al showed that the tri-cultures developed 
much more significant vasculature and also showed increased expression of 
VEGF, PDGF-B and Ang-134. The importance of these factors was further 
confirmed when Hao and colleagues reported increased vascular development in 
the infarcted myocardium of mice in response to hydrogel-delivered VEGF-A and 
PDGF-BB67. In addition to traditionally recognized proangiogenic factors, some 
hormones and cytokines with unrelated primary functions have been shown to 
improve vasculature in engineered cardiac tissues; specifically, insulin-like growth 
factor 1 (IGF-1) and stromal cell-derived factor 1 (SDF-1) along with VEGF 
increased the vascular development in an engineered cardiac patch68. This effect 
was at least partially mediated by SDF-1’s ability to attract CD34-positive 
hematopoietic progenitor cells. 
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 The functional mechanisms of cytokines and hormones are often complex 
and influenced by the method of delivery. Alberti and colleagues concluded that 
these effects can drastically alter stem cell fate by showing that immobilizing 
Leukemia Inhibitory Factor in a gelatin matrix significantly improved its ability to 
maintain pluripotency in hESCs69. Similarly striking effects have been observed in 
studies of biochemical control of vascularization. Early experiments revealed that 
heparin-mediated binding of VEGF to a collagen matrix promoted endothelial cell 
proliferation 70 and that immobilizing VEGF promoted penetration of endothelial 
cells into collagen matrices71. Chiu and Radisic subsequently demonstrated that 
endothelial cells formed significantly more vasculature on scaffolds with covalently 
immobilized VEGF and Ang-1 than scaffolds treated with soluble factor72. In that 
experiment the authors utilized 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) and N-hydroxysulfosuccinimide (sulfo-NHS) to covalently 
bind VEGF and Ang-1 to the collagen substrate. Factor immobilization using 
sulfonated alginate matrices has proven a very effective tool for promoting 
vasculature in complex tissue environments with many cell types, including cardiac 
tissue. FGF presented in this matter produced twice the blood vessel density as 
soluble FGF when implanted subcutaneously in mice and matrix-bound 
hepatocyte growth factor (HGF) similarly increased vascular density by nearly two-
fold over all controls in mouse hindlimb ischemia model73,74. Despite these 
advances, the utility of presenting pro-cardiac molecules in this manner has not 
been rigorously evaluated as, for the most part, experiments using multiple cell 
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types have administered these molecules either before they are used in the patch 
or by including them as soluble factors in the media. 
6.2 Effect of Substrate Stiffness, Guidance, & Alignment Cues: 
Of the many characteristics of the extracellular matrix, the mechanical 
stiffness has been identified as particularly important to cellular differentiation and 
behavior. The role of matrix stiffness in supporting cardiomyocytes is poorly 
understood and a wide range of elasticities has been reported as optimal for their 
culture. In one of the earliest studies on this topic, Jacot et al reported that 
NRVCMs grown on 10 kPa polyacrylamide (PA) displayed improved markers of 
functional maturity, such as contractile force generation and sarcoplasmic calcium 
stores75. Similarly, Engler and colleagues found that embryonic cardiomyocytes 
isolated from rats displayed much greater functional maturity on collagen-coated 
polyacrylamide matrices with elastic moduli in the range of normal rat myocardium 
(~11kPa) as opposed to stiffer matrices falling in the range of infarcted myocardium 
(~34kPa)76. However, shortly thereafter it was reported that NRVCMs cultured on 
very soft, 3 kPa PA scaffolds developed more electrophysiologically mature 
phenotypes but that other measures of functional maturity such as cellular 
elongation and contractile force generation were optimized on stiffer 50 kPa 
scaffolds77. The question of optimal substrate stiffness is further complicated by 
evidence that cardiomyocytes require different levels of substrate stiffness at 
different stages of differentiation. In 2010 Young and Engler found that a hyaluronic 
acid matrix engineered to stiffen over time increased expression of maturity 
markers in NRVCMs nearly threefold over standard scaffolds 78 and a recent report 
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suggested that CMs derived from iPSCs display improved initial differentiation on 
protein-coated tissue culture plastic (elastic modulus ~2GPa) but that they 
developed more mature beating behavior and contractile function on 20kPa PA 
scaffolds79. 
Stiffness is also an important consideration in vascularization as evidenced 
by experiments showing that angiogenesis in hydrogels seeded with HUVECs is 
strongly affected by the elastic modulus of the hydrogel. In a key report, Sieminski 
and colleagues showed that the softer collagen gels (Young’s Modulus = 6 kPa) 
developed much more robust vascular networks than the stiffer gels (10 kPa) they 
tested80. This report also suggested that the relative magnitudes of the matrix 
stiffness and the force of endothelial cell traction regulate angiogenesis. They 
found that human blood outgrowth endothelial cells (HBOEC), which exert more 
traction force than HUVECs, formed thin, branched vasculature with thick walls in 
floating 10kPa gels while HUVECs formed vasculature with thin walls and larger 
lumens. However, if the stiffness was decreased to 6kPa, both cell types formed 
narrow, thick-walled structures while if the apparent stiffness was increased by 
mechanically restraining the gel, both cell types formed thin-walled vasculature 
with large lumens.  
Determining the ideal elasticity for vascularization of cardiac tissues is 
further complicated by inconsistencies in the literature. Wide varieties of matrix 
materials have been utilized but it is very possible that optimal stiffness is different 
for each material. Also, stiffness is measured and reported differently throughout 
the literature with some authors reporting elastic modulus and others choosing to 
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measure storage or complex moduli; these are related but they can be 
substantively different in the context of viscoelastic materials. Despite these 
irregularities, it is likely that substrates optimized for endothelial proliferation and 
angiogenesis are much softer than those optimized for cardiomyocyte maturation 
as the reported stiffnesses of angiogenic substrates have ranged from under 100 
Pa to about 6 kPa80–82 while cardiomyocyte differentiation and maturation has been 
reported to thrive in matrices with elastic moduli in the range of 10-50kPa and has 
been shown to be actively suppressed on very soft (1-3 kPa) substrates79,83. 
6.3 Alignment: 
Anisotropy and cellular alignment is a prominent characteristic of cardiac 
physiology and the alignment of cardiomyocytes is critical to normal 
electrophysiological and contractile behavior. In comparing cultures of NRVCMs 
grown on a flat surface with random orientation to cultures grown on a grooved 
substrate with increased alignment, Chung et al found that the aligned cultures 
exhibited increased conduction velocities84. Alignment of 3D NRVCM cultures was 
also shown to increase the stimulated force of contraction53. Reproducing this 
organization has been a major goal of the tissue engineering field and 
cardiomyocyte alignment is frequently used as a measurement of tissue maturity 
and predictor of functional capacity.  
This anisotropy is not limited to cardiomyocytes as it is also present in the 
vasculature of native myocardium, where blood vessels are highly aligned in near-
parallel organization85,86. There have been efforts to recapitulate this vessel-level 
alignment to maximize biosimilarity and because, in theory, microvascular 
   - 24 - 
alignment could improve nutrient delivery and promote the survival of 
cardiomyocytes in the construct. An experiment in which pre-vascularized cardiac 
patches, formed with either randomly oriented or uniaxially aligned vasculature, 
were grafted onto infarcted myocardium in mice showed improved lumenal density 
and network length among the aligned samples in vitro but also showed that their 
in vivo effects were indistinguishable as they displayed similar total and perfused 
luminal densities as well as similar improvements in scar tissue formation and 
functional outcomes56. These results have raised questions regarding the 
importance of vascular alignment to the function of engineered cardiac tissues. In 
another set of experiments, researchers combined separately generated layers of 
aligned microvessels and aligned cardiomyocytes. They found that the combined 
patch exhibited much greater force of contraction in vivo and that it significantly 
reduced scar formation in mouse myocardial infarction models, while patches just 
containing CMs did not 38, but without controlling for a patch with randomly oriented 
vasculature, the importance of the alignment is impossible to assess. 
6.4 Electrical and Mechanical Stimulation: 
Electrical and mechanical stimulation applied in culture can have a 
significant impact on the maturation of CMs and the development of vasculature in 
tissue engineered constructs. In the development of engineered cardiac tissues 
that recapitulate the behavior of native myocardium, the ability to control the 
cellular environment and apply external stimuli is very important. Therefore, 
significant investment has been made in developing devices capable of reliably 
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applying electrical and mechanical stimulation to these tissues and investigating 
optimal stimulation for cardiac development and angiogenesis. 
6.5 Electrical Stimulation: 
Electrical forces play a key role in cardiac development as spontaneous 
electrical activity begins in what will become the sinoatrial node as early as 20 days 
after fertilization87. Electrical stimulation has proven a useful tool in cardiac tissue 
engineering since Radisic and colleagues showed that applying electrical pulses 
at 1 Hz to cardiomyocyte-laden hydrogels resulted in improved CM alignment, a 
50% increase in maximum capture rate, a 3-fold increase in gap junctions, and a 
4-fold increase in the fractional change in the surface area of the construct induced 
by each beat, suggesting increases in electrical coupling, electromechanical 
coupling and force of contraction88. It has since been demonstrated that a ±2.5 V 
biphasic pulse applied at 1 Hz can drive progenitor cells toward cardiomyocyte 
lineages, evidenced by increases in cell length and alignment along with increased 
expression of GATA-4, Cx43, and troponin T apparent after only 1 day of 
stimulation89. It has also been suggested that “electrical conditioning” can help 
establish automaticity in CMs, since the cultures electrically paced for 7 days 
displayed autonomous beating at the stimulated rate even after the stimulus has 
been removed90. 
Electrical activity certainly has some effect on vasculature as sympathetic 
nervous signaling is an important regulator of vascular tone and sub-millisecond, 
250 V electrical pulses applied at 10 Hz has been shown to cause vascular 
contraction in less than 10 seconds and reduce blood loss in models of acute 
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traumatic injury91. However, the effects of electrical stimulation on endothelial cells 
and angiogenesis are much more poorly understood. Various kinds of electrical 
stimulation have been shown to increase angiogenesis in a wide array of settings 
including diabetic ischemia and neural progenitor cell treatment for ischemic 
stroke92,93. These effects are believed to be primarily mediated by upregulation of 
VEGF in other cell types as opposed to by directly acting on endothelial cells94, 
though there is some evidence that direct current electrical stimulation can 
upregulate VEGF receptors on endothelial cells, essentially priming them for 
biochemical stimulation95,96.  
Experiments using electrical stimulation to promote angiogenesis generally 
utilize constant electrical fields as opposed to experiments focusing on 
cardiomyocyte development which usually use regular electrical pulses. Thus far, 
investigations of cardiomyocyte-endothelial cell co-cultures have opted to either 
forego electrical stimulation or have used periodic electrical stimulation regimens 
created for CMs, even though the effects of periodic electrical stimulation on 
endothelial cells and angiogenesis is largely unknown. More directed investigation 
would be critical to understanding how electrical stimulation of engineered tissues 
can be optimized for both CM maturation and for vascular development. 
In the design of bioreactors with electrical stimulation capabilities, the 
application of field pulses to a 3D culture is relatively easily adapted from 2D 
systems. A common configuration for such devices involves using two parallel 
electrodes to generate an electric field across a substrate89,97–99. Tandon and 
colleagues, for example, developed a system that uses carbon rods to induce an 
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electric field across a chamber that can support monolayers, 3-dimensional cardiac 
tissue constructs and micropatterned cellular substrates97. In subsequent studies, 
1 Hz stimulation applied using this setup was shown to improve CM elongation 
and alignment, increase conduction velocity and strengthen the tissue-level force 
of contraction100. This strategy has proven successful even with more complicated 
systems like the Biowire platform, a cell culture system that utilizes both 
architectural and electrical signaling to generate more mature cardiomyocyte98. 
The system consists of a collagen matrix embedded with cardiomyocytes and 
supporting cell types surrounding a single surgical suture, all within a template 
PDMS channel. This platform has since been expanded to also allow for perfusion 
of the Biowire systems during culture, facilitating an array of pharmacologic 
experiments. 
6.6 Mechanical Stimulation: 
Myocardial development depends on a complex series of mechanical forces 
acting in concert to promote cardiomyocyte maturation, organization and 
electrophysiological function. Animal studies provided strong evidence for the 
importance of mechanical stimulation as they showed that altering hemodynamic 
pressure and contractility in the fetal heart had dramatic effects on myocardial 
function101–103. It has since been established that imposing static or cyclic strain 
onto an engineered tissue has the ability to induce cardiomyocyte hypertrophy, 
promote maturity in stem cell-derived CMs, and improve myocardial 
organization104,105. Cyclic strain has come to be understood as particularly 
important to CM development. Gwak and colleagues showed that applying 10% 
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strain at 1 Hz to rat ESC-CMs upregulated cardiomyocyte-specific genes and 
resulted in a more mature microstructure with Z-line formation and more organized 
myofibrillar bundles106. Another study found that the frequency of strain 
applications could have important differential effects on gene expression. Using 
ESC-CMs, they found that 10% strain applied at 3 Hz for 3 days resulted in a two-
fold increase in -cardiac actin expression compared to unstretched controls while 
1 Hz and 2 Hz stimulation did not produce statistically significant changes107. 
Mechanical forces also play a powerful role in regulating endothelial cell 
behavior and vascularization. In vitro and in vivo studies have confirmed that the 
shear stress caused by blood flow strongly affects the phenotype of vascular 
endothelial cells108. However, in engineered cardiac tissues, where there is 
generally no blood flow during in vitro culture, the field has relied on tissue-level 
strain instead. Like cardiomyocytes, endothelial cells in engineered scaffolds have 
been shown to respond positively to uniaxial static strain, displaying improved 
angiogenesis and vascular alignment109,110. However, the effect of cyclic strain on 
angiogenesis is more controversial. Some early reports suggested that cyclic 
uniaxial strain can actually disrupt endothelial networks and result in more random 
vascular organization111. Other studies have presented evidence that cyclic strain 
promotes endothelial cell and vascular alignment parallel to the strain110,112–114, 
and some have suggested that the strain induced by surrounding cell contraction 
is sufficient to induce that effect115. Again, the frequency of this strain is an 
important factor as experiments using human coronary artery endothelial cells 
showed that a minimum threshold frequency of 0.1 Hz was required to elicit an 
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alignment effect and that the alignment developed more robustly and on a shorter 
time scale when the strain was applied at 1 Hz113. 
Experiments culturing endothelial cells and cardiomyocytes together along 
with a variety of vascular support cell types (detailed above) have thus far been 
conducted used either cyclic strain conditions or no induced strain at all. These co-
culture and tri-culture experiments have produced significant advancements in 
generating vascularized cardiac tissue, but very little work has been done to 
evaluate whether using these conditions are optimal for promoting both 
cardiomyocyte development as well as endothelial cell survival and vascular 
network formation. It is very possible that conditions chosen to promote 
cardiomyocyte maturation are impeding angiogenesis in the tissues. Careful 
optimization of mechanical stimulation will be important in the continued 
development of these systems.  
6.7 Combined Electrical and Mechanical Stimulation: 
Applying strain conditions and electrical stimulation together has proven a 
particular engineering challenge and several bioreactors have been designed with 
the aim of incorporating these stimuli into hydrogel cultures116–120. These devices 
take advantage of the full diversity of mechanical strain modalities detailed above 
an have been configured to apply uniaxial and circumferential strain116,118–121. 
Across these devices, though, the vast majority generates electrical stimulation 
using the parallel electrode setup. A notable exception is the bioreactor reported 
by Cook and colleagues which applies electrical impulses via the integration of a 
direct contact in the clamping mechanism that secures the tissue in place120. There 
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are several characteristics that vary widely between these devices including 
substrate material compatibility, sterility requirements, incubator compatibility, and 
the integration of sensors, all of which must be considered in selecting the 
appropriate system for a particular application. 
7.CONCLUSIONS:  
Multi-cellular systems have been developed to mimic the native 
myocardium and prolong survival of cardiac grafts when implanted in vivo. Several 
strategies utilizing simultaneous seeding, sequential seeding, and the combination 
of vascularized and cardiac constructs have been explored to achieve fully 
vascularized, contractile grafts. While a complete human system will be critical to 
the clinical translation of this technology, there are important questions 
surrounding the maturation of pluripotent stem cell derived cardiomyocytes that 
must be addressed. Several techniques are under investigation to improve the 
maturation of those cells and the overall organization and functionality of 
engineering cardiac grafts including electrical stimulation, mechanical stimulation, 
and a combination of electromechanical stimulation. Recent developments have 
greatly improved the physiological relevance and translational potential of 
engineered cardiac patches, but further applications will hinge on the incorporation 














Figure 2: Schematic demonstrating the theoretical application of a myocardial 
patch placed over an infarct to aid in restoration of lost contractility. 
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Figure 3: Strategies for the development of vascularized cardiac tissue grafts for 
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Table 1: Summary of Cell Types used for Tri-Culture Systems 
 

















• Contract ex vivo 
• Relatively easy to form in monolayers  
• Well documented electrophysiological 
properties  
• Reproducibility of phenotype 
• Easily accessible 
• Rodent specific 
• No direct clinical translatability 
• Little to no plateau phase  
• Immature calcium handling 
• Limited t-tubule formation 








s • Contractile 
• Well documented electrophysiological 
properties 
• Derived from human embryos 
• Mimics human cell characteristics 
• Can be sorted by markers like VCAM-1 
• Ethics 
• Teratoma Formation 
• Accessibility 
• Immunogenicity  
• Genetic Instability 









• Contractile upon differentiation 
• Obtained from reprogrammed somatic cells 
with factors (Oct 4, Sox 2, Klf4, and c-Myc1 
or Oct4, Nanog, Sox2, and Lin28) 
• Have the potential to provide unlimited 
numbers of cardiomyocytes 
• Mimics human cell characteristic  
• Model monogenic diseases  
• Can be sorted to increase purity 
• Autologous/Patient Specific with less 
immunogenicity  
 
• Reprogramming techniques vary 
• Scale Up 
• Inter line variability 
• Cell purity 
• Relatively immature  
• Fetal Like Sarcomere Organization 
• Fetal Like Force Generation 
• Fetal Like Ion Channel Expression 
• Mononucleated 
• Polygonal in cell shape 
• Mixed Phenotypes 
• Epigenetic memory 
123,13,7 





































• Mature like endothelial cells  from large 
vessels 
• Easily expanded 
• Positive for markers CD31, CD54, CD62e, 
vWF, and AcLDL  
• Responsive to exogenous growth factors (i.e. 
VEGF, FGF2) 
• Ability to anastomose with host vasculature 
in vivo  
• Allogenic 
• Typically are pooled from multiple donors 
• Sensitive to cell density during expansion 


















• Progenitor Cells 
• Found in circulation 
• CD31, CD34, CD105, CD144, CD146, vWF, 
eNOS, VEGFR2 positive 
• Autologous/Patient Specific 
• Ability to anastomose with host vasculature 
• Found in sites of ischemia and wound 
healing 
• Paracrine support for myocytes  
• Express Connexin 43 (Cx-43) and Cx-45 
• Integrate with resident vasculature 
• Can be used for many passages in vitro 
• Low in number in peripheral blood 
• Require many expansions 









• Can form tubes like structures in vitro with 
sorted pure population 
• Can anastomose with host vasculature in 
vivo 
• CD31 positive  
• Ethics 
• Immunogenicity 
• Teratocarcinoma Formation 
• Differentiation protocol varies causing potential instability 
in passages post differentiation 









• Autologous/ Patient Specific 
• Can be disease specific 
• Can form tubes like structures in vitro with 
sorted pure population 
• Can anastomose with host vasculature in 
vivo 
• Have the ability to develop large numbers of 
endothelial cells quickly 
• Various differentiation protocols 
• Interline variability due to reprogramming methods. 
• Differentiation protocol varies causing high heterogeneity          
       in the derived ECs. 

























 • Patient Specific 
• Easily Accessible 
• Multipotent 
• Perivascular potential 
• Can act as pericyte-like cell when coupled 
with endothelial cells 
• Limited Perivascular Potential 
• Characteristics vary based off of site of isolation 














• Cardiac specific  
• Major cellular component of the native 
myocardium 
• Maintain cardiac structure and function 
• Found in wound healing post infarction  
• Promoted sprouting of endothelial cells in co-
culture. 
• Causes damage to myocardium upon isolation 
• Has experimentally slowed conduction in co-culture with 











• CD73, CD90, and CD105 positive 
• Pericyte-like cell 
• Multipotent 
• Autologous/Patient Specific 
• Stabilize vasculature  
• Secrete VEGF, bFGF, Ang-1 and EGF when 
co-cultured with ECs 
 
• Painful Isolation 
• Limited Cell Numbers 
• Can potentially differentiate down the osteogenic lineage 
in the myocardium 







• High perivascular potential 
• Differentiate down the smooth muscle 
lineage when co-cultured with ECs 
• Relatively easy isolation 
• Immunomodulatory 
• May develop gap junctions when coupled 
cardiomyocytes 
 











s • Promote vascular stabilization 
• Secrete pro-angiogenic growth factors 
• When coupled with cardiomyocytes in vivo 
have shown improvement post MI in ejection 
fraction and fractional shortening 
• Difficult to isolate 
• Not an abundant cell source 
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Table 2: Tri-Culture studies used for engineering vascularized cardiac grafts 
 
 









• 80,000 – 160,000 
cells/disk 
• Percentage: 40 – 80% 
D4T Endothelial Cells 
• 8,000 – 24,000 
cells/disk 
Percentage: 4 – 13% 
Cardiac Fibroblasts 
• 28,000 – 48,000 
cells/disk 
• Percentage: 16 – 47% 
• Matrigel-coated PEG disks 
Size: 0.32cm2  
• Microchannels: 
100 – 200 m diam × 3 – 4 
mm  
• PEG Disk were coated with 
Matrigel 
• Supporting cells cultured for 
2 days before addition of 
NRVCMs 
• Cell Tracking: Day 1 and Day 
4 
Advantages 
• Excitation Threshold: statistically 
similar in the 65:17:18 group (4 
V/cm) and NRVCM control 
(3.2V/cm) 
• Maximum Captured Rate: 
Statistically similar in tri-culture 
groups and NRVCM only control 
(value) 
Limitations: 
• Cardiomyocytes were clustered 
into cell aggregates   
Advantages 
• Positive staining for 
CD31/PECAM-1 
• 31% EC yielded statistically 
higher percentage of positive 
staining for CD31 compared to 
47% and 16% 
Limitations: 





• 1,140,000 cells 
• Percentage: 57% 
Neonatal Cardiac 
Fibroblasts 
• 580,000 cells 
• Percentage: 29% 
Rat Aortic Endothelial 
Cells 
• 280,000 cells 
• Percentage: 14% 
• Microtemplated PMMA with 
PC molds for fibrin hydrogels  
• Fibrin hydrogels were 
rehydrated through sterile 
PBS 
• 2mm diameter biopsy punch 
was used to establish 
scaffold 
• 200mg/ml Fibrinogen 
• Tri-culture cellular mixture 
was pipetted into fibrin 
hydrogel 
• Constructs were cultured for 
8 days 
Advantages: 
• Cardiomyocytes survived in the 
scaffolds over time 
• Positive staining for Desmin for 
cardiomyocytes 
• Revealed maintenance of stiffness 
of fibrin hydrogels in the presence 
of Factor XIII and Aprotinin  
Limitations: 
• No functional characterization of 
the cardiomyocytes 
Advantages 
• Vessel formation occurred in 
pore channels of the scaffold 
• RECA-1 positive staining 
colocalized within pore 
channels 
• Vessels appeared to form 
lumens 
Limitations: 
• Vessels density not robust 
• Vessel quantity not 
characterized 
36 
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NRVCM 
• 500,000 cells 
• Percentage: 77 -90 
% 
hASCs 
• 50,000 – 100,000 
cells 
• Percentage: 9 – 16% 
HUVECs 
• 5,000- 50,000 cells 
• Percentage: 1 – 8% 
• Monolayer Culture on Plastic 
Coverslips: 2cm2 
• Coated with Fibronectin 
• NRVCM cells cultured 2 
days before addition of 
supporting cell types. 
• Cells were optically mapped 
on days 5-8 
Advantages: 
• Electrophysiological properties are 
similar to NRVCM only group (Max 
Captured rate ~ 7 Hz) 
• Assessed the  
Limitations: 
• Cultured on monolayer  
• Cardiomyocyte source is not 
clinically translatable to humans. 
• Maturation of cardiomyocytes in 
the presence of supporting cell 
types not evaluated  
Advantages: 
• Dense vessel networks were 
created in the presence of all 
three cell types at 500:50:25 
ratio 
Limitations: 
• Cord-like structures 
• No 3D vessels with lumens 
• Vasculature is not organized 










• 400,000 cells 





• Percentage: 20-33% 
hESC-EC or HUVECs 
• 400,000 cells 
• Percentage: 33-40% 
 
• 50% PLLA: 50% PLGA 
Size: 9mm3 (3mm x 3mm x 
1mm) 
• Pore Size: 212 - 600m  
93% Porosity 
• Cultured for 2 weeks 
• 8-10 L Culture 
Media:Growth Factor 
Reduced Matrigel Mix (1:1) 
• Simultaneously seeded  
 
Advantages: 
• Spontaneous beating occurred at 
day 4 
• Ca 2+ impulse propagation in line 
with contraction 
• Contractility is responsive to 
cardiac drugs like isoproterenol 
and carbamylcholine 
• Increased proliferation of 
cardiomyocytes in the presence of 
endothelial cells 
Limitations: 
• Alignment of cardiomyocytes were 
not characterized 
• Electrophysiological properties not 
characterized (i.e. conduction 
velocity and maximum captured 
rate) 
Advantages 
• No significant difference with 
between 1:1 and 1:2 (FB:EC) 
• Tri-culture resulted in 5.12 
lumen density while endothelial 
was 1.57 
• Implanted in vivo and becomes 
functional with host vasculature 
Limitations: 
• Did not organize into blood 
vessels without fibroblasts 
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hESC-CM 
• 2,000,000 cells 
• Percentage: 40% 
Mouse Embryonic 
Fibroblasts (MEF) or 
NHDF 
• 2,000,000 cells 
• Percentage: 40% 
hESC-EC or HUVECs 
• 1,000,000 cells 
• Percentage: 20%  
• Spheroid/ Cell Clusters 
• Cultured in Low Attachment 
Plates 
• Cultured for 3 days and 8 
days 
• Placed in vivo in a skeletal 
muscle defect and nude rat 
hearts 
Advantages: 
• Human cardiac tissues patches 
contracted and could be paced up 
to 2-3 Hz. 
• Increased collagen content in the 
tri-culture 
• Increased force of contraction ~8 
mN/mm2 compared to 2 mN/mm2 
• Increased normalized force in the 
presence of all three cell types  
• Increased force in tri-culture with 
increased differential strain 
Limitations: 
• Unorganized structure 
• Lack of mechanical integrity 
Advantages: 
• Vessel structures increased in 
HuEB Media as compared to 
RPMI B27 
• Increased CD31 staining 
compared to cardiomyocyte 
only control 
• Anastomosis with host 
vasculature in vivo. 
Limitations: 
• Vessel length not assessed in 
vitro before implantation 
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hESC-CM /NRVCM  
• 32 million cells 
• Percentage: 80% 
hMSC 
• 4 million cells 
• Percentage: 10% 
HUVECs 
• 4 million cells 
• Percentage: 10% 
 
• POMaC base of scaffold 
• 5 mm length 
• 3.1mm width 
• 150-300m thickness 
• Fibrin hydrogel for seeding 
cells (33mg/mL fibrinogen 
and 25 U/mL thrombin) 
 
Advantages: 
• Synchronous contractions occurred 
as early as day 4  
• Conduction velocity was near 4.8 
cm/s in vascularized samples 
without conduction block 
• Responsive to epinephrine 
• Cultured with perfusion in 
bioreactor 
• Tunable mechanical properties 
based off of design 
• Lactate dehydrogenase decreased 
with perfusion 
Limitations: 
• Not uniformly aligned although 
anisotropic design 
• Electromechanical stimulation 
needed to improve 
electrophysiology 
Advantages: 
• Endothelial cells coated the 
lumen structure in the 
parenchymal space.  
• Connection of vasculature 
throughout scaffold 
• 3D microvasculature observed 
• Connected to the femoral 
vessels in vivo 
Limitations: 
• Vasculature is not interspersed 
through cardiomyocytes which 




• Not Provided 
hMSC 
• Not Provided 
HUVECs 
• 375,000 cells 
 
 
• Decellularized Spinach Leaf 
• Coated with 10µg/mL 
fibronectin for cell 
attachment 
• Grown for 14 days 
Advantages: 
• Cardiomyocytes have the ability to 
attach to the surface of the leaf 
with ECM protein coating 
• Spontaneous beating at day 5 
• Calcium activity was maintained for 
21 days on spinach leaf 
Limitations: 
• Cardiomyocytes clustered across 
the spinach leaf rather than making 
a syncytium  
• Decreased contractility over time 
• Contractility strain on TCPS was 
higher than spinach substrates 
• Structural integrity for in vivo 
implantation 
Advantages: 
• HUVECs perfused into 
decellularized plant vasculature 
to obtain develop vasculature 
Limitations: 
• Vasculature is not interspersed 
through leaf while 
cardiomyocytes which is not 
similar to the native 
myocardium 
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• 2 million cells 
• Percentage: 33% 
hiPSC-SMC 
• 2 million cells 
• Percentage: 33% 
hiPSC-EC 
• 2 million cells 
• Percentage: 33% 
• Fibrin Hydrogel loaded with 
IGF-1 for cell survival 
• Directly injected cells into 
hydrogel on the myocardium 
• Cells are differentiated into 
three lineages (CM, SMC, 
and EC) and injected directly 




• Improved functionality in vivo with 
tri-culture and patch present and 
reduced CM apoptosis of myocytes 
• Increased ejection fraction 
• Decreased infarct size 
• Cell survival was greatest in tri-
culture cells + patch group 
Limitations: 
• Cardiac electrophysiology not 
characterized prior to in vivo 
implantation 
Advantages: 
• Tri-culture promoted survival 
and proliferation of 
cardiomyocytes 
• Engineered Vasculature 
promotes host vasculature 
angiogenic response 
Limitations: 
• Vasculature was not 
characterized before 





• 1 million cells 
• Percentage: 76% 
hMSC 
• 400,000 cells 
(w/hiPSC-ECM) 
• 300,000 cells 
(w/hCMVECs) 
• Percentage: 23% / 
38% 
hCMVECs 
• 500,000 cells 
• Percentage: 63% 
• 3D Collagen Cell Carrier 
• hMSC/hCMVECs culture for 
7 days under vascular 
conditions 
• hMSC/hiPSC-ECMs cultured 
for 7 -14 days on top pre-
vascularized cultures 
Advantages: 
• Positive staining for Cardiac MHC 
across the construct 
• Rhythmic contractions 
• Calcium flux monitored across 
system 
Limitations: 
• Cardiomyocyte orientation not 
controlled 




• CD31 Positive cord-like 
structures established  
• Pericyte-like cell stained 
positive for SMA 
• Sequential seeding of 
vasculature cells 
• Positive staining for AcLDL and 
vWF in the tri-culture system 
Limitations: 
• Vasculature is reduced in the 
presence of all three cell types 
144 
hiPSC-CM 
• 14,850 – 23,100 
cells 
• Percentage: 45-70 % 
hCF 
• 0 to 13,200 cells 
• Percentage: 0-40% 
HUVECs 
• 4,950 – 9,900 cells 
• Percentage: 15-30 % 
• 3D Bioprinting (0.32cm3) 
• Single layer of cell 
aggregates (cardiospheres) 
that were 450 to 550 m in 
diameter 
• Printed on Needle Array 
• Cardiac patch was matured 
for 72 hours with needle 
array in place 
Advantages: 
• Electrophysiological parameters 
quantified 
• Ventricular-like action potentials 
• Developed gap junctions (Cx-43) to 
propagate signal as a syncytium 
• Low levels of cell death from 
TUNEL assay 
• Conduction velocity near 4.6 cm/s  
 
Advantages: 
• CD31 staining throughout the 
cardiosphere 
• Nascent vasculature 
development in vivo 
Limitations: 
• Vasculature not quantified  
• Presence of 3D lumens not 
investigate or represented 
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 • Cardiospheres beat after 2 
days and fused after 
removal of needle array 
• Cardiospheres were 
implanted onto myocardium 
and secured with tissue glue 
in vivo  
Limitations: 
• Conduction velocity decreased with 









• 4 M/mL 
• Percentage: 65% 
hPC 
• 0.36 M/mL 
• Percentage: 6% 
 
BOEC 
• 1.82 M/mL cells 
• Percentage: 29% 
 
• Fibrin Hydrogel 
• 8.4mm x 5 mm 
• 4 mg/mL fibrinogen  
• 120µL total volume 
• Bilayer patch was created by 
coating with fibrinogen and 
10U/mL thrombin 
• Grown for 14 days   
Advantages: 
• Bilayer patch resulted in increased 
CM density compared to control 
(237 vs 35 CM/mm2) 
• CM only patches underwent more 
apoptosis than bilayer (75.4% vs 
37.5%) 
• Bilayer patch output was 
2.17nN/input CM vs 0.3 nN/input 
CM 
Limitations: 
• Electrophysiological properties not 
analyzed 
• Alignment of cardiomyocyte 
Advantages: 
• ~34 lumens/mm2 
• ~65 vessels/mm2 in vivo 
• ~67% perfused fraction of 
vasculature 
Limitations: 
• Vasculature developed 
independently of cardiomyocyte 
culture which is not similar to 


















Modular Approach to Vascularized 
Cardiac Tissue: Exploring Cell-Cell 
Interactions in a Tri-Culture System 
 
1. INTRODUCTION:  
 
Cardiac tissue engineering is a promising approach to regenerate the 
damaged myocardium. The native myocardium is composed of many different cell 
types which all play a specific role in the functionality and survival of the organ. 
These cell types include cardiomyocytes, endothelial cells, and fibroblasts 5,6,146. 
Although cardiomyocytes account for the largest volume of cells at 80-90% 147, 
supporting cell types account for the largest number of cells 123,146,148. Endothelial 
cells, which are primarily responsible for blood vessel development, provide the 
heart with nutrient and oxygen supply through the coronary vasculature 149. In 
addition to dense vessel networks, the heart has a large population of fibroblasts. 
Fibroblasts have been shown to make up greater than 50% by number of the 
cellular population in the adult mammalian heart 23,146. Fibroblasts maintain the 
mechanical properties of the heart, provide the structure of the extracellular matrix, 
and produce growth factors 138,140,148,150.  
Previous studies have shown that utilizing the native cellular makeup for 
cardiac muscle improves cardiomyocyte survival, force of contraction, and 
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maximum capture rate of engineered grafts and promotes vascular development 
for possible anastomosis with host vasculature to provide prolonged survival 6,142. 
A delicate balance of cellular ratios is necessary to develop vascularized cardiac 
tissue that is able to maintain normal electrophysiological function while developing 
robust vascular structures149,151–153.  
Fibroblasts have traditionally been excluded from cultures of NRVMs as 
they can impede and/or alter the electrophysiological function (e.g. action potential 
conduction) of cardiomyocytes 154. However, fibroblasts also provide mechanical 
and biochemical support and have at times been intentionally included in co-
cultures with cardiomyocytes 155.  Previous tri-cultures have utilized fibroblasts 
from lung or foreskin as a means to stabilize the nascent vasculature formed by 
endothelial cells  39,49. The source of the fibroblast impacts the levels of pro-
angiogenic factor secretion 20. In several studies mesenchymal stem cells have 
served as fibroblast replacements 33. Bone marrow-derived mesenchymal stem 
cells (BM-MSCs) can be an attractive cell source, but isolations are painful and 
result in low cell yields. BM-MSCs have been shown to aid in the stabilization of 
vasculature in the presence of endothelial cells, but when co-cultured with 
cardiomyocytes have been shown to fuse and reduce the electrophysiological 
properties of cardiomyocytes 156,157. Consequently, there is a need for a cell 
population that has the potential to act as vascular mural cells 158 and does not 
significantly inhibit the electrical functioning of cardiomyocytes.  
Human adipose derived stem/stromal cells (hASCs) are a clinically relevant 
stem cell source that is of mesodermal origin and are available in large quantities 
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upon isolation. They have the ability to differentiate into vascular mural cells 29,31, 
and form gap junctions with electrically excitable cells allowing the electrical signal 
to propagate across and trigger calcium transients 28. The hASCs in co-culture with 
endothelial cells display a pericyte-like phenotype, ultimately stabilizing newly-
formed vascular networks (Merfeld-Clauss et al., 2014, 2010). Crisan et al.  has 
shown that cells derived from white adipose tissue can display perivascular 
markers such as CD146, α-SMA, NG2 and showed negative expression of 
endothelial markers CD31 and CD144 160–162. They also have the ability to 
withstand temporary ischemia, release trophic and paracrine factors, and prevent 
inflammation 136,163. These properties of hASCs suggested that it might be 
beneficial to assess their role as fibroblast replacements in co-culture with 
NRVCMs and HUVECs.  
In this study, we aimed to determine the potential benefits of using hASCs 
relative to dermal fibroblasts to provide vascular stabilization while maintaining the 
electrophysiological properties of cardiomyocytes in a tri-culture system. In the 
development of a vascularized cardiac tissue, prior studies have demonstrated that 
tri-cultures (cardiomyocytes, endothelial cells, and fibroblasts) exhibit significantly 
better outcomes with the development of stabilized vasculature structures, 
decreased excitation threshold, and maintenance of maximum capture rate 
relative to enriched cardiomyocyte populations and co-culture systems in which 
cardiomyocytes and endothelial cells alone were utilized 39,49. We assessed the 
functional outcomes of co-cultures of varying ratios of NRVCM:hASC (and 
NRVCM:hDF) in a well-established monolayer model utilizing optical recordings of 
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transmembrane voltage. We also evaluated the effect of the ratio of hASC:HUVEC 
(and hDF:HUVEC) on vessel length and interconnectivity. This information was 
used to develop a tri-culture system with a ratio of NRVCM:hASC:HUVEC that 
incorporated the benefits of hASCs for vascularized cardiac regeneration while 
maintaining the electrophysiology of enriched cardiomyocyte cultures.  
 
2. MATERIALS & METHODS: 
 
2.1 Isolation of Adipose Derived Stem Cells: 
Isolation of human adipose derived stem/stromal cells (hASCs) was 
performed at the Stem Cell Biology Laboratory, Pennington Biomedical Research 
Center, under an Institutional Review Board approved protocol according to 
published methods 164. Briefly, fresh human subcutaneous adipose lipoaspirates 
were obtained under informed consent from healthy Caucasian female donors with 
a mean age of 47.6 ± 1.9 years and mean body mass index of 27.1 ± 0.6 and 
undergoing elective liposuction surgery. The lipoaspirate tissue was extensively 
washed with warm Dulbecco's phosphate-buffered saline solution (DPBS) to 
remove erythrocytes and then digested in DPBS supplemented with 0.1% 
Collagenase Type I (Worthington), 1% BSA, and 2 mM CaCl2 for one hour at 37°C. 
Following room temperature centrifugation at 300 g and suspension in Stromal 
Medium (DMEM/F-12 (Life Technologies) supplemented with 10% FBS (Atlanta 
Biologicals) and 1% penicillin/streptomycin), the stromal vascular pellet obtained 
from 35 mL of digested lipoaspirate was plated in a T175 flask (0.2 mL per cm2). 
After 24 hours of incubation at 37 °C, 5% CO2, the adherent cells were washed 
with warm DPBS and maintained in Stromal Medium until reaching 80-90% 
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confluency. The adherent population (“passage 0”) was harvested by digestion 
with trypsin with 0.05% EDTA (1 mM) at 37 °C for five minutes, washed with 
Stromal Medium, and cryopreserved for shipment to Johns Hopkins University. 
Prior studies have shown that there are no deleterious effects on hASCs due to 
cryopreservation, such as loss of viability or multipotency 164. For expansion, 
hASCs were thawed and cultured in expansion medium, which consists of DMEM 
high glucose (Life Technologies), 10% FBS (Atlanta Biologicals), 0.5% 
penicillin/streptomycin (Cellgro), 0.5% antibiotic/antimycotic, 1ng/mL Fibroblast 
Growth Factor-2 (bFGF/FGF-2) (PeproTech). Cells were utilized at passage 4 (P4) 
to minimize contamination of heterogenic cell types. 
2.2 Isolation of Neonatal Rat Ventricular Cardiomyocytes: 
All procedures with animals were completed in accordance with the 
regulations set forth by the Johns Hopkins Committee on Animal Care and Use 
along with all state and federal regulations. In brief, Neonatal Rat Ventricular 
Cardiomyocytes (NRVCMs) were enzymatically dissociated from the hearts of 1-3 
day old Sprague Dawley rats (Charles River Laboratories, Frederick, MD) as 
previously described 165,166.   Freshly isolated cells were suspended in NRVCM 
culture media (Medium 199 (Life Technologies), 1% HEPES buffer solution (Life 
Technologies), 1% MEM non-essential amino acids (Life Technologies), 2mM L-
glutamine (Life Technologies), 20μM glucose (Sigma Aldrich), 4g/mL Vitamin B12 
(Sigma Aldrich), 1% Penicillin (Cellgro), and 10% or 2% Heat Inactivated (HI)-FBS 
(Sigma Aldrich)) and pre-plated in flasks twice, for one hour each time in order to 
reduce the proportion of fibroblasts.   
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2.3 Human Umbilical Vein Endothelial Cell Culture: 
A vial of pooled Human Umbilical Vein Endothelial Cells (HUVECs) (Lonza) 
were expanded in tissue culture flasks up to passage 4-5 using Endothelial Basal 
Medium 2 (EBM-2) culture medium (Lonza, USA) supplemented with the 
Endothelial Growth Medium-2 (EGM-2) Bullet Kit (Hydrocortisone, human 
fibroblast growth factor (hFGF)-2, vascular endothelial growth factor (VEGF), R3-
insulin-lke growth factor (IGF)-1, ascorbic acid, human epidermal growth factor 
(hEGF), Gentamicin & Amphotericin (GA-1000), and Heparin) and 2% FBS. 
HUVECs were used for experimentation at Passage 5-6. 
2.4 Fibroblast Expansion and Characterization: 
The human Dermal Fibroblast-BJ Cell Line (hDF) (ATCC) was expanded in 
tissue culture flasks up to passage 5 (P5) using DMEM (Life Technologies), 10% 
FBS (Atlanta Biologicals), and 0.5% penicillin/streptomycin (Cellgro), 0.5% 
antibiotic/antimycotic (Life Technologies). The cells were examined for CD73, 
CD90, and CD105 as mesenchymal markers, CD31, CD34, and CD309 as 
vascular markers. 
2.5 Flow Cytometric Analysis of hASCs and hDFs: 
Cells were detached with 0.05% Trypsin/EDTA and washed with phosphate 
buffer saline (DPBS) containing 2% FBS. They were then incubated with 
monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC) or 
phycoerythrin (PE) to detect mesenchymal markers (CD73, CD90, and CD105) or 
vascular markers (CD31, CD34, and CD309 (VEGFR2)) for 30 minutes at 4 °C. 
Similarly conjugated isotype controls (BD Biosciences) were used as negative 
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controls. After incubation with the antibodies, cells were washed three times for 5 
minutes each with DBPS containing 2% FBS, then analyzed with the BD Accuri 
C6 flow cytometer.  
2.6 Co-Culture and Tri-Culture Experiments: 
Cells were plated onto bovine fibronectin (5mg/mL diluted in cold distilled 
water) (Sigma Aldrich)-coated 14 mm-diameter plastic coverslips that were placed 
in 24 well plates.  All studies were performed on 2cm2 surfaces. We will utilize the 
consistent nomenclature – thousands of NRVCM:hASC:HUVEC (or 
NRVCM:hDF:HUVEC) per  cell culture well – to describe co-culture and tri-culture 
cell plating densities throughout the manuscript. Therefore, for NRVCM:hASC co-
cultures, the HUVEC concentration is reported as zero. Likewise, in hASC:HUVEC 
experiments, the NRVCM numbers are reported as zero. The design of the 
protocol was based on keeping the total number of NRVCMs constant. The results 
of the co-culture studies were used to obtain the input cell ratios for the tri-culture 
studies (Fig 1). 
2.7 NRVCM-hASC/hDF Co-Culture:  
NRVCMs were plated at a concentration of 500,000 cells in NRVCM 
medium containing 10% FBS. This number of NRVCMs was determined to form a 
confluent monolayer and was kept constant in all experiments. On the next day, 
different amounts of hASCs were plated on top of the NRVCMs resulting in ratios 
of 500:500:0, 500:250:0, 500:100:0, 500:50:0, and 500:0:0. An hASC-only well 
(0:500:0) was utilized as a negative control. Medium was switched to 2% FBS-
containing medium, to reduce fibroblast proliferation, on the following day and 
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refreshed every other day. Upon day 5-8, cells were assessed using optical 
mapping and were fixed with 4% paraformaldehyde for immunocytochemistry 
analysis. These studies were used to assess the maximum number of hASCs that 
could be added without causing significant changes in electrophysiology. To 
compare hASCs and hDFs, the studies were repeated for hDFs with cell ratios of 
500:100:0 and 500:50:0.  
2.8 hASC/hDF-HUVEC Co-Culture:  
hASCs and HUVECs were mixed together in ratios of 0:100:100, 0:100:50, 
0:100:20, 0:100:10, 0:50:50, 0:50:25, 0:50:10, and 0:50:5, and plated on coated 
cover slips. A HUVEC-only control 0:0:100 or 0:0:50 was included. The constructs 
were cultured in vitro for 7 days and fed every other day with EGM-2 (Lonza).  
2.9 NRVCM /hASC/HUVEC Tri-Culture: 
NRVCMs were plated at a concentration of 500,000 cells in NRVCM media 
containing 10% FBS. On the following day, the media was removed, and coverslips 
were washed with DPBS prior to simultaneously plating hASCs and HUVECs to 
give final ratios of 500:100:50, 500:100:20, 500:100:10, 500:50:25, 500:50:10, 
500:50:5. Two additional controls were included: no hASCs (500:0:50) and 
NRVCM only (500:0:0). Tri-cultures were fed EGM-2 (Lonza) media containing 2% 
HI-FBS (Sigma Aldrich), 20μM glucose (Sigma Aldrich), 0.5% 
penicillin/streptomycin (Cellgro), and 0.5% antibiotic/antimycotic (Life 
Technologies). Culture media was refreshed every other day.  
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2.10 Optical Mapping: 
Co-cultures and tri-cultures containing NRVCMs were optically mapped 
using voltage-sensitive dye in order to record changes in their transmembrane 
voltage and visualize their excitation and repolarization (Tritthart, 2005). Optical 
mapping was performed on days 5-8. Coverslips containing cell monolayers were 
stained with 10 μM of the voltage-sensitive dye di-4-ANEPPS (Invitrogen), in 
Tyrode’s solution for 10 minutes at 37 °C while being protected from light.  
After staining, the dye solution was removed, cells were washed with 
Tyrode’s solution, and placed on a heated stage in Tyrode’s solution with 5 μM 
blebbistatin to prevent motion artifacts due to contraction. Optical mapping was 
performed using a CMOS camera (MiCAM Ultima, Scimedia, Costa Mesa, CA). 
Cells were electrically stimulated by placing a bipolar point electrode near the edge 
of the coverslip, out of the field of view of the camera, and paced starting at 0.5 Hz 
and incrementally increased by 0.5 Hz. At each new pacing rate, the cell 
monolayers were stimulated for 1 minute to achieve steady state before an optical 
recording was taken. Pacing rate was increased until the ability of the sample to 
be captured at the pacing rate (i.e., action potential response with each pacing 
pulse) was lost or reentrant spiral waves were formed.  
2.11 Immunocytochemistry: 
On day 7, or after mapping, if applicable, co-cultures and tri-cultures were 
fixed in 4% paraformaldehyde for 20 minutes at room temperature. After removing 
formaldehyde, cells were washed three times with DPBS for 30 minutes each time. 
Samples were permeabilized with 0.2% Triton X-100 (Sigma Aldrich) for 10 
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minutes and then blocked with 10% normal goat serum (Sigma Aldrich) in DPBS 
for 30 minutes. Coverslips were then incubated overnight at 4 C with 1) mouse 
(Ms) anti-Sarcomeric α-Actinin [1:200] (Sigma Aldrich), rabbit (Rb) anti-Connexin-
43 [1:100] (Sigma Aldrich), or 2) mouse anti-Vimentin [1:200] (Dako) and TRITC 
conjugated Phalloidin [1:50] (Sigma Aldrich), or 3) mouse anti-CD31 [1:250] 
(Sigma Aldrich). Primary antibodies were diluted in DPBS with 5% normal goat 
serum. Coverslips were washed three times with DPBS, then incubated overnight 
at 4°C with secondary antibodies DyLight 488-conjugated goat anti-mouse [1:200] 
and DyLight 649-conjugated goat anti-rabbit [1:200] (Jackson ImmunoResearch) 
that were diluted in 5% normal goat serum in DBPS. Samples were washed three 
times with DPBS and then incubated for 10 minutes at room temperature with DAPI 
[1:2000] (Sigma Aldrich) diluted in DPBS. Following the initial round of 
immunostaining, the samples stained with mouse anti-Sarcomeric α-Actinin and 
rabbit anti-Connexin-43 were further blocked in 5% normal mouse serum in DPBS. 
Following blocking, samples were incubated with Cy3 conjugated mouse anti-α 
Smooth Muscle Actin [1:400] (Sigma Aldrich) diluted in 5% normal mouse serum 
in DPBS incubated overnight at 4 °C. Coverslips were subsequently washed three 
times with DPBS. Samples were mounted with mounting medium and imaged 
under a Zeiss Axio Observer inverted fluorescence microscope or a Zeiss LSM 
510 confocal microscope with 5x, 20x, and 40x objectives. 
2.12 Image Analysis: 
5x z-stacks were taken with 15 m spacing, while 20x z-stacks had 3 m spacing.  
Immunostained images were z-projected and thresholded in order to calculate 
   - 53 - 
vessel parameters including network length and junctions in the 3,240 mm2 imaged 
region. Thresholded images were subsequently analyzed with AngioQuant 
software to determine the total vessel length, area, and interconnectivity. Using a 
custom Image J macro, connexin 43 (Cx-43) stained images were thresholded, 
and the number of stained foci were calculated. Cx-43 foci counts were divided by 
the area to report as Cx-43 foci/mm2. 
2.13 Statistical Analysis: 
Quantitative data is reported as the mean +/- the standard deviation. One-
way ANOVA with Dunnett’s post-hoc test or Tukey’s post-hoc test was performed 
to determine statistical difference between testing groups.  Differences were 
considered statistically significant at *p < 0.05; **p < 0.01; ***p < 0.001.  
3. RESULTS: 
 
3.1 Effect of hDFs and hASCs on electrophysiological parameters of 
cardiomyocytes.  
 
NRVCMs and hASCs were plated on sequential days, as described in the 
Methods, at varying ratios in order to determine the maximum number of hASCs 
that did not induce a statistically significant decrease in the conduction velocity or 
change in action potential duration when compared with NRVCM-only cultures. 
During testing, the action potential durations at 80% repolarization (APD80) during 
1 Hz pacing were significantly longer in the 500:500:0 (325 ± 42 ms) and 500:250:0 
groups (268 ± 64 ms) relative to the 500:0:0 (cardiomyocyte only) group (168 ± 17 
ms). APD80 of the other co-culture ratios, 500:100:0 (201 ± 30 ms) and 500:50:0 
(188 ± 13 ms) was not significantly different from that of the cardiomyocyte-only 
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group (Fig. 2A). Similar trends occurred with APD30  with values of  137 ± 26 ms 
(500:500:0),  83 ± 29 ms (500:250:0), 56 ± 9 ms (500:100:0), 50 ± 9 ms (500:50:0), 
and 48 ± 10 ms (500:0:0)  (Fig. 2A) (n=2-6) . These trends held at other pacing 
rates as seen in Fig. S1A. Maximum capture rate (MCR) decreased from roughly 
4 ± 0.4 Hz (500:0:0) to 1.5 ± 0.03 Hz  (500:500:0) with the addition of 500,000 
hASCs. MCRs were statistically indistinguishable in the 500:250:0, 500:100:0, 
500:50:0, and 500:0:0 groups but exhibited a statistically significant decrease in 
the 500:500:0 group (Fig. S1C).  
Based on these results, we compared the effects of co-culturing NRVCMs 
with hDFs or hASCs using a subset of these cell ratios – 500:100:0 and 500:50:0 
– as these groups did not exhibit significant increases in APD80 or APD30 compared 
to the cardiomyocyte-only cultures. Flow cytometry was performed to characterize 
the two cell populations.  P5 hDFs and P4 hASCs were primarily positive for 
mesenchymal markers, CD73 (99.4%/ 99.8%), CD90 (99.9%/ 99.9%), and CD105 
(99.9%/ 92.8%), respectively and mostly negative for vascular markers CD31 
(0.39%/0.02%), CD34 (0.01%/ 1.6%), and CD309/VEGFR2 (0.23%/ 0.08%) (Fig. 
2B) (n=3). Immunocytochemistry revealed the presence of hDFs and hASCs in the 
co-cultures via positive staining for vimentin, a marker of fibroblast-like cells (Fig. 
S2A).  APD80 and APD30 values were significantly shorter in the hASC co-cultures 
compared to the hDF co-cultures at both cell ratios. At 1.5 Hz, APD80 was 173 ± 
12 ms (500:100:0) and 169 ± 15 ms (500:50:0) for NRVCM:hDF co-cultures, 
compared to 126.5 ± 27 ms and 125.6 ± 27 ms for NRVCM:hASC cultures at 
500:100:0 and 500:50:0 ratios, respectively (Fig. 2C, D). The NRVCM only control 
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resulted in an APD80 of 112 ± 20 ms. APD30 ranged from 57 ± 5 ms in the 500:100:0 
mixture containing hDFs to 40 ± 7 ms 500:50:0 containing hASCs, while APD30 was 
consistently near 47 ± 11 ms in the NRVCM only control group (500:0:0) (Fig. 2E). 
The conduction velocity (CV) at all pacing rates was maintained between 15 ± 2 
and 19 ± 2 cm/s in both NRVCM:hDF and NRVCM:hASC co-cultures with no 
significant differences between groups (Fig. 2F,G). The NRVCM-only group 
(500:0:0) had CVs ranging from 15.7 ± 6 to 20.6 ± 7 cm/s at pacing rates from 0.5 
Hz to 2.0 Hz (Fig. 2F,G) (n=4-6). 
We were able to pace co-cultures with hASCs at faster rates (MCR=5 ± 1.5 
Hz for 500:100:0 and 6 ± 1.3 Hz for 500:50:0 ratio) than co-cultures containing 
hDFs (2.08 ± 0.7 Hz and 3 ± 1.6 Hz, respectively, Fig. 2H). We also noted 
NRVCM:hASC co-cultures exhibited increased expression of Cx-43, (500:100:0 
and 500:50:0) as compared to NRVCM:hDF co-cultures (Fig. S2B, C). Although 
there was increased expression of Cx-43 in the NRVCM:hASC co-culture relative 
to pure NRVCM cultures, there were no significant differences in conduction 
velocity compared to NRVCM:hDF co-cultures.  Other pacing rates exhibited 
similar trends (Fig. S3). 
3.2 Effect of hASC and HUVEC concentration on vessel formation.  
To determine the effects of cellular concentration on vessel assembly, we 
co-cultured hASCs and HUVECs. Two hASC seeding densities were used – 
100,000 cells/well or 50,000 cells/well – as these were the numbers of hASCs that 
did not significantly increase the APD80 of the cardiomyocytes in the 
NRVCM:hASC co-cultures (Fig. 2A). Various numbers of HUVECs were tested 
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with these hASC concentrations.  At a HUVEC density of 10,000 cells per well, 
vessel length increased when more hASCs were seeded (Fig 3B). For 
hASC:HUVEC co-cultures containing 100,000 hASCs/well, vessel lengths and 
number of junctions both increased with decreasing amounts of HUVECs (Fig 
3B,C). No vessels were formed in HUVEC-only controls. Staining in Fig. 3A shows 
that the endothelial cells have not yet formed vasculature structures. For 
hASC:HUVEC co-cultures with only 50,000 hASCs/well, the opposite results were 
observed, and vessel lengths and number of junctions both decreased with 
decreasing amounts of HUVECS (Fig 3B,C).  hASCs in co-culture with HUVECs 
appeared to take on a pericyte-like cell phenotype and stained positively for -
smooth muscle actin (Fig S4). Similar ratios were tested with dermal fibroblasts 
and resulted in vessels structures that did not develop like those in groups with 
hASCs (Fig S5). 
3.3 Effect of tri-culture on cardiomyocyte electrophysiology.  
Based on the results of our initial studies, tri-cultures were established using 
only hASCs and not hDFs. The NRVCM:hASC:HUVEC ratios were determined by 
the previous co-culture studies and included (i) the amount of hASCs that did not 
significantly increase the APD80 (50,000 and 100,000) and (ii) the ratios of 
hASCs:HUVECs that allowed for formation of robust vasculature. The study 
employed six ratios of NRVCM:hASC:HUVEC in addition to no hASC controls 
(500:0:50) and NRVCM only controls (500:0:0). Samples were stained with 
CD31/PECAM-1 to indicate endothelial cell elongation and connectivity of 
endothelial cells. Groups which formed vessel networks included 500:100:50, 
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500:100:20, 500:100:10, 500:50:25, and 500:50:10 ratios (Fig 4A). Samples were 
also stained  for Cx-43 and CD31, revealing that Cx-43 positive loci were present 
near CD31-positive cells, and thus, that gap junctions, sites of the electrical 
connections of the cardiomyocytes, formed in close proximity to nascent 
vasculature (Fig. 4A). Generally, vessel lengths decreased when the ratio of 
hASCs:HUVECs increased. There were no vessels detected in the ratios of 
500:50:5, 500:0:50, and 500:0:0 (Fig 4B). Vessel interconnectivity was determined 
by the number of junctions, which also tended to decrease when the ratio of 
hASCs:HUVECs increased (Fig 4C). We found that the 500:50:25 ratio ultimately 
provided the best vessel assembly with the longest vessel length and supporting 
one of the higher amounts of interconnectivity extrapolated through number of 
junctions. In this group, average total vessel length was 70 mm per 3,240 mm2, 
and vessel networks had an average of 454 junctions (n=3).  
Following tri-culture vessel characterization, electrophysiological properties 
of the tri-cultures were evaluated. There was no statistical difference in APD80 of 
any of the tested tri-culture groups as compared to the cardiomyocyte-only control 
(120 ± 9 ms at 1.5 Hz pacing rate) (n=4-6)  (Fig. 5A,B). Although no level of 
significance was reached, there appeared to be a trend of increasing APD80 with 
more hASCs present in cultures. The APD30 values were measured and calculated 
similarly. All tri-culture groups’ APD30 values were not significantly different from 
the NRVCM only control (51 ± 5 ms at 1.5 Hz pacing rate) (n=4-6) (Fig. 5C). Similar 
trends were noted at the 2 Hz pacing rate for both APD80 and APD30 (Fig S6A,B,). 
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 CVs of the ratios 500:50:25 and 500:0:50 were not statistically different 
when compared to the NRVCM control (500:0:0), while all other groups had 
significantly lower CVs (25 ± 1 ms at 1.5 Hz pacing rate for control) (Fig 5D,E). 
MCR was not significantly different between groups and fell between 6.7 ± 0.8 Hz 
(500:100:50) and 7.2 ± 0.2 Hz (500:0:0) (n=4-6) (Fig 5F). Similar trends were noted 
at the 2 Hz pacing rate for CV (Fig S6C). 
4. DISCUSSION: 
Previous tri-cultures have utilized either embryonic stem cell-derived 
cardiomyocytes (ESC-CM) or NRVCMs with endothelial cells that were either 
embryonic stem cell-derived (ESC-EC) 6,142, or mature, such as HUVECs 142. For 
example, Caspi et al. (2007) developed a tri-culture system with ESC-CMs, ESC-
ECs, and mouse embryonic fibroblasts (MEFs) cultured on poly(l-lactic-
acid)/poly(lactide-co-glycolide) PLLA/PLGA scaffolds. MEFs provided vascular 
stabilization, increased proliferation, and reduced apoptosis of ESC-ECs, and the 
presence of stabilized vasculature correlated with increased cardiomyocyte 
proliferation.  Additionally, Iyer et al. (2009a; 2009b; 2012) investigated 
simultaneous seeding and sequential seeding of tri-culture systems. Simultaneous 
seeding of all three cell types impeded the development of gap junctions between 
cardiomyocytes and resulted in the presence of rounded cardiomyocytes with no 
ability to contract. Just as importantly, simultaneous seeding of cardiomyocytes 
with endothelial cells and fibroblasts resulted in endothelial cells that did not 
elongate to form vessel-like structures. However, when cardiomyocytes were 
seeded first and allowed to attach and form electrical connections with each other 
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prior to adding other cell types, they elongated and expressed the gap junction 
protein Cx-43, and cardiac troponin. Thus, we utilized a sequential seeding 
approach, where a high density of NRVCMs was plated into each well one day 
prior to the addition of co-culture or tri-culture cells. In hASC-HUVEC co-cultures, 
cells were seeded simultaneously. The main objectives of this study were to 
assess the potential for using hASCs as a suitable cell source for vascular 
stabilization in tri-cultures with HUVECs and NRVCMs and to determine the 
appropriate cell ratios required for the development of vascularized cardiac 
tissues.  The key success criteria were that the tri-cultures should be capable of 
maintaining similar electrophysiological function (maintenance of repolarization 
rates and maximum capture rates) compared to NRVCM-only controls and 
simultaneously demonstrate the presence of well-developed vascular structures.   
Previous studies have also used hDFs with endothelial cells to establish in 
vitro models of vasculogenesis 172,173 though, more recently, studies of vascular 
co-culture have shown that hASCs outperform hDFs and SMCs as vascular 
support cells 29. Previously published studies of tri-culture systems with NRVCM 
and endothelial cells used primary cardiac fibroblasts 49 and embryonic fibroblasts 
142 as vascular support cells. Therefore, in our studies, we compared hASCs to the 
hDF cells to incorporate the functionality of the previous tri-culture systems with 
the improved vascular support of hASCs. Previous studies have also 
demonstrated the potential of hASCs to act as cardiomyocyte support cells 28 as 
well as perivascular cells to maintain the stability of nascent vascular structures 
formed by endothelial cells 30–32. To determine an upper limit of their role as support 
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cells, we probed the maximum concentration of hASCs that could be added to pure 
cultures of NRVCMs before the electrophysiological properties of the NRVCMs 
would be significantly compromised. Typically, co-cultures of cardiomyocytes with 
fibroblasts or fibroblast-like cells in culture have increased action potential 
durations and reduced conduction velocities 174. Similarly, we found that NRVCMs 
co-cultured with either hASCs or hDFs at concentrations above a threshold level 
had similar CVs but shorter action potential durations than NRVCM-only control 
groups. hASC concentrations that exceeded 20% of the cardiomyocytes reduced 
the maximum capture rates, increased the duration of action potentials, and 
reduced the rates of conduction (Fig S1). This led us to conduct further studies 
with NRVCM:hASC co-cultures at ratios of 20% or less (500:100:0 and 500:50:0). 
When hASCs were directly compared with hDFs, we found that hDFs had 
significantly lower maximum capture rates and significantly longer repolarization 
times at equivalent concentrations. hASCs thus proved to be a more attractive cell 
source than hDFs for tri-culture systems. It is interesting to note that co-cultures of 
NRVCMs with hASCs exhibited increased Cx-43 expression, relative to 
NRVCM:hDF co-cultures (Fig. S2). However, further experiments are needed to 
identify the exact underlying mechanisms for improved outcomes with hASCs as 
opposed to hDFs.  
To assess the effect of hASCs on the development of vascular structures, 
we co-cultured them with HUVECs. Prior studies have reported that EPCs or 
HUVECs co-cultured with hASCs developed robust vascular structures in cell 
monolayers 29,30. These findings indicated that hASCs can act as a vascular mural 
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cell which contributes to the development and stabilization of cord-like vessel 
structures. Mechanistically, hASCs promote vascular development by paracrine 
signaling 25,160, including growth factor secretion 175, and direct cell-cell contact (for 
stabilization) with the endothelial cells 29–31,175. Vessel development occurred at all 
tested ratios of hASC:HUVEC co-cultures. In these studies, we kept the initial 
numbers of hASCs constant at 100,000 cells/well and 50,000 cells/well to be 
consistent with the hASC numbers that did not significantly alter APD, CV and 
MCR in the NRVCM:hASC studies. There were measurable differences in the total 
vessel length and interconnectivity among the various ratios. However, no general 
trends emerged: when 100,000 hASCs were used per well, lower numbers of 
endothelial cells resulted in longer vascular structures, while the opposite was true 
when 50,000 hASCs/well were used. However, HUVECs were unable to form 
network structures in the absence of hASCs. When hDFs were used in lieu of 
hASCs, the ability of HUVECs to form vascular structures was significantly lower 
(Fig. S3). Our study did not assess the mechanistic reason for this difference in 
pro-angiogenic potential of hASCs and hDFs. However, prior studies suggest that 
hASCs may secrete higher concentrations of VEGF than hDFs 136. Another study 
compared co-cultures of EPCs and hASCs to co-cultures of EPCs and hDFs, and 
found that total tube length and branch points were significantly decreased in the 
dermal fibroblast group 29. We note that the vascular structures developed in our 
cultures are two-dimensional and may not contain lumens. However, the data 
gleaned from this study provides fundamental insights for subsequent studies in 
3D scaffolds and hydrogel systems.  
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These two co-culture studies of NRVCM:hASC and hASC:HUVEC,  were 
used to provide starting cell ratios for the tri-culture system. Based on the superior 
performance of hASCs relative to hDFs in both NRVCM and HUVEC co-culture 
systems, we did not assess the efficacy of hDFs in our tri-culture studies. The 
concentrations of NRVCMs were maintained constant at 500,000 cells/well and 
plated a day prior to the addition of hASCs and HUVECs. Based on NRVCM:hASC 
co-culture studies, we tested only two concentrations of hASCs (50,000 cells/well 
and 100,000 cells/well). We assessed three hASC:HUVEC ratios 
(0:100:50/0:50:25; 0:100:20/0:50:10, and 0:100:10/0:50:5), and consequently, 
HUVEC seeding densities varied from 5,000 cells/well up to 50,000 cells per well. 
The six resulting ratios for the tri-culture were compared to cultures of pure 
NRVCMs. Interestingly, the relative cell numbers in the tri-cultures do not reflect 
the reported cell ratio for the native myocardium. The   total number of NRVCMs 
found in our monolayer cultures is necessary for high levels of connectivity possibly 
due to the limited proliferative potential of NRVCMs compared to hASCs and 
HUVECs 176. We found that vessels developed in all tri-culture groups except for 
500:50:5, where the number of endothelial cells may have been too low. Likewise, 
the absence of hASCs from the cultures (500:0:50) resulted in no vascular 
structures forming indicating that the hASCs were essential for vascular 
morphogenesis in these cultures. Vessel development was highest at the ratio of 
500:50:25.  While previous studies suggest that VEGF-VEGFR2 signaling 
correlates with increased Cx-43 expression and maintenance of 
electrophysiological function (i.e. excitation threshold and maintenance of 
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maximum capture rate) 171, our tri-cultures maintained relatively similar conduction 
velocities and maximum capture rates, however, increased concentrations of non-
cardiomyocytes resulted in increased repolarization times. 
5. CONCLUSION: 
The high metabolic demands of the myocardium require robust 
vascularization to maintain survival/viability, maintain force of contraction, and 
prevent necrosis due to ischemia in deeper layers of the engineered tissue. 
Therefore, a tissue engineered cardiac tri-culture must include a ratio of cells that 
maximizes formation of nascent vasculature without compromising 
electrophysiological function of the graft. Multiple cell types are essential for 
complex tissue assembly, but they should not interrupt the formation of functional 
cardiac syncytium. In this study, we demonstrated that a 500:50:25 ratio of 
NRVCM:hASC:HUVEC facilitated the development of a graft with unaltered 
electrophysiological parameters with dense capillary-like vessel structures. The 
success of this tri-culture system was supported by the use of hASCs, which 
played a critical role as a vascular mural cell that did not impede the electrical 
activity of cardiomyocytes, as fibroblasts do. Additionally, hASCs performed 
significantly better than dermal fibroblasts in forming vascular networks and 
maintaining electrophysiological properties that were similar to cardiomyocyte only 
controls. These findings suggest that ASCs may be a highly suitable cell source 
for use in future tri-culture studies for engineering functional, vascularized 
myocardium. 
  





Figure 1: Schematic of Experimental Design: Co-culture experiments were 
used to compare the effects of hASCs and hDFs on NRVCM electrophysiology 
and on vessel formation. The cell ratios obtained from co-culture studies were used 
to inform the inputs for the NRVCM:hASC:HUVEC tri-culture system.  
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Figure 2: Effects of NRVCM:hASC and NRVCM:hDF ratios on 
electrophysiological function. (A) APD80 and APD30 values for different 
NRVCM:hASC:HUVEC ratios at a pacing rate of 1 Hz (n=3-5). NC = not captured. 
*= p < 0.05 compared to 500:0:0.  The red box indicates the groups that were used 
in subsequent studies as the electrophysiological parameters were not statistically 
different from NRVMs only. (B) Phenotypic profile of P5 hDFs and P4 hASCs. 
Mesenchymal markers are CD73, CD90, and CD105, while vascular markers are 
CD31, CD34, and VEGFR2. (C) Action potential traces showing shorter durations 
in hASCs co-cultures relative to hDF co-cultures. (D) Comparison of APD80 among 
different experimental groups (n=5-6), *= p < 0.05; **p < 0.01; ***p < 0.001. (E) 
Comparison of APD30 among different experimental groups (n=5-6) (F) 
Representative activation maps of selected cell ratios with isochrones 5 ms apart. 
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(G)  Comparison of conduction velocities among different experimental groups *= 
p < 0.05; **p < 0.01; ***p < 0.001. (H) Maximum captured rates at identical ratios 
of NRVCM:hASC:HUVEC and NRVCM:hDF:HUVEC. *= p < 0.05 compared to 
identical ratio of NRVCM:hDF:HUVEC.  
 
Figure 3: Effect of hASC:HUVEC ratios on vessel formation: A) 
Immunofluorescent staining of CD31 positive vascular structures (green) and cell 
nuclei (DAPI; blue). Scale Bar is 200 µm. B, C) Quantification of vessel structure 
based on length (n=3)  (B) and interconnectivity (n=3)  (C). ND designates not 
detected. *p < 0.05; **p < 0.01; ***p < 0.001.  
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Figure 4: Vessel formation in Tri-Culture System: A) Immunofluorescent 
staining of CD31 positive vascular structures (green), connexin-43 (Cx-43; purple), 
and cell nuclei (DAPI; blue). Scale Bar is 200 µm. --- surrounds groups with no 
hASCs present that were cultured as controls. B, C) Quantification of vessel 
structure based on length (n=4-6)  (C) and interconnectivity (n=4-6)  (D). ND 
designates not detected. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Figure 5: Effects of tri-culture ratios on electrophysiological function:  Effects 
of tri-culture ratios on A). Representative action potential traces of all selected 
ratios.  B). APD80 (n=4-6), C) APD30 (n=4-6), D). Activation maps of selected ratios 
with isochromes 5 ms apart E). conduction velocity at 1.5 pacing rates (n=4-6). F). 
Assessment of maximum capture rate for various tri-culture ratios. *p < 0.05 
compared to the cardiomyocyte only group (500:0:0).  
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Supplementary Figure 1: Effect of NRVCM:hASC ratios on 
electrophysiological function at different pacing frequencies. A). APD80 and 
APD30 values (n=3-5). B). Conduction velocities (n=3-5).  C). Maximum capture 
rates. * p < 0.05; **p < 0.01; ***p < 0.001 compared to the cardiomyocyte only 
group (500:0:0) D). Representative action potential traces of all selected ratios. 
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Supplementary Figure 2: Immunofluorescent staining of NRVCM:hASC and 
NRVCM:hDF co-cultures. A) Immunofluorescent staining of vimentin (green), F-
actin (red), and DAPI (blue) in co-cultures. B) Immunofluorescent staining of αSMA 
(red), connexin 43 (purple), α-actinin (green) and DAPI (blue) in co-cultures. Scale 
Bar is 200 µm. C). Quantification of connexin43 (Cx-43) expression.  
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Supplementary Figure 3:  Comparison of the electrophysiological impact of 
hASCs and hDFs co-cultured with NRVCMs. A). APD80 values of NRVCM:hDF 
and NRVCM:hASC co-cultures at various pacing rates. B). APD30 values of 
NRVCM:hDF and NRVCM:hASC co-cultures at various pacing rates. C). 
Conduction velocity values of NRVCM:hDF and NRVCM:hASC co-cultures at 
various pacing rates. NC = not captured. *= p < 0.05 compared to identical ratio of 
NRVCM:hDF:HUVEC (n=5-6).  
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Supplementary Figure 4: hASC:HUVEC co-culture results in pericyte-like cell 
phenotype in hASC. Immunofluorescent staining of CD31 (green), αSMA (red), 
and DAPI (blue) showing pericyte-like differentiation of hASCs in close proximity 
to CD31 cells. Scale Bar is 200 µm. 
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Supplementary Figure 5: Effect of hDF:HUVEC ratios on vessel formation. 
Immunofluorescent staining of CD31 positive vascular structures (green) and cell 
nuclei (DAPI; blue). Scale Bar is 200 µm. 
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Supplementary Figure 6: Electrophysiological properties of various tri-
culture ratios paced at 2 Hz. A). APD80 values of NRVCM:hASC:HUVEC tri-
cultures at 2 Hz. B). APD30 values of NRVCM:hASC:HUVEC tri-cultures at 2 Hz. 
C). Conduction velocity values of NRVCM:hASC:HUVEC tri-cultures at 2 Hz. *= p 
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Myocardial Infarction (MI) is one of the leading causes of death in the Western 
world.1 According to the Center for Disease Control (CDC), there are nearly 
790,000 infarcts that occur annually, with  approximately 500,000 of those being 
first time MI. During MI, occlusion of the coronary arteries causes apoptosis and 
necrosis of cardiomyocytes which, due to the limited endogenous regenerative 
potential of the myocardium, ultimately results in a fibrotic response and ventricular 
wall thinning. 177 Cardiac tissue engineering is a promising approach to repair the 
infarcted area and attempts to restore lost functionality.  Several strategies have 
been used to regenerate the damaged myocardium and these range from direct 
injections of cells suspended in saline to biomaterial-based strategies. 2,50,178 The 
use of biomaterials is generally considered to be more promising. However, due 
to the complex architecture of the native myocardium, it may be necessary to 
employ multifaceted scaffold designs to guide regeneration of fully functional 
tissues.  Key features of cardiac scaffolds that may be controlled to maximize the 
regenerative response include alignment topography, compliance, 
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biodegradability, flexibility, and the ability to integrate with the native myocardium 
46.   
 Fibrin is an attractive biomaterial substrate for engineering vascularized 
cardiac grafts due to its mechanics, degradation and remodeling properties, and 
its ability to promote both cell survival and angiogenesis 137,141,179. Fibrin based 
scaffolds exhibit strain stiffening behavior similar to that displayed by the 
myocardium 155 and have the ability to undergo remodeling and degradation as the 
cells secrete their own extracellular matrix (ECM) over time. Fibrin has been shown 
to stimulate the secretion of extracellular matrix 141. Recently, fibrin has been 
electrospun into microfibers, which are extruded on the range of ~10m. The 
electrospun microfibers offer tunable mechanical properties in the range of the 
native myocardium (10-20 kPa in the short myofiber direction and 40-50kPa in the 
long microfiber direction 48,180,181). Substrate mechanics influences cell maturation, 
action potential duration, contractility 75,182,183, gene expression and twitch force 
184,185. Electrospun microfibers can also mimic alignment cues, flexible geometry, 
and the structure of the native ECM 58.  
Contraction of the myocardium is mediated by tightly packed interconnected 
cardiomyocytes. 186 The high metabolic demands of the cardiomyocytes are 
supported by densely packed vasculature (endothelial cells supported by vascular 
mural cells) 187. Likewise, the survival of tissue engineered grafts relies on the 
development of interconnected capillary networks that can anastomose quickly 
with the host vasculature upon implantation 35,152. Therefore, the objective of these 
studies is to engineer contractile myocardial grafts with dense vascular network 
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assembly capable of integrating with the native myocardium and enhancing tissue 
function following MI. To accomplish this goal, we work with electrospun fibrin 
microfiber sheets of two varying stiffness that correlate with physiologic and 
pathophysiologic myocardial tissues. We used these to test the effect of elastic 
modulus on tissue assembly. We hypothesized that the softer substrate would 
provide increased electrophysiological parameters and increased functionality 
compared to the stiffer substrate. 57,145,185 To establish the vascular network, we 
incorporated human adipose-derived stem cells (hASCs) and human umbilical 
vein endothelial cells (HUVECs) with neonatal rat ventricular cardiomyocytes 
(NRVCMs). We assessed the contractile and histologic properties of the resulting 
grafts and implanted them in vivo to evaluate their potential for regenerating 
functional myocardial tissues.  
2. MATERIALS & METHODS: 
2.1 Fibrin Microfiber Sheet Production: 
Fibrin microfiber sheets were formed using two different fibrinogen concentrations. 
The 0.75% fibrin microfiber sheets were spun using a solution of 0.75 wt% 
fibrinogen in 0.2% PEO while the 2.0% fibrin microfiber sheets were generated 
using 2.0 wt% fibrinogen. PEO is prepared as a 1.0 wt% stock in DI water that is 
dissolved over several days at 37°C. To prepare at 0.75 wt% fibrinogen precursor 
solution, ~9 mg of fibrinogen is added to an empty 2 ml round bottom Eppendorf 
tube (~24 mg added for 2.0 wt% fibrinogen). Once added, the fibrinogen was 
dissolved by adding 1.2 ml of 0.2 wt% PEO to the 2 ml Eppendorf tube, which was 
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then placed in a 37°C water bath for at minimum least 15 minutes to ensure 
dissolving into solution. 
Following dissolution of the fibrinogen, the precursor solutions were sterile filtered 
into autoclaved round bottom Eppendorf 2 ml tubes using a 0.22 µm filter. The 
filtered fibrinogen was loaded into a 1 cc syringe and large air bubbles were 
dislodged by gently moving the syringe plunger back and forth while the syringe is 
facing upwards. The syringe was then loaded onto a syringe pump set to dispense 
at a rate of 5.0 ml/hr for 0.75 wt% fibrinogen or 3.25 ml/hr for 2.0 wt% fibrinogen. 
A collection solution of 20 U/ml thrombin in 50 mM CaCl2 was prepared by 
dissolving 1 ml of a 1000 U/ml thrombin stock solution into 50 ml of sterile filtered 
50 mM CaCl2. The DC motor controller was turned on and the power to the 
collection wheel motor was increased until the wheel was rotating at ~45 RPM, at 
which point the 50 ml collection solution was added. The linear stage upon which 
the syringe pump sits was powered on and begins rastering at a rate of ~ 3 cm/min 
over a distance of 1.5 cm. The syringe pump was set to run and begins dispensing 
the fibrinogen solution at which point the power supply was turned on and set to 
4.5 kV to initiate jet formation. 
Fibrin microfibers were developed by extruding fibrinogen from a syringe  onto a 
rotating stage containing thrombin and calcium chloride for crosslinking (Figure 
1A,D). The solutions were electrospun onto the collector for 17 minutes when 
using 2.0 wt% fibrinogen or 20 minutes total using 0.75 wt% fibrinogen with a 
pause in spinning after 10 minutes to refill the syringe. Upon completion of the spin 
time, the fibrin sheets are allowed, at minimum, two additional minutes in the 
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crosslinking solution to ensure fibrinogen deposited later in the spin has had 
sufficient time to stabilize with the power supply off. A 1 cm x 1 cm plastic frame 
was then placed onto the resulting fibrin sheet and a cut was made along one side 
of the fibrin sheet (typically the side of the frame distal to the operator). The frame 
was flipped end over end towards the operator a total of six times, being careful to 
ensure entrapped air bubbles did not significantly disrupt alignment. A single spin 
will normally yield six frames with six fibrin layers. Once collected with the frames, 
fibrin sheets were placed in DI water to dilute residual thrombin for a minimum of 
30 minutes before use. Sheets can be stored in DI at 4°C indefinitely should there 
be no contamination if sheets were not needed on the day they were spun.  
Prior to cell seeding, excess water was wicked away from the fibrin sheets by 
touching the frame edge against autoclaved KimWipes and then briefly touching 
the fiber sheet face against the same KimWipes. This has been found to enhance 
the adhesion of cardiomyocytes. Once partially dried, sheets were placed vertically 
in a 24 well plate and stored at 4°C until use to prevent sheets from drying out. 
Partially dried fibrin sheets were used within a couple days to prevent damage to 
fibrin sheets due to dehydration.       
2.2 Scanning Electron Microscopy (SEM):  
SEM images for the native tissue samples and hydrogel microfibers sheets (with 
or without cells) were acquired using an SEI Quanta 200 Environmental SEM. All 
samples were fixed with cold methanol and then thoroughly washed with 
Dulbecco’s Phosphate Buffer Saline (5x wash, 30 minutes each at room 
temperature). Then, the samples underwent gradual ethanol dehydration (25%, 
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50%, 75% 100%), after which they were critical point dried using a Tousimis 
Samdri-795 and sputtered with 4 nm of Pd layer using an Anatech USA Hummer 
6.2. Samples were then imaged.  
2.3 Mechanical Testing:  
Fiber stiffness experiments were performed using a custom bioreactor developed 
in our lab.1 Bulk cylindrical fibers (3 cm × 1 mm) were clamped between the 
actuator and the force sensor in the bioreactor system allowing for an active region 
of approximately 18 mm between the clamped regions. The use of the custom 
bioreactor system allowed for the sample to stay hydrated throughout the duration 
of the testing period. The elastic modulus was determined through extension of the 
fiber to a 20 percent strain at 1 percent strain/ second. The sample length was 
increased through the movement of the linear actuator to which the sample is 
clamped. This motion is controlled by a linear stepper motor and motor controller 
(Haydon Kerk). The force associated with extending the fiber was recorded as 
voltage changes through the force sensor (Cooper Instruments 50 gram max load 
cell) attached to a strain gauge amplifier unit (Industrologic SGAU). The voltage 
output from this system was read through the Lab Jack U3-HV and was recorded 
in real time through Lab Jack’s custom software. Following the tensile test, the 
data was converted to stress by measuring the diameter of the fiber through bright-
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2.4 NRVCM Culture on Fibrin Microfiber Sheets:  
NRVCMs were seeded at a concentration of 1.5 × 106 cells/cm2 in 80L of NRVCM 
media containing 10% FBS onto fibrin microfibers with the dimensions of 1cm × 1 
cm. Fibrin microfiber sheets were placed on to agarose coated culture plates to 
prevent cells from attached to tissue culture plastic. After 1.5 hour of incubation at 
37C allowing the cells to attach to the fibrin microfibers, cells were fed 3mLs of 
10% containing NRVCM media with 33g/mL Aprotinin (USB Affymetrix). On the 
next day microfiber sheets were washed with DPBS and fed with 10% containing 
NRVCM media with 33g/mL Aprotinin (USB Affymetrix). On day 3 of culture, 
microfibers were washed with DPBS and feed 6% containing NRVCM media with 
33g/mL Aprotinin (USB Affymetrix). Media was changed every other day until and 
electrophysiological and functional testing occurred.  
2.5 Tri-Culture of NRVCM:hASC:HUVEC Fibrin Microfiber Sheets: 
We will utilize the consistent nomenclature – thousands of NRVCM:hASC:HUVEC 
per  fibrin microfiber  – to describe co-culture and tri-culture cell plating densities 
throughout the manuscript. Therefore, for NRVCM:hASC co-cultures, the HUVEC 
concentration is reported as zero. Likewise, in hASC:HUVEC experiments, the 
NRVCM numbers are reported as zero. 
NRVCs were seeded at a concentration of 1.5 × 106 cells/cm2 in NRVCM media 
containing 10% FBS in 80L onto fibrin microfiber sheets (1cm2) were seeded onto 
agarose coated culture plates to prevent cells from attached to tissue culture 
plastic. After one hour of incubation and allowing the cells to attach to the fibrin 
fibers, cells were fed 3mLs of 10% containing NRVCM media with 33g/mL 
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Aprotinin (USB Affymetrix). On the next day microfibers were washed with DPBS 
and fed with 10% containing NRVCM media with 33g/mL Aprotinin (USB 
Affymetrix). On day 3 of culture, microfibers were washed with DPBS and feed 6% 
containing NRVCM medium with 33g/mL Aprotinin (USB Affymetrix). Media was 
changed every other day until day 14. On day 14, media was removed and hASCs 
and HUVECs were added at specific concentration (i.e. 3.7 × 104 hASC/cm2 and 
1.5  × 105  HUVEC/cm2) in 20L of tri-culture media. After one hour of incubation, 
cells were fed 3mL tri-culture media containing 33g/mL Aprotinin. Media was 
refreshed every other day until 21 days of culture. At 21 days, microfiber sheets 
underwent functional testing, which consisted of optical mapping and force of 
contraction.  Upon harvest, cells were assessed using optical mapping and were 
fixed with ice-cold methanol overnight at -20C for immunocytochemistry analysis.  
2.6 Optical Mapping & Analysis: 
Optical mapping measures changes in transmembrane voltage of electrically 
conductive cells and has the overall objective of providing a method to visualize 
patterns of excitations and repolarization.168 Fibrin fibers were stained with 10 μM 
di-4-ANEPPS (Invitrogen), which is a voltage sensitive dye, in Tyrode’s solution 
for 10 minutes at 37 °C while being protected from light. Di-4-ANEPPS works by 
incorporating into the plasma membrane of cells by binding to the outer layer of 
cell bilayer membranes. The dye is then excited by a light source and responds to 
an increase in membrane potential with a decrease in fluorescence (440nm to 
530nm). Electronic structure changes with transmembrane potential/voltage. 
There is an excitation from a shorter wavelength to a longer wavelength. 167–170 
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After staining, the dye solution was removed and cells were then washed with 
Tyrode’s solution. After being washed with Tyrode’s solution, the cells were then 
placed on a heated stage in Tyrode’s solution with 5 μM blebbistatin, which stops 
contraction to remove motion artifacts. Cells were electrically stimulated by placing 
an electrode near the edge of the coverslip, out of the field of view of the lens, and 
paced starting at 0.5 Hz and incrementally increased by 0.5 Hz until the sample is 
unable to capture the paced cycle length or has reentrant spiral waves. Between 
each new cycle length, fibrin fibers were allowed to be stimulated for 1 minute to 
achieve steady state before losing the ability to maintain signal propagation at set 
pacing rate. Optically mapping occurred using a CMOS camera (MiCAM Ultima).  
2.7 Force of Contraction: 
Force of contraction experiments were performed using a custom bioreactor 
developed in our lab 188 and modified for the cardiac patch system. Following the 
indicated culture period and conditions, longer microfiber sheets (3 cm x 1 cm) 
were clamped between the actuator and the force sensor in the bioreactor system 
allowing for an active region of approximately 18 mm between the clamped 
regions. The bioreactor allows the sample to be maintained in media and in the 
incubator for the duration of the testing period. Following the loading of the sample 
between the clamps, the bioreactor was allowed to sit in the incubator for 15 min 
to ensure that the sample had time to resume contraction following the change in 
environment. The force of contraction measurements was recorded as voltage 
changes through the force sensor (cooper instruments 50 gram max load cell) 
attached to a strain gauge amplifier unit (Industrologic SGAU). The voltage output 
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from this system was read through the Lab Jack U3-HV and was recorded in real 
time through Lab Jack’s custom software. The spontaneous force of contraction 
was recorded for 10 min following the 15 min equilibration period. Following these 
recordings, a custom built stainless steel and platinum point electrode was 
attached to the bioreactor and placed such that it contacted the sample along the 
outer edge half way along the length of the sample. The sample was stimulated 
with 10 volts of direct current with a 20 ms pulse width at a variety of frequencies 
until it was no longer able to keep up with the stimulus. This testing was performed 
at 1 Hz intervals starting at 1 Hz and increasing up to 4 Hz. The force length 
relationship data was measured at a frequency of 1 Hz as this was the frequency 
that most samples were able to be paced. The sample length was increased 
through the movement of the linear actuator to which the sample is clamped. This 
motion is controlled by a linear stepper motor and motor controller (Haydon Kerk). 
The sample was extended in intervals of 2% of the initial length and the stimulated 
(1 Hz, 10V) contractions were recorded at each length up to 20% strain.  
2.8 Immunocytochemistry: 
Samples were permeabilized with 0.2% triton X-100 in DPBS with 5mM HEPES 
for 10 minutes and then blocked with 10% normal goat serum (Sigma Aldrich)  or 
normal donkey serum (Sigma Aldrich) for 3 hours at room temperature. The 
samples were incubated overnight with mouse anti-Sarcomeric α-Actinin [1:200] 
(Sigma Aldrich), rabbit anti-Connexin-43 [1:100] (Sigma Aldrich), and Cy3 
conjugated mouse anti- α Smooth Muscle Actin [1:400] (Sigma Aldrich) or mouse 
anti-Vimentin [1:200] (Dako)), or mouse anti-CD31 [1:250] (Sigma Aldrich) primary 
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antibodies diluted in DPBS with 5mM HEPES with 10%  normal goat serum or 
normal mouse serum at 4 °C. Primary antibody was washed three times with 
deionized water. Samples were incubated with secondary antibodies DyLight 488-
conjugated goat anti-mouse [1:200] and DyLight 649-conjugated goat anti-rabbit 
[1:200] (Jackson ImmunoResearch) or corresponding donkey secondary 
antibodies. Samples were washed three times with deionized water. Samples were 
incubated with DAPI (1:2000) (Sigma Aldrich) diluted in deionized water. 
Coverslips were mounted with mounting medium and imaged under Zeiss Axio 
Observer inverted fluorescence microscope or Zeiss LSM 510 confocal 
microscope with a 5x, 20x, 40x, and 63x objective. Immunostained images were 
z-projected and thresholded in order to calculate vessel parameters including 
network length and junctions. Thresholded images were subsequently analyzed 
with AngioQuant software to determine the total vessel length, area, and 
interconnectivity.  
2.9 In Vivo Implantation: 
Immunodeficient female 9-12 week old athymic nude rats (Charles River 
Laboratories) were used as patch candidates for the in vivo implantation. Rats 
were intubated and induced with anesthesia by using 4% isoflurane inhalation and 
maintained with 2% inhalation during procedures. Hearts were exposed through a 
left lateral thoracotomy. Visceral pericardium was removed by using 2.5% trypsin 
(Invitrogen/GIbco). After removal of the pericardium, 20L fibrin hydrogels 
20mg/mL fibrinogen (Sigma-Aldrich) diluted DPBS and 10U/mL (Sigma Aldrich) 
diluted in calcium containing DPBS) were placed on the myocardium. 
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Subsequently, fibrin microfibers were sided cell side down onto the fibrin gel. Co-
culture vasculature patches were placed on the right ventricle. Myocardial 
infarction was induced by ligation of the left anterior descending coronary artery. 
Subsequently, steps are the same as the vascular co-culture implantation.  
2.10 Echocardiogram:  
Echocardiography (Vevo2100, Visualsonics) was performed prior to myocardial 
infarction (MI), the day following MI, 7 days post MI, 14 days post MI, and 28 days 
post MI. Rats were imagined in the supine position at the fourth and fifth intercostal 
space with a 710B transducer. The transducer was moved around to avoid the 
lung and rib obstruction while obtaining a clear heart image. Both 2D and M-mode 
images were used for experimental measurements, and images were later 
analyzed. From the 2D guided M-mode images, measurements of the left ventricle 
anterior wall thickness, posterior wall thickness, ejection fraction, and fractional 
shortening were measured.  
2.11 Histology: 
Following euthanasia, hearts were either placed into OCT solution and flash frozen 
in cold 2-methylbutane (Sigma-Aldrich) or fixed in 60% methanol, 10% Glacial 
Acetic Acid, and 30% water. Tissue sections were section in the cryostat or paraffin 
embedded and sectioned on the microtome. Slides were stained with hematoxylin 
and eosin (H&E) or Masson’s Trichrome.  
For immunostaining, slides obtained from cryosectioning were fixed in ice cold 
acetone and washed with DPBS 3x for 5 minutes. Subsequent steps are the same 
as immunocytochemistry.   
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2.12 Statistical Analyses: 
All experiments were conducted with a minimum of three biological replicates. 
Quantitative data are expressed as the mean  standard deviation. Statistical 
analysis was performed using GraphPad Prism 5/6 software. Statistical 
significance was determined by two-way ANOVA with Bonferroni post-hoc test or 
t-test and is denoted as * p< 0.05, **p<0.01, ***p<0.001.  
3. RESULTS: 
 The overall flow of data in these experiments is depicted in Fig. S1. We 
characterized the physical properties of the fibrin microfiber sheets used for 
these studies and then evaluated the growth of NRVCM only, hASC and HUVEC 
co-cultures, and tri-cultures on these scaffolds.  Through the process, we 
determined the appropriate cell seeding densities, medium compositions, and 
growth periods required to enable the formation of robust, contractile, 
vascularized cardiac patches that could be sutured onto rat myocardium 
following induction of MI.  
3.1 Fibrin Microfiber Sheets Development and Characterization: 
SEM images were used to compare the structure of the fibrin microfiber 
sheets to the native myocardium. The acellular fibrin microfiber sheets exhibited 
similar alignment topography to the decellularized myocardium, while regions of 
the NRVCM-seeded microfiber sheets showed a similar architecture compared to 
the native myocardium (Fig. 1B). Tensile testing demonstrated the elasticity of 
0.75% and 2.0% fibrin microfiber sheets and the resulting stress-strain curves were 
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used to determine their tensile moduli of 50.0 ± 11.2 (n=3) and 90.0 ± 16.4 kPa (n=3), 
respectively (Fig. 1C). 
3.2 NRVCM Cultures on Fibrin Microfiber Sheets: 
NRVCMs cultured on both 0.75% and 2.0% fibrin microfiber sheets 
appeared to elongate and align on the substrate (Fig. 2A, Fig. S2). Data from the 
PicoGreen DNA assay demonstrated similar DNA content in both groups at 1, 7, 
and 14 days following seeding of freshly isolated NRVCMs on both 0.75% and 
2.0% fibrin microfiber sheets. Both groups exhibited similar cell viability at Day 14 
with calcein AM (LIVE) and ethidium bromide (DEAD) stain (Fig. S2).  
The optical mapping data for the NRVCMs exhibited smooth propagations 
when point paced across the field of view in both groups. Cells grown on both the 
0.75% and 2.0% fibrin microfibers were optically mapped at 7, 14, 28, and 56 days. 
We noted that the cardiomyocytes cultured on the 0.75% fibrin sheets exhibited 
slightly higher conduction velocities than those on 2.0% fibrin sheets at early time-
points. Conduction velocities peaked at 22  2.1 cm/s (n=3) on day 28 in the 0.75% 
fibrin group and at 13  0.9 (n=3) cm/s on day 14 in 2.0% fibrin when samples were 
paced at 1 Hertz (Hz) (Fig. 2B).  Similar trends were also noted across several 
pacing rates. The average maximum captured rate peaked at 4.2  0.6 Hz on the 
0.75% fibrin microfibers and 3.5  1.0 Hz on the 2.0% fibrin microfibers (Fig. 2H).  
The fibers were paced from the center to detect the presence of anisotropy 
and the 0.75% fibrin fibers exhibit an anisotropy ratio of 2.2 (Fig. 2C,D).  Action 
potential durations (APD) at both 80% repolarization (80) and 30% repolarization 
(30) increased over time in both the 0.75% and 2.0% fibrin concentrations. APD80 
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at 1 Hz pacing ranged from 133  19 ms (n=5) at day 7 to 229  51 ms (n=8) at 
day 56 in the 0.75% fibrin group (Fig. 2F). A similar trend was noted with the 2.0% 
fibrin fibers. APD30 ranged from 43.6  6 ms (n=5) at day 7 to 59  12 (n=8) at day 
56 in the 0.75% fibrin group when paced at 1 Hz (Fig. 2G).  
NRVCM-seeded fibrin sheets were spontaneously contractile (Video S1,2). 
We measured the spontaneous contractile forces of NRVCMs at Day 14 using 
custom-designed bioreactors. Cardiomyocytes generated 2.3  0.7 mN and 1.4  
1 mN of force on 0.75% and 2.0% fibrin microfiber sheets, respectively (Fig. 3A,B) 
at frequencies of 0.4  0.3 Hz and 0.5  0.4 Hz respectively. When stimulated at 1 
Hz, the stimulated forces of contraction were 1.8  0.4 mN and 0.9  0.5 mN on 
the 0.75% and 2.0% fibers, respectively (Fig. 3C). Constructs were paced up to 3 
Hz but typically lost capture at higher pacing rates.  Fibers were strained up to 20% 
at 1 Hz pacing to generate force-length relationship data. There was a maxima at 
~10% strain in 2.0% fibrin groups (Peak normalized force: 1.3  0.4), while the 
maximum force on 0.75% fibrin was measured at 2% strain (Peak normalized 
force: 1.1  0.3) (Fig. 3D).  
3.3 Tri-Cultures of NRVCM:hASC:HUVEC on Fibrin Microfiber Sheets 
To engineer vascularized cardiac patches, hASCs and HUVECs were 
cultured together with the NRVCMs. We utilized our published culture protocol 
established for cells grown on glass coverslips in which the optimal 
NRVCM:hASC:HUVEC ratio was 20:2:1 41. Therefore, maintaining the NRVCM 
seeding density at 1500 cells/mm2, we tested the equivalent ratio (1500:150:75) 
as well as an additional ratio in which the concentrations of hASCs and HUVECs 
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were further reduced (1500:75:37.5). At these ratios, the electrophysiological 
properties of the cells were significantly impaired and the vascular networks were 
not considered sufficiently extensive or interconnected (Fig. S4).   
  To address this, we followed a step-wise approach to improve the 
system. (Step 1) We co-cultured NRVCMs and hASCs in the absence of HUVECs 
and found that 1500:37.5:0 was the highest ratio of hASCs that could be co-
cultured with NRVCMs without completely inhibiting the ability of the cultures to be 
optically mapped (Fig. S5). However, electrophysiological properties such as 
conduction velocity and maximum capture rate of the co-cultures at this ratio were 
significantly inhibited compared to NRVCM only cultures. (Step 2) We then 
cultured hASCs and HUVECs in the absence of NRVCMs to assess vascular 
assembly on the fibers. We used 37.5 hASC/mm2 to be consistent the cell densities 
determined in the NRVCM:hASC co-cultures and varied the concentration of 
HUVECs. Robust vessel assembly was observed on 0.75% and 2.0% fibrin 
microfiber sheets at the ratios of 0:37.5:75 and 0:37.5:150 (Fig. S6). Since the 
NRVCM cultures required a minimum of 6% serum, we tested vascular assembly 
in the presence of 6% serum. Quantification of vessel length and interconnectivity 
yielded similar results as 2% serum (optimal serum concentration for culturing 
HUVECs).  
(Step 3) In addition to determining suitable hASC and HUVEC 
concentrations, we assessed postponing seeding of hASCs and HUVECs (to a 
time later than Day 3). Since the NRVCM only cultures exhibited mature 
electrophysiological characteristics at Day 14, the tri-culture system was 
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developed in which NRVCMs were seeded at 1500 cells/mm2 and cultured for 14 
days before hASCs/HUVECs were added (Fig. 4A). Three groups were studied 
using the ratios 1500:37.5:37.5, 1500:37.5:75, and 1500:37.5:150 and compared 
to a NRVCM only (1500:0:0) control. Through CD31 staining, we observed 
increased vessel length and interconnectivity as the concentration of HUVECs 
increased (Fig. 4B-D). After 21 days of culture, constructs were optically mapped. 
At 1 Hz pacing, there were no significant differences in the tri-culture conduction 
velocities on the 0.75% or the 2.0% fibrin groups compared to the respective 
controls.  Conduction velocities of 0.75% and 2.0% fibrin for the ratio 
1500:37.5:37.5, were 13  1.3 cm/s (n=6) and 14  1.5 cm/s (n=4) respectively. 
Similarly, the 1500:37.5:75 displayed conduction velocities of 15  1.9 cm/s (n=6) 
and 13  1.5 cm/s (n=9) (0.75% and 2.0% respectively) and 1500:37.5:150 had 14 
 2.3 cm/s (n=7) and 14  0.6 cm/s (n=5) compared to the controls of 14  2.1 cm/s 
(n=6) and 13  1 cm/s (n=4) (Fig. 4E,F). We saw similar trends using other pacing 
rates (Fig. S7). We found that there was no statistical difference in action potential 
duration (both 80% and 30%) between the control groups and the ratio 
1500:37.5:150 but the action potentials appeared to be prolonged in the 
1500:37.5:37.5 and 1500:37.5:75 after 21 days of total culture time on both 
stiffness groups (Fig. 4G,H). The control group had a maximum captured rate of 
3.4  1.3 Hz (n= 6) (0.75%) and 3.2  0.4 Hz (n= 10) (2.0%) compared to those of 
the 1500:37.5:150 groups, which achieved higher rates at 3.8  1 Hz (n= 6) 
(0.75%) and 3.9  0.7 Hz (n= 5) (2.0%) (Fig. 4I). We tested the stimulated force of 
contraction of the 1500:37.5:150 groups at 1 Hz pacing and found statistically 
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higher forces on the 2.0% fibrin group (1.1  0.8 mN) compared to the 0.75% fibrin 
(0.5   0.1 mN).  
3.4 In Vivo Proof-of-Principle Vascularized Cardiac Patch 
Preliminary in vivo studies showed that both 0.75% and 2.0% fibrin fibers 
could be sutured to the rat ventricular walls, however, due to the increased 
mechanical integrity of the 2.0% fibrin microfiber sheets, they were easier to handle 
and remained stretched across the myocardium better than the 0.75% fibrin 
sheets. Preliminary studies were also used to establish the surgical protocol that 
included enzymatic removal of the pericardium with 2.5% trypsin, the incorporation 
of fibrin hydrogel adhesive, and suturing all four corners of the patch. These 
techniques enabled better integration of the patch with the native myocardium and 
host vasculature appeared to grow into the patches (Fig. 5A). To track the survival 
of transplanted NRVCMs, we transduced them with luciferase. We were able to 
detect the luminescence of the cultures pre-implantation (not shown) and up to 1 
month post-implantation (Fig. 5B,C). To test the potential for using these 
engineered grafts as cardiac patches, we utilized an established a rat MI model 
40and applied the 2.0% fibrin microfiber sheets (Video S3,4). We cultured 
NRVCM:hASC:HUVEC in the 1500:37.5:150 ratio using the previously described 
protocol and assessed functional metrics up to 28 days post-MI. The results for 2 
rats with identical treatment regimes are presented. In both rats, the ejection 
fraction decreased significantly following MI (Rat 1: 78%  37%; Rat 2: 78%  
38%). Following treatment with the patch, the ejection fraction in Rat 1 remained 
unchanged, while the ejection fraction in Rat 2 increased to 56% at Day 14 and 
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68% at Day 28).  In the untreated control, the ejection fraction remained at 38%.  
The values of end diastolic volume and end systolic volume also indicated 
functional improvements in Rat 2 beginning at Day 14 and continuing through Day 
28.  At Day 28, the end diastolic volumes were 552 µL (Rat 1) and 298 µL (Rat 2) 
(Pre-MI: 98 µL; Untreated control: 271 µL).  The end systolic volumes were 343 µL 
(Rat 1) and 97 µL (Rat 2) (Pre-MI: 21 µL; Untreated control: 168 µL) (Fig. 5C-E).  
Using echocardiography, we observed beating of the ventricular walls in Rat 2 from 
the M-Mode image after 28 days in the host (Fig. 5F-H). We did not observe 
measurable changes in morphologic parameters assessed using the 
echocardiography (Fig. S8). After 1 month in the host, we removed the heart from 
Rat 2 and used optical mapping to assess integration of the patch. The maximum 
captured rate was 3Hz (point stimulation) and 7Hz (field stimulation). (Fig. S9).  
4. DISCUSSION: 
The ultimate goal of cardiac tissue engineering is the development a cardiac 
graft that can be used as a source of functional regeneration of the myocardium. 
In this present study, we demonstrate that fibrin microfibers cultured with 
NRVCMs, HUVECs, and hASCs resulted in the development of a vascularized 
cardiac graft that can be implanted into the infarcted myocardium and maintain 
survival and improve functional outcomes. This study was broken into several 
components in which we assessed cardiomyocyte survival and functionality, 
vascular assembly, vascularized cardiac tissue formation, and acute myocardial 
treatment with the vascularized cardiac graft.  
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Electrospun fibrin microfiber sheets provide a unique advantage relative to 
bulk fibrin hydrogels. Previous researchers have utilized isotropic fibrin hydrogels 
that rely on cell-generated stresses to create cell alignment189,190 with limited 
capacity to tune the mechanical properties. These previous studies utilize tension 
to allow for the cardiomyocytes to elongate, connect, and form a syncytium. To 
achieve tension these groups utilize PDMS hexagonal posts, flexible silicon posts, 
and other types of post to culture the fibrin hydrogels. In contrast to fibrin hydrogels, 
fibrin microfibers sheets display tunable mechanical properties, provide uniaxial 
alignment, have flexible geometry, are customizable in dimensions, and can be 
sutured onto organs like the myocardium58. To mimic the mechanical properties of 
native tissue extracellular matrix during homeostasis and the stiffer state that is 
present following myocardial infarction as these two conditions will impact the 
contractile response of cardiomyocytes. Fibrin microfiber sheets are spun using 
two compositions of fibrinogen under sterile conditions. Electrospun fibrin 
microfiber sheets were developed at 2 unique tensile moduli, 49 kPa and 90 kPa.  
Researchers have found the rat myocardium has a tensile modulus in the long 
myofiber direction, the direction that is parallel to cardiomyocyte alignment, of 43 
 9 kPa and the epicardium has a stiffness of 12 kPa at birth in neonatal rats to 
39kPa in adult rats  48,191. The stiffness of the softer substrate has a similar order 
of magnitude.  
Fibrin microfibers grafts were cultured with NRVCMs-only for up to 2 
months. Electrophysiological properties, specifically conduction velocity increased 
over time up until 28 days and gradually decreased after 2 months of culture. We 
   - 95 - 
found that the conduction velocity was significantly higher in the 0.75% fibrin group 
compared to the 2.0% group over time.  This finding was consistent with previous 
reports indicating that stiffer substrate negatively influenced the maturation and 
electrophysiology of cardiomyocytes. Specifically, it was shown that cells cultured 
on softer matrices or near the stiffness of the native myocardium show larger 
calcium transients, contained more sarcoplasmic calcium stores, and generated 
more force75,77,182,185. While substrate stiffness in NRVCM-only cultures appeared 
to have an effect on conduction, the time frame in which maximum conduction 
velocity was achieved could be attributed to the fact that cardiomyocyte maturation 
in 3D substrates takes a slightly longer time frame than monolayer cultures to 
achieve faster conduction. These differences can be attributed to cell-matrix 
interactions and the ability of cells to undergo morphogenic changes and form 
matrix adhesions that are more in vivo-like 192.                                                                                                                                                                                                                                               
Culture of cardiomyocytes on the 0.75% fibrin resulted in an anisotropy ratio 
similar to the rat myocardium as compared to the 2.0% fibrin microfiber sheets193 
which is near 2.3. Similarly, the 0.75% fibrin microfibers, the softer of the two 
substrates, exhibited increased force of contraction compared to the 2.0% 
microfibers. Previous engineered constructs have shown that the force of 
contraction can range from as high as ~3.0 mN to as low as ~0.1 mN 57,194–196. In 
our system, force of contraction is on the higher end of the range at ~2.3 mN of 
force. To improve the force of contraction, researchers have found that introducing 
electromechanical stimulation into a culture system has the potential to increase 
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the force of contraction due to the increase in cardiac troponin  and SERC2a 
expression 119. 
 Fibrin microfiber sheets also support the development of dense vascular 
structures. We find that in both the 0.75% and 2.0% fibrin microfiber there is robust 
vascular assembly. Current literature suggests that softer substrates support 
HUVEC network formation and substrates at ~25 kPa support proliferation of 
endothelial cells 197,198.  In our study, we found that vessel assembly occurred at 
both stiffness ranges and vessel length is relatively similar amongst experimental 
groups and ratios. This can be possibly explained by the paracrine effects of 
hASCs and their role as supportive vascular mural cells. Wang et al. suggests that 
smooth muscle cells, like hASCs, can be highly proliferative in the presence of 
PDGF and substrate stiffness of ~84 kPa which would ultimately preserve and 
support vascular assembly and explain the presence of robust dense vascular 
structures 199,200. In addition to substrate stiffness, we investigated changing serum 
concentration from 2% to 6% because the cardiomyocytes are cultured in 6% 
serum. Serum concentration could potentially play a role in vessel assembly and 
maintenance of cardiomyocyte functionality. There were no relative differences in 
vessel length between the two concentrations of serum.  Bala et al has shown that 
increasing serum up to 20% can be detrimental to HUVEC morphology and 
proliferation rate, which would explain that vessel assembly would not be 
jeopardized until this threshold has been reached with serum concentrations201. 
Developing a contractile, electrically responsive, vascularized cardiac patch 
required several iterations of cell concentration and seeding time points.  In initial 
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studies we utilized a protocol optimized for tri-culture on tissue culture.  We found 
that culturing cardiomyocytes for 2 days prior to the addition of hASCs and ECs 
yielded grafts with poor electrophysiological properties although vessel assembly 
was successful (Fig. S4). NRVCMs on the electrospun fibrin microfiber sheets took 
longer to elongate and form gap junctions with other cardiomyocytes compared to 
those cultured on traditional tissue culture plastic202. To overcome these 
limitations, it was necessary to increase NRVCM seeding concentrations six-fold, 
lower the concentration of serum used in the cultures (to mitigate the effects of 
cardiac fibroblast proliferation), and to reduce the relative ratio of NRVCM:hASCs 
(20:1) compared to previously reported values. 41  Interesting, while 
1,500,000:37,500 (NRVCM:hASC) cultures resulted in reproducible conductivity 
(CV: 10 cm/s (50kPa) & 6 cm/s (90kPa)), the conduction velocities increased 
further when HUVECs were included in the 1,500,000:37,500:75,000 cultures (CV: 
15 cm/s (50 kPa) & 13 cm/s (90kPa)). This compared favorably with NRVCM-only 
control samples (14 cm/s (50 kPa) & 13 cm/s (90 kPa). We speculate that paracrine 
factors secreted by endothelial cells could enhance NRVCM-hASC crosstalk 
leading to better conduction properties203. Previous studies have shown that 
paracrine signaling from vessel networks promote survival of cardiomyocytes and 
enhanced electrophysiological properties 49. 
After characterizing the tri-culture system in vitro, the vascularized cardiac 
patches were implanted into the myocardium following acute MI. In vivo studies 
were performed primarily with the stiffer scaffolds, which exhibited near identical 
electrophysiological properties and vessel network characteristics as the softer 
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scaffolds (Fig. 4), but were easier to handle surgically. These studies were 
performed as proof-of-principle and confirmed the potential for using these grafts 
to enhance cardiac function. Bioluminescence imaging demonstrated that roughly 
10% of the NRVCMs survived at least one month in the ischemic environment. 
Additionally, there appeared to be anastomosis between the host and implanted 
vasculature. In one of the rats tested, the cardiac patch demonstrated 
improvement in ejection fraction, end systolic volume, and end diastolic volume. 
Additionally, data from optical mapping of the whole heart suggest that the patches 
potentially integrated with the myocardium. To confirm electrical connectivity 
between the patch and the heart, future studies will utilize a calcium reporter gene 
to display the activity of the patch and show the alignment or the dissonance of the 
patch implanted onto the myocardium.  
 
5. CONCLUSIONS: 
We have successfully generated vascularized, electromechanically coupled 
cardiac patches that could be directly applied to treat infarcted myocardial tissues. 
To achieve this, we employed uniaxially aligned fibrin microfiber sheets with 
biomimetic stiffnesses and developed a protocol for successfully co-culturing 
NRVCMs, hASCs, and HUVECs. These studies confirmed previous reports that 
NRVCM physiology is enhanced on softer substrates (50 kPa vs. 90 kPa), but also 
provided novel insight in demonstrating that the effect of substrate stiffness on 
cardiomyocyte function is not fixed, but is also influenced by heterotypic cell-cell 
interactions. Ultimately, tri-cultures on the two substrates yielded identical 
electrophysiological and vessel network characteristics in vitro though cells on the 
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stiffer substrates generated higher contractile forces in response to electrical 
stimulation. The patches show considerable regenerative potential, improving 
cardiac function in one of two transplanted rats and anastomosis of transplanted 
vasculature with little to no observable fibrosis between the host and graft.  These 
studies indicate that fibrin microfiber sheets are a potentially viable source for 





Figure 1:  Fibrin microfiber sheet development and characterization A) 
Schematic illustrating the electrospinning process used to fabricate fibrin 
microfiber sheets. B) Representative SEM images comparing the decellularized or 
native myocardium to acellular or NRVCM-seeded fibrin microfiber sheets. C) 
Stress strain curve of bulk fibrin microfiber sheets depicting the Young’s Modulus 
of each concentration of fibrin. D) Representative image of 1cm  × 1cm fibrin 
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microfiber sheets on mylar frame. Yellow dashed line indicates inner edges of the 
mylar frame and the boundaries of the scaffold.  
   
 
Figure 2: Morphological and Electrophysiological characterization 
cardiomycoytes on fibrin microfiber sheets. A) Immunofluorescent staining of 
αActinin (green) and Connexin-43 (red) on both 0.75% and 2.0% fibrin microfiber 
sheets. Scale Bar is 100µm and 25µm B) Representative time course (14, 28, and 
56 days) activation maps of selected of 0.75% and 2.0% fibrin microfiber 
cardiomyocyte only group. C) Anisoptropy ratio of 0.75% and 2.0% fibrin 
microfibers at 1.0 Hz pacing rate after 2 weeks of culture. D) Representative 
activation map of 0.75% fibrin microfiber pacing from the center at 1.0 Hz pacing 
rate. E) Comparison of conduction velocity of .075% and 2.0% fibrin microfibers 
(n=4-9)  F) Comparison of action potential duration 80% and G) 30% amongst 
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0.75% and 2.0% fibrin microfibers sheets from 7-56 days (n=4-9)  H) Comparison 
of maximum captured rates between 0.75% and 2.0% fibrin fibers * p < 0.05; **p < 
0.01; ***p < 0.001  
 
Figure 3: Force of Contraction measurements of Fibrin microfiber sheets. A) 
Representative spontaneous force trace measurement of 0.75% fibrin 
concentration microfibers. B) Representative spontaneous force trace 
measurement of 2.0% fibrin concentration microfibers. C) Representative 
stimulated force of contraction trace of both 0.75% (black) and 2.0%(red) fibrin 
microfibers paced at 1 Hz. D) Force length relationship of fibrin microfibers up to 
20% strain.  
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Figure 4: Engineered functional vascularized cardiac graft. A) Schematic 
showing the additional seeding of supporting cells (hASC and HUVECs) types after 
14 days of CM culture. B) Immunofluorescent staining of CD31/PECAM-1 (green) 
vessel structures along with cardiac Troponin I (red) on both  the 0.75% and 2.0% 
fibrin microfibers sheets with cell concentrations ranging from 1500:37.5:37.5-
1500:37.5:150. C) Comparison of vessel length between tittered endothelial cells 
in tri-culture D) Comparison of the interconnectivity of vessel structures developed 
in tri-cultures. E) Representative activation maps of both 0.75% and 2.0% fibrin 
microfiber sheets with tri-cultures at the ratio of 1500:37.5:150  F) Conduction 
velocity of tri-cultures compared to NRVCM only cultures in both 0.75% and 2.0% 
fibrin microfibers G) Comparison of Action Potential Duration 80 and H) Action 
Potential Duration 30  of both 0.75% and 2.0% fibrin microfibers I) Maximum 
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captured rates comparing both fiber stiffness and ratios of 
NRVCM:hASC:HUVECs p < 0.05; **p < 0.01; ***p < 0.001  
 
Figure 5: Implantation of Function Vascularized Cardiac Patch. A) Image of 
fibrin microfiber attached to myocardium post infarction after implantation B) Image 
of bioluminescence of vascularized cardiac patch implanted onto infarcted 
myocardium C) Quantified flux of fibrin microfibers over time E) Ejection Fraction 
measurements over time of treated rats F) End diastolic volume measurements 
over time G) End systolic volume measurements over time H) M-mode image of 
myocardium pre-infarct I) M-mode image of myocardium 24 hours post-infarct J) 
M-mode image of myocardium 28 days post-infarct 
   - 104 - 
 
Figure 6: Histology and Immunostaining of  Implanted Vascularized Cardiac 
Patch. A) H&E staining of 5µm slice of patch placed on myocardium.  B) Masson’s 
tri-chrome staining of 5µm slice of patch placed on myocardium.C)  
Immunostaining of 5µm patch 29 days post implantation for αActinin 
(cardiomyocytes) and DAPI D) Immunostaining of 5µm patch 29 days post 
implantation for rat CD31(green) for host vasculature, human CD31 (red) for 
engineered vasculature and DAPI  
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Supplemental Figure 1: Schematic of experimental design. Fibrin microfiber 
sheets were characterized 0.75% and 2.0% fibrin microfibers were used for the 
remaining studies. NRVCMs were characterized on fibrin microfibers and resulted 
in the concentration of cardiomyocytes and culture conditions. NRVCMs and 
hASCs consistently mapped at the ratio of 1500:37.5:0.  Vessel development was 
characterized at the ratio of 0:37.5:75 and 0:37.5:150. This information resulted in 
the tri-culture conditions and ultimately the patch implanted onto the infarcted 
myocardium.   
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Supplemental Figure 2: Survival of cardiomyocytes on fibrin microfiber 
sheets. A) Immunofluorescent staining of cardiomyocytes on fibrin microfibers at 
Day 0 alpha Actinin (cardiomyocytes) in green on top panel  and  immediately 
below vimentin (fibroblast) in green and cardiac troponin I (cardiomyocytes) in red. 
B) Immunofluorescent staining of 0.75% and 2.0% fibrin microfiber sheets C) DNA 
quantification of cardiomyocytes on fibrin microfiber sheets (0.75% and 2.0%) over 
14 days relative to Day 0. D) Representative images of calcein AM and ethydium 
bromide stained fibers to qualitatively examine cardiomyocyte survival.  ***p < 
0.001  
   - 107 - 
 
Supplemental Figure 3:  Electrophysiological characterization of 
cardiomyocytes at 0.5, 1.5, and 2.0 Hz Pacing A) Conduction velocity of both 
0.75% and 2.0% fibrin over time B) Action potential duration 80 of both 0.75% and 
2.0% fibrin over time C) Action potential duration 30 of both 0.75% and 2.0% fibrin 
over time D) Normalized triangulation over time.  
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Supplemental Figure 4: Development of functional tri-culture. A) Schematic 
showing the additional seeding of supporting cells types after 2 days of CM culture. 
B) Conduction Velocity of tri-culture C) Maximum captured rate D) Action Potential 
Duration 80 E) Action Potential Duration 30 F) Normalized Triangulation G) 
Immunofluorescent staining of CD31/PECAM-1 vessel structures. 
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Supplemental Figure 5: Cardiomyocyte and hASC co-cultures on fibrin 
microfiber sheets. A) Schematic of sequential seeding of hASCs after 
cardiomyocytes. 0.75% fibrin microfibers at several pacing rates B) Conduction 
velocity C) Action potential duration 80 D) Action potential duration 30 E) 
Normalized Triangulation.  2.0% fibrin microfibers at several pacing rates F) 
Conduction velocity G) Action potential duration 80% H) Action potential duration 
30% I) Normalized Triangulation. 
These parameters were consisted of conduction velocity at 10  1.4 cm/s (n=3), 
APD 80 261  28 ms (n=3), APD 30 85  11 ms (n=3), and a normalized 
triangulation of 0.7   0.02 (n=3) (Supplemental Figure 6). The 2.0% fibrin group 
seeded similarly to the 0.75% fibers displayed similar electrophysiological 
characteristics (Supplemental Figure 6).  
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Supplemental Figure 6: Characterization of vessel development on fibrin 
microfiber sheets.  A) Schematic of vessel development on fibrin microfibers B) 
Immunostaining of vessel assembly after several 7 days of culture C) Vessel 
length of assembled vasculature with both 2% and 6% serum D) Interconnectivity 
of assembled vasculature with both 2% and 6% serum  
Vessel lengths and interconnectivity were slightly greater in the 0:37.5:75 ratio 
compared to the 0:37:150, which peaked at 80  14 mm and 940  408 
respectively.  
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Supplemental Figure 7:  Electrophysiological characterization of tri-
cultures at 0.5, 1.5, and 2.0 Hz Pacing A) Conduction velocity of both 0.75% 
and 2.0% fibrin over time B)  Action potential duration 80 of both 0.75% and 
2.0% fibrin over time C) Action potential duration 30 of both 0.75% and 2.0% 
fibrin over time D) Normalized triangulation over time.  
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Supplemental Figure 8: Implantation of Vascularized Cardiac Patch. A) 
LVID;d over time B) LVID;s over time C) IVS;d over time D) LVPW;d over time E) 
Fractional shortening F) Stroke volume over time G) M-mode image of 
myocardium pre-infarct of Rat 1 H) M-mode image of myocardium 24 hours post-
infarct of Rat 1 I) M-mode image of myocardium 28 days post-infarct of Rat 1 
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Supplemental Figure 9: Whole Heart Optical Mapping of Vascularized 
Cardiac Patch. A) Treated rat heart on Langendorff perfusion chamber for 
optical mapping B) Maximum captured rate of point paced and field paced heart 
C) Activation Map of 3 Hz point paced myocardium D) Activation Map of 3 Hz 
field paced myocardium E) Action potential duration map of point paced and F) 
field paced.  
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Supplemental Figure 10: Infarct model characterization . A) M-mode image 
of myocardium post-infarction B) Ejection Fraction measurements over time of 
infarcted rat C) End diastolic volume measurements over time D) End systolic 
volume measurements over time E) H&E staining of infarct after 7 days  F) 
Masson’s trichrome staining of infarct after 7 days  
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In the United States (US) nearly 800,000 new cases of myocardial infarction 
occur per year.1 With a shortage of donor hearts and the inherent limited endogenous 
repair of the native myocardium, there is a critical need for new therapeutic approaches 
to regenerate the injured myocardium. Tissue engineering offers a method to engineer 
cardiac tissue that mimics the native cellular make-up and could potentially be used to 
restore lost functionality.6,152 The native myocardium is mainly composed of 
cardiomyocytes, endothelial cells, and fibroblasts. More recently, it has been discovered 
that endothelial cells make up the largest number of cells found in the myocardium due 
to the highly metabolic nature of cardiomyocytes.186 While supporting cell types are 
important, finding a suitable cardiomyocyte source, which is the primary electrically 
excitable cell in the heart, is essential for functionality. This is a critical problem because 
cardiomyocytes have a life-span of nearly 100 years and do not often divide to repair 
damaged regions of the myocardium.  
Early discoveries have utilized human embryonic stem cells (hESCs) as a 
promising cell source for generating functional cardiomyocytes. While a promising cell 
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source, hESCs  have drawbacks which include ethics, the potential to form teratomas 
when implanted in vivo, and genetic instability.204 More recently induced pluripotent stem 
cells have been developed with the promise of offering similar differentiating potential to 
embryonic stem cells but the ability to be  patient specific and developed in larger 
quantities. 205,206 Cardiomyocytes derived from human pluripotent stem cells (hiPSC-
CMs) are a promising cell source that can be utilized for in vitro cardiac 
electrophysiology studies, investigation of cardiac drugs (respond to cardioactive drugs), 
models of disease, and patient-specific therapeutic applications. 207 Although hiPSC-
CMs are a promising cell source, there are still roadblocks with these cells. hiPSC-CMs 
are immature in their cardiac development with respect to morphology, 
electrophysiology, ion channels location and function, and gap junction localization.  
Currently studies have indicated that non-myocyte co-cultures can aid in the 
maturation of cardiomyocytes. Particularly the development of a vascularized cardiac 
system in vitro with hiPSC-CMs has shown an increase in gene expression of cardiac 
markers and morphological changes of cardiomyocytes. (Vuorenpaa H. et al. 2014) 
From this study we learn that there is also a need to investigate endothelial cells that 
have unlimited self renewal capacity and have the potential to be patient specific. 
Currently human umbilical vein endothelial cells (HUVECs) and endothelial progenitor 
cells/endothelial colony forming cells (EPCs/ECFCs) are used for vessel development 
studies. HUVECs are not clinically translatable cells because they come from the 
umbilical cord and are allogenic. EPCs/ECFCs are clinically relevant and can be 
obtained from peripheral blood, but are slow growing initially and require many passages 
to achieve large number of cells.128,141,208 Similar to cardiomyocytes, researchers have 
differentiated pluripotent stem cells into endothelial cells.209 ESC/iPSC derived 
endothelial cells express phenotypic markers that are similar to both HUVECs and 
ECFCs. hiPSCs have unlimited self-renewal potential which could ultimately provide an 
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abundant source of endothelial cells.   Differentiated hESC/hiPSC-ECs have the ability 
to form cord like structures when culture in 2D and develop 3D lumens when cultured in 
hydrogels. hESC/hiPSC-EC derived endothelial cells can anastomose with host 
vasculature when implanted in vivo. hiPSC-ECs can be autologous and/or disease 
specific and also have the ability to be differentiated towards the arterial and venous 
lineage.  
In an effort to develop a vascularized cardiac tissue, the tri-culture system 
consists of cardiomyocytes, endothelial cells, and a stromal cell. Research has 
shown that human adipose derived stem/stromal cells have the ability to serve as 
the non-myocyte support cell for cardiomyocytes as well as the vascular support 
cell for vessel stabilization. Stromal cells like hASCs can aid with matrix 
deposition and signal transduction when coupled with cardiomyocytes. Stromal 
cells, like fibroblasts, have shown improved contractile force in co-culture with 
pluripotent stem cell derived cardiomyocytes. In addition, fibroblasts co-cultured 
with hiPSC-CMs have shown to reduce calcium transients and upregulated 
sarcoplasmic reticulum calcium uptake which is more adult like. (Kane C, et al. 
2016). We compared the electrophysiological properties of suitable stromal cells 
(bone-marrow mesenchymal stem cells (BM-MSCs), dermal fibroblasts, and 
cardiac fibroblasts) to hASCs. Similarly, with vasculature development and 
stabilization, we compared supporting cell types to hASC in co-cultures with 
endothelial cells. The results could ultimately be combined to determine a 
vascularized cardiac model.  
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2. MATERIALS and METHODS: 
2.1 Human Cardiomyocyte Differentiation: 
 hESC-CM (H9 cell line, wild type) differentiated by a monolayer-based 
protocol. Undifferentiated hESC monolayers were maintained in E8 media 
(Thermofisher Scientific, USA) on 1:200 diluted GelTrex (Thermofisher Scientific, 
USA)-coated 6-well tissue culture plates prior to differentiation. A directed 
differentiation protocol was used to differentiate hESC into the cardiac lineage 
once cells reached near 80% confluency. At day 0 of differentiation (d0), media 
was switched to RPMI 1640 (Thermofisher Scientific, USA) with B27 without 
insulin (Thermofisher Scientific) until day 9 (d9). Media was supplemented with 
6µM CHIR99021 (Selleckchem, USA) for 48 hours (d0-2), then 5µM IWR-1 
(Sigma-Aldrich, USA) for 48 hrs (d3-5). On day 9, media was switched to RPMI 
1640 with B27 with insulin (Thermofisher Scientific, USA). Cardiomyocytes 
began to spontaneously beat starting from d7 to d10. On day 10-12, cells were 
dissociated using 0.05% trypsin and re-plated on 1:200 GelTrex-coated tissue 
culture plates at a density of 250,000 cells/cm2 to form confluent monolayers  210. 
 hiPSCs were generated from a healthy patient (JHUCCL2 line, wild type) 
and plated onto 6-well plates coated 1:200 GelTrex:DMEM/F-12. The same 
differentiation protocol for hESC-CMs was used for hiPSC-CMs.  
2.2 Human Adipose Derived Stem/Stromal Cells: 
Human adipose derived stem/stromal cells (hASCs) isolation was performed at 
the Johns Hopkins University, under an Institutional Review Board approved 
protocol according to published methods. Briefly, fresh human subcutaneous 
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adipose lipoaspirates were obtained under informed consent from healthy donors 
undergoing elective liposuction. The lipoaspirate tissue was extensively washed 
with warm phosphate buffer saline solution to remove erythrocytes and then 
digested in PBS supplemented with 0.1% Collagenase Type I (Worthington), 1% 
BSA, and 2 mM CaCl2 for one hour at 37°C. Following room temperature 
centrifugation at 300G and resuspended in stromal vascular fraction medium 
(DMEM/F-12) (Life Technologies) supplemented with 10% FBS (Atlanta 
Biologicals) and 1% penicillin/streptomycin), the stromal vascular pellet obtained 
from 35mL of lipoaspirate digest was plated in a T175 flask (0.2mL per cm2). 
After 24 hour of incubation at 37°C, 5% CO2, the adherent cells were washed 
with warm PBS and maintained in stromal medium until 80-90% confluent. The 
adherent population (“passage 0”) was harvested by digestion with trypsin 
(0.05%)/EDTA(1mM) at 37°C for five minutes, washed with Stromal Medium and 
cryopreserved. Prior studies have shown that there are no deleterious effects on 
hASCs due to cryopreservation, such as loss of viability or multipotency 164 . For 
expansion, hASCs were thawed and cultured in expansion medium which 
includes DMEM high glucose (Life Technologies, USA), 10% FBS (Atlanta 
Biologicals, USA), 0.5%penicillin/streptomyocin (Cellgro, USA), 
0.5%antibiotic/antimycotic, 1ng/mL FGF2 (PeproTech). Cells were utilized at 
passage 2. 
2.3 Human Endothelial Cell Differentiation: 
To initiate mesodermal induction, Essential 6 medium (Gibco, USA) 
supplemented with 6 μM CHIR-99021 (STEMCELL Technologies, USA) was 
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added to one well of hiPSCs (BC1 cell line, wild type) at 70% confluence. In early 
vascular differentiation, cells were plated onto collagen IV (Corning, USA) coated 
plates at 2 x104 cells/cm2 with ROCK inhibitor and cultured in endothelial cell 
growth medium (Promocell, USA) supplemented with 50 ng/mL VEGF (R&D, 
USA) and SB-431542 (Sigma-Aldrich, USA), internally referred to as high VEGF 
media. Early Endothelial Cells (day 8) were magnetically sorted using VE 
cadherin-PE (BD Biosciences, USA) and the MACS sorting system (Miltenyi 
Biotech, USA) according to the manufacturer’s instructions. Sorted ECs were 
cultured on collagen IV coated plates in high VEGF media to mature 133,135. 
2.4 Human Dermal Fibroblast (hNDF) Culture: 
Adult Human Normal Dermal Fibroblast (hNDF) (ATCC, USA) were expanded in 
tissue culture flasks up to passage 3 (P3) using Fibroblast Basal Media (ATCC, 
USA) and Fibroblast Growth Kit Low Serum which contains 2% FBS (ATCC, 
USA), 5 ng/mL rhFGF-2, 7.5mM L-glutamine, 50 g/mL Ascorbic Acid,1g/mL 
Hydrocortisone Hemisuccinate, 5 g/mL recombinant human Insulin, and 1.0% 
antibiotic/antimycotic (Life Technologies, USA). NHDFs were used between 
passage 3-4.  
2.5 Human Cardiac Fibroblast-Ventricular (hNCF-V) Culture:  
Adult normal human cardiac fibroblast-ventricular (Lonza, USA) were expanded 
in tissue culture flasks and cultured with Fibroblast Basal Medium (Lonza,USA) 
and the Fibroblast Growth Medium-3 (FGM-3) Bullet Kit which contains 10% 
FBS. NHCF-Vs were used at between Passages 2-3.   
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2.6 Human Bone-Marrow Derived Stem Cells (hBM-MSC) Culture: 
Human bone-marrow derived stem cells (Lonza) were expanded from passage 0 
to passage 2 using expansion medium which consisted of Dulbecco's modified 
Eagle medium (DMEM) with 4.5 g/l glucose (Life Technologies, USA) 
supplemented with 10% (vol/vol) fetal bovine serum (FBS; Atlanta Biologicals, 
USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Cellgro, USA), and 1 
ng/ml basic fibroblast growth factor (FGF-2) (PeproTech, USA). hBM-MSCs were 
used at between Passages 3-4 
 
2.7 Human Umbilical Vein Endothelial Cell Culture (HUVEC) Culture: 
A vial of pooled human umbilical vein endothelial cells (HUVECs) (Lonza, USA) 
were expanded in tissue culture flasks up to passage 3-5 using Endothelial Basal 
Medium 2 (EBM-2) culture medium (Lonza, USA) supplemented with the 
Endothelial Growth Medium-2 (EGM-2) Bullet Kit (Hydrocortisone, human 
fibroblast growth factor (hFGF)-2, vascular endothelial growth factor (VEGF), R3-
insulin-lke growth factor (IGF)-1, ascorbic acid, human epidermal growth factor 
(hEGF), gentamicin & amphotericin (GA-1000), and Heparin) and 2% FBS. 
HUVECs were used for experimentation at Passage 4-6. 
2.8 Human Endothelial Colony Forming Cells (hECFC) Culture: 
Human endothelial colony forming cells (hECFCs) (Lonza, USA) were used for 
experiments between passages 5 and 9. hECFCs were expanded in flasks 
coated with type I collagen (BD Biosciences, USA) in Endothelial Basal Medium-
2 (EBM-2; Lonza USA) supplemented with EGM-2 Bulletkit (Lonza) and 10% 
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fetal bovine serum (FBS; Hyclone, USA). ECFCs were fed every other day, 
passaged every 5 to 7 days using 0.05% trypsin/0.1% ethylenediaminetetraacetic 
acid (EDTA; Invitrogen, USA). 
2.9 Flow Cytometry Analysis of hASCs, hNDFs, hNCFs-V, and hBM-MSCs: 
Cells were detached with 0.25% Trypsin/EDTA and washed with phosphate buffer 
saline (DPBS) containing 2% FBS. They were then incubated with monoclonal 
antibodies for mesenchymal markers (CD73 and CD105) and vascular markers, 
(CD31, CD34, and CD309 (VEGFR2)), hematopoietic marker (CD45), and MHC 
receptor (HLA-DR) and isotype controls (BD Biosciences) were conjugated to 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), and Per CP-Cy 5.5 for 30 
minutes at 4 °C. Cells were analyzed with the BD Accuri C6 flow cytometer.  
2.10 Optical Mapping:  
Optical mapping was performed on days 14-28. Cell monolayers were stained with 
10 μM of the voltage-sensitive dye di-4-ANEPPS (Invitrogen), in Tyrode’s solution 
for 10 minutes at 37 °C while being protected from light. After staining, the dye 
solution was removed, cells were washed with Tyrode’s solution, and placed on a 
heated stage in Tyrode’s solution with 5 μM blebbistatin to prevent motion artifacts 
due to contraction. Optical mapping was performed using a CMOS camera 
(MiCAM Ultima, Scimedia, Costa Mesa, CA). Cells were electrically stimulated by 
placing a bipolar point electrode near the edge of the coverslip, out of the field of 
view of the camera, and paced starting at 0.5 Hz and incrementally increased 
several intervals. At each new pacing rate, the cell monolayers were stimulated for 
1 minute to achieve steady state before an optical recording was taken.  
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2.11 DNA Assay: 
500µL Deoxyribonucleic Acid (DNA) lysing solution (10mM Tris, 1mM EDTA, 
0.1% Triton X-100, and 0.1 mg/mL proteinase K) was placed on monolayers and 
removed and placed into Eppendorf tubes and frozen at -20°C. Samples were 
subsequently heated at 50 °C overnight to digest proteins and inactivate 
nucleases. PicoGreen dsDNA quantification assay was carried out according to 
the manufacturer’s instructions. Briefly, the samples were combined with 
PicoGreen reagent (100 µL sample + 100 µL PicoGreen) and transferred (200 
µL) into a black 96-well plate along with DNA standards. Fluorescence was 
measured at excitation 485nm / emission 528 nm using a fluorescent plate 
reader. 
2.12 Fluorescence Recovery After Photobleaching (FRAP): 
hCMs were plated at low density (100,000 cells per 35 mm MatTek dish) and 
cultured for 14 days. DiI (Life Technologies, USA) stained non-myocytes 
(hASCs) were added to culture two days before experiment. Cells were 
incubated with 0.5 uM calcein AM (Life Technologies, USA)  for 20 minutes at 
37C, rinsed with DPBS and culture media was added to the stained cells. In pairs 
of cells (one CM and one DiI-labelled non-myocyte) or in groups of cells (one DiI-
labelled non-myocyte surrounded by CMs), the non-myocytes were photbleached 
with a 488 laser and consecutive images were taken for up to 7 minutes to 
determine the recovery of fluorescence.  
 
 





Cells were fixed with 4% paraformaldehyde for 20 minutes at room temperature. 
Formaldehyde was washed three times with DPBS for 30 minutes each time. 
Samples were permeabilized with 0.2% triton X-100 for 10 minutes and then 
blocked with 10% normal donkey serum (Sigma Aldrich, USA) for 30 minutes. 
The samples were incubated overnight with goat anti-CD31 (Santa Cruz 
Technologies, USA) and rabbit anti-von Willebrand Factor (Sigma Aldrich, USA) 
primary antibodies diluted in 10% normal donkey serum at 4°C. Primary antibody 
was washed three times with DPBS. Samples were incubated with secondary 
antibodies AlexFluor 488-conjugated donkey and  AlexaFluor 647-conjugated 
donkey anti-rabbit (Jackson ImmunoResearch, USA). Samples were washed 
three times with DPBS. Samples were incubated with DAPI (Sigma Aldrich) 
diluted in DPBS. Petri dishes were imaged under Zeiss Axio Observer inverted 
fluorescence microscope and the Zeiss LSM 510 confocal.  
2.14 Image Analysis: 
Vascular assembly images were taken at 2.5x on a Zeiss Axio Observer inverted 
fluorescence microscope, which the conversion of the images is 4.0145 m/pixel. 
Thresholded images were subsequently analyzed with AngioQuant software to 
determine the total vessel length, area, and interconnectivity. 
2.15 Statistical Analysis: 
Quantitative data is reported as the mean  the standard deviation. One-way 
ANOVA with Dunnett’s post-hoc test or Tukey’s post-hoc test was performed to 
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determine statistical difference between testing groups.  Differences were 
considered statistically significant at *p < 0.05; **p < 0.01; ***p < 0.001.  
3. RESULTS: 
3.1 Effect of hASCs on human stem cell derived cardiomyocyte 
electrophysiology: 
 Both human embryonic stem cell derived cardiomyocytes (hESC-CMs) 
and human induced pluripotent derived cardiomyocytes (hiPSC-CMs) were 
cultured for a week prior to the addition of hASCs. After culturing the 
cardiomyocytes for 7 days to establish cell-cell contact, hASCs were seeded at 
various ratios from 300:30:0, 300:60:0, 300:150:0, and 300:300:0 
(hCM:hASC:hEC). In the hESC-CMs co-cultured with hASCs group, the 
conduction velocity increased with the addition of hASCs in co-culture slightly in 
the presence of hASCs as compared to the control. At 1 Hz pacing rate, 
conduction velocity ranged from 14  6 cm/s (n=11) (control) to a peak of 18  2 
cm/s (n=7) (300:150:0) (Supplemental Figure 2B). It is noteworthy that within 
the 0.5 Hz and 0.7 Hz there was a similar trend in conduction velocity but there 
was statistical significance between the 300:150:0 group compared to 300:0:0 
(Supplemental Figure 3A).  
 Action potential duration at 80% repolarization (APD80) ranged from the 
control of 321  66 ms (300:0:0) to highest at 377  80 ms (300:300:0) 
(Supplemental Figure 2C). There were no statistical differences amongst APD80 
with the control and the varied hASC ratios. We notice similar trends in the APD30 
which ranged from 167  20 ms (300:30:0) to 185  30 ms (300:300:0) 
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(Supplemental Figure 2D). In addition, there is statistical significance in the 
normalized triangulation comparing the control (300:0:0) of 0.43  0.06 to the 
ratio 300:300:0 of 0.5  0.03 ( Supplemental Figure 2E). These rates were 
acquired at 1 Hz pacing. We observe similar findings at other pacing rates of 0.5 
Hz and 0.7 Hz (Supplementary Figure 3B-D). The maximum captured rate 
tended to be increased with the presence of hASCs which maxed at 2.4  0.2 Hz 
(300:300:0) as compared to 1.8  0.5 Hz (300:0:0). 
 Similarly to hESC-CM, hiPSC-CMs displayed slightly increased 
electrophysiological properties as compared to the control group (300:0:0). At 1 
Hz pacing, the conduction velocity peaked at 16  2 cm/s (n=12) (300:300:0) and 
lowest at 14  2 cm/s (n=11) (300:60:0) (Figure 2B).  Similar trends exist at other 
pacing rates and we also find that at increased concentrations of hASCs 
increased the conduction velocity when paired with hiPSC derived CMs 
(Supplementary Figure 2A). APD80 increased as to a maximum of 321  52 ms 
(n=12) at the ratio of 300:300:0 and was lowest at 261 50 ms (n=8) (300:30:0) 
(Figure 2C). APD30 ranged from 104  35 ms (n=11) (300:60:0) and 171  52 ms 
(n=12) (300:300:0) (Figure 2D). There were no statistical differences in 
conduction velocity, APD 80 and 30, or normalized triangulation. Similar to 
hESC-CMs, hiPSC-CMs coupled with hASCs displayed increased maximum 
captured rates. While maximum captured rate was higher than the control group 
in all ratios, the 2 ratios that were statistically significant compared to the control 
were 300:60:0 and 300:150:0 which rates were 3.4  0.4 Hz (n=12) and 3.0  0.9 
Hz (n=7) respectively (Figure 2F).  The DNA assay data demonstrated that the 
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paracrine effects of hASC did not increase cardiomyocyte proliferation 
(Supplemental Figure 6), which lead us to further believe that the increases in 
conduction can be attributed to another mechanism. In Supplemental Figure 7,  
the fluorescent recovery after photobleaching (FRAP) suggested that slight 
recovery was occurring in the hASCs that were connected to cardiomyocytes. 
This leads to the potential that hASCs could develop gap junctions with 
cardiomyocytes and aid in signal transduction.   
3.2 Effect of hBM-MSC, hNDF, and hNCF-V on human stem cell derived 
cardiomyocyte electrophysiology: 
 In an effort to understand the role of mural cell types other than hASCs, 
we compared cardiomyocyte electrophysiology amongst hBM-MSCs, hNDF, 
hNCF-V, and pluripotent stem cells (PSCs) in co-culture with either hESC-CMs 
or hiPSC-CMs. We initially characterized the surface markers of hASCs, hBM-
MSCs, and hNCF-V and found that the cells were positive for mesenchymal 
markers CD73 (99.8%-hASCs, 99.9%-hBM-MSCs, and 91.9%-nHCF-V) and 
CD105 (99.3%-hASCs, 95.8%-hBM-MSCs, and 99.9%-nHCF-V), slight to no 
expression of endothelial markers CD31(0.16%-hASCs, 0.45%-hBM-MSCs, and 
1.83%-nHCF-V), CD34 (3.21%-hASCs, 0.006%-hBM-MSCs, and 8.28%-nHCF-
V), and VEGFR2 (0.06%-hASCs, 0.07%-hBM-MSCs, and 1.54%-nHCF-V). All 
supporting cell types were negative for hematopoietic marker CD45 and only 
hBM-MSCs were positive for HLA-DR at 20.2%. (Supplementary Figure 4) 
After sequential addition of supporting cells types, electrophysiologically 
we have discovered that supporting when coupled with hESC-CM or hiPSC-CMs 
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conduction velocity is lower than the control samples at 1 Hz pacing rate. 
Although not statistically significant, it appeared that supporting cell types hBM-
MSC, hNDF, and hNCF-V coupled with hESC-CMs displayed conduction 
velocities that were slower than the control group. The conduction velocities were 
as follows, hBM-MSC (7  0.8 cm/s) (n=16), hNDF ( 8  1.2 cm/s) (n=11), hNCF-
V (8  1.3 cm/s) (n=6) which were compared to the control (9  2 cm/s) (n=12) 
(Supplemental Figure 5B) . Pluripotent stem cells hPSC (10  1 cm/s) (n=6) 
appeared to increase conduction velocity as compared to the control. We notice 
similar relationships with other pacing rates. hiPSC-CM samples displayed trends 
that mirrored hESC-CMs. These conduction velocities were hBM-MSC (7  0.6 
cm/s) (n=9), hNDF (8  1.7 cm/s) (n=11), hNCF-V (6  0.8 cm/s) (n=8), hPSC (9 
 0.8 cm/s) (n=4) compared to the control of 8 cm/s (Supplemental Figure 5F).  
 Action potential duration both 80 and 30 were not statistically significant 
when comparing hBM-MSC, hNDF, hNCF-V, or hPSC in co-culture with hESC-
CMs. The APD80 values ranged from a minimum of 321  66 ms (hBM-MSC) 
(n=16) to a maximum of 362  72 ms (hNDF) (n=11) at 1 Hz pacing 
(Supplemental Figure 5B). We noted similar trends with APD30 as APD80 which 
resulted in no statistical increases or decreases in duration as compared to the 
control samples (Supplemental Figure 5C). The normalized triangulation was 
also not statistically different amongst the various cells types in co-culture with 
CMs (Supplemental Figure 5D). Maximum captured rate peaked at 2.4  0.7 Hz 
(hPSC) (n=6) but there was no statistical difference amongst other cell types 
compared to the hESC-CM control (Supplemental Figure 5E). Supporting cells 
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co-cultured with hiPSC-CMs resulted in action potential duration 80 that were 
282  25 ms (hBM-MSC) (n=9), 344  36 ms (hNDF) (n=11), 326  28 ms 
(hNCF-V) (n=8), and 351  26 ms (hPSC) (n=4) compared to control of 310 ms 
at 1 Hz pacing rate (Figure 3C). APD30 resulted in 142  13 ms (hBM-MSC) 
(n=9), 176  23 ms (hNDF) (n=11), 172  11 ms (hNCF-V) (n=8), and 214  14 
ms (hPSC) (n=4) compared to control of 139 ms at 1 Hz pacing rate. There were 
no statistical differences in normalized triangulation (Figure 3D). The maximum 
captured rate was greatest with hNDF at 2.4  0.7 Hz (Figure 3E). 
3.3 Effect of hASC co-cultured with hECFC, HUVEC, or hiPSC-EC on 
vascular assembly: 
 In an effort to determine vascular assembly of mature endothelial cells and 
progenitor endothelial cells, we held hASCs constant at 230,000 cells/cm2, 
92,000 cells/cm2, or 46,000 cells/cm2 and tittered endothelial cells to determine 
the vascular assembly coupled with cellular concentration. These co-cultures 
would be used to generate a range of concentrations for vascular development 
with hiPSC-EC as the primary endothelial cell.  We show that hECFCs and 
HUVECs formed similar vessel lengths and interconnectivity at various ratios. At 
a 1:1 ratio (~i.e 0:60:60) we observe that there are clusters of endothelial cells 
that are not contributing to vessel network formation.  Vessel lengths were as 
follows for the ratios of 0:60:6, 0:60:12, 0:60:30, 0:60:60 were 162  79 mm, 168 
 13 mm, 225  28 mm, and 292  63 mm (n=4) (hECFC) (Supplemental Figure 
9) and 221  16 mm, 240  70 mm, 316  22 mm , and 321  22 mm (n=3-4) 
respectively (Supplemental Figure 9). Interconnectivity of vasculature ranged 
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from 270  160 junctions to 2,074  726 junctions in hASC:hECFC co-cultures 
and displayed similar trends in hASC:HUVEC co-cultures (Supplemental Figure 
9). Learning from the information of hASC:hECFC/HUVEC co-cultures, hiPSC-
EC co-cultures studies were carried out in the range of 0:150:15 to 0:150:150 
(hCM:hASC:hEC) and characterized for vessel length and interconnectivity 
(Figure 4A).  With increasing endothelial cells, there was increase in vessel 
network and number of junctions formed. The peak vessel length at 0:150:150 
was 280  20 mm (n=3) and 1525  330 junction s (n=3) (Figure 4B,C). 
 
3.4 Effect of hBM-MSC, hNDF, or hNCF-V co-cultured with hiPSC-EC on 
vascular assembly: 
 In addition to electrophysiological effects of hBM-MSCs, hNDFs, or 
hNCFs-V when coupled with cardiomyocytes, we assessed their effects of vessel 
network assembly when coupled with hiPSC-ECs. We found that hBM-MSCs and 
hNCFs-V displayed cord like structures that were seen with hASC:hiPSC-ECs 
co-cultures (Figure 5). With respect to hNDF, we found that there were only 
small areas of vessel network assembly, but majority of the field of view 
consisted of endothelial cells clustered together. These cultures were seeded at 
the ratio of 0:150:150 and comparing vessel lengths with hASCs cultured at this 
same ratio, we find that they generate greater interconnectivity and comparable 
vessel lengths. Interconnectivity for these fibroblast-like cells were hBM-MSC 
(1356  546) (n=5), hNCF-V (628  266) (n=4), and hASC (1525  330) (n=3) 
(Figure 5). Vessel lengths for these cell types were hBM-MSC (296  43 mm) 
(n=5), hNCF-V (240  43 mm) (n=4), and hASC (280  20 mm) (n=3) (Figure 5). 
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4. DISCUSSION: 
 To develop a system that resembles the native make-up of the native 
myocardium requires the use of several different cell types. Previous efforts have 
used rodent or human cardiomycotyes (hESC or hiPSC), typically dermal 
fibroblasts or stromal cells, and endothelial cells.44,49,57,142  Previous studies have 
demonstrated that the presence of non-myocytes improves the 
electrophysiological maturation of CMs as well as increase the generated force of 
CMs.211–215 In addition, non-myocytes (stromal cells) can also potentially prolong 
survival of CMs when implanted in vivo.  Stromal cells are also necessary for 
vascular stabilization. Therefore, we investigated the role of hASCs as a suitable 
stromal cell source for hPSC-CM and hPSC-EC cultures. The co-culture of these 
cell types, hPSC-CMs with hASCs and hASCs with hPSC-ECs, has not been 
well studied and established. With the enhanced benefits of hASCs in previous 
cardiac and vascular studies, there is a need to establish these models.  
Similarly to neonatal rat cardiomyocytes co-cultured with fibroblasts, 
hESC/hiPSC-CMs are co-cultured with fibroblasts. hASCs have shown to 
maintain electrophysiological properties of neonatal rat cardiomyocytes  when 
co-cultured, while hNDF were deleterious. 41 These interactions have not been 
studied with hESC/hiPSC-CM in co-cultures. While both embryonic stem cell 
derived and induced pluripotent stem cell derived cardiomyocytes are not 
inherently adult-like in their initial differentiation, they provide a vast resource for 
generating large amounts of cells and hold the promise of maturing through 
biochemical factors, electro-mechanical stimulation, and multi-cellular 
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cultures.(Lundy, Zhu, Regnier, & Laflamme, 2013) We simultaneously compare 
hESC-CMs and hiPSC-CMs to show similar effects in multiple lines of pluripotent 
stem cells. 
While hESC and hiPSC-CMs are phenotypically similar, hiPSC-CM 
provide functionally similar cardiomyocytes that do not have the ethical hurdles 
and can be completely autologous.217 Co-culture of hESC-CMs with hASCs 
proved to increase conduction velocity, while maintaining the action potential 
duration at both 30% and 80% repolarization relative to the cardiomyocyte 
control. Increased conduction velocity and increased maximum captured rate can 
potentially be attributed to improved calcium handling amongst the myocytes.212  
In addition, we have previously demonstrated that hASCs express connexin-43 
and the increased presence of gap junctions could explain the increased 
electrophysiological outputs57,218.  Similar effects were noted with the hiPSC-
CMs.  
The myocardium has a large fibroblast population, there was a need to 
compare phenotypically similar cells of hASCs to ensure that hASCs are the 
most beneficial cell source for supporting cardiomyocytes and vascular 
stabilization. Therefore, other fibroblast-like cells (hBM-MSCs, hNDFs, and 
hNCF-V) were examined to determine their electrophysiological effects on co-
cultures with cardiomyocytes. This would determine if hASCs are truly superior to 
other stromal cells.   We found that conduction velocity of cardiomycoytes was 
slightly decreased in the presence of hBM-MSCs and hNCF-V. hNDFs seem to 
slightly increase the conduction velocity. The action potential duration appears to 
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be relatively similar amongst supporting cell types. Previous studies have shown 
that the incorporation of fibroblasts can maintain electrophysiological properties 
of neonatal rat cardiomyocytes and mouse embryonic stem cell derived 
myocytes.219,220 In addition, the literature suggests that hBM-MSCs and atrial 
cardiac fibroblasts that are in co-culture with hiPSC-CMs appear to increase  
action potential duration. 221 Comparing these effects of hASCs to other 
supporting cell types, hASCs appear to maintain or slightly enhance the 
electrophysiological properties of cardiomyocytes. Pericytes were not included 
because previous researchers have shown that they are phenotypically similar to 
hBM-MSCs and have similar effects on cardiomyocytes and vasculature 222.  
 After investigating the role of hASCs paired with human cardiomyocytes, 
we investigated the role of hASC:hEC co-cultures in vessel assembly. These 
studies were initiated by determining a suitable cellular concentration range to 
culture hASC: hiPSC-EC co-cultures and establish cord like structures. To 
establish the cellular concentration, both hECFCs and HUVECs were utilized as 
the initial endothelial cell source. Previous researchers have explained that 
hiPSC-ECs generally express both progenitor and mature endothelial cell 
markers making both hECFC and HUVECs applicable to determining appropriate 
cell range.15 By utilizing both a progenitor cell (hECFC) and a mature endothelial 
cell (HUVECs), our hopes were  to extrapolate a suitable range for culturing 
hiPSC-ECs.20 It is understood that vascular structures need a mural cell to 
maintain and support developed structures, hence the use hASCs30. 
Similar trends in vascular development occurred between hECFCs and 
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HUVECs. Noticeably in both groups at the 1:1 ratio of the 230,000 cells/cm2 and 
92,000 cells/cm2, vascular development contains both cord-like structures 
coupled with clustering of endothelial cells. In previous reports, cellular 
concentrations are imperative to the development of vascular structures. By 
observing similar trends amongst groups, proceeding forward hASCs were held 
constant at 92,000 cells/cm2 and hiPSC-ECs were tittered. In these cultures, it 
appeared that the presence of more endothelial cells resulted in increased vessel 
length and increased junctions. The development of robust vessel structures was 
present in these cultures. Similar to hASCs, hBM-MSCs have previously have 
been characterized for its perivascular potential and shown to develop robust 
vasculature when co-cultured with endothelial cells. 25,26,137 In addition, we find 
that cardiac fibroblast support vessel network formation, although not as robust 
as hASCs and hBM-MSCs.  
 Ultimately the supportive nature of hASCs in co-culture with pluripotent 
stem cell derived cardiomyocytes and their perivascular potential when co-
cultured with pluripotent stem cell endothelial cells offers the promise of 
developing an autologous vascularized cardiac tissue.  
5. CONCLUSIONS:  
Due to the limited endogenous regenerative potential of the native 
myocardium, it is important to find alternative sources to ameliorate damage 
caused by cardiac events like myocardial infarction. Human induced pluripotent 
stem cells are attractive cell sources that can be used to generate patient specific 
cells that can be differentiated into the lineage of interest. Specifically in this 
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study, we examine the effects of recapitulating the native cellular make of the 
myocardium by exploring hiPSC-CMs coupled with human adipose derived 
stem/stromal cells as well hiPSC-ECs coupled with hASCs.  From this study, we 
were able to examine the effects of hASCs on cardiomyocyte electrophysiology 
as well vasculature development. We saw that hASCs were not deleterious to 
electrophysiological properties of cardiomyocytes and in some cases have the 
potential to enhance them. When comparing similar fibroblast-like cells, we find 
that there may be detraction of electrophysiology (i.e conduction velocity). 
Vascular assembly proved to be robust in the presence of hASCs. While hBM-
MSCs have the potential to generate robust vessels like hASCs, these effects 
are diminished with the loss of electrophysiological properties when coupled with 
cardiomyocytes. It appears that hASCs prove to be a supportive cell that can be 
used to regenerate the damaged myocardium in a tri-culture system that can be 
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Figure 1: Schematic of cell sources for engineering a vascularized cardiac 
tissue. 
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Figure 2: Effects of hCM:hASC ratios on electrophysiological function. (A) 
Activation maps of cardiomyocyte co-cultures with hASCs (B) Conduction 
velocity of hiPSC-CM:hASC at 1 Hz pacing (n=7-12), (C) APD80 and (D) APD30 
values for various hiPSC-CM:hASC ratios at a pacing rate of 1 Hz (n=7-12), (E) 
Normalized triangulation of hiPSC-CM:hASC ratios (n=7-12), (F) Maximum 
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Figure 3: Effects of hiPSC-CM and hBM-MSC, hNDF, hNCF-V, or hPSC co-
cultures on electrophysiological function. (A)Conduction Velocity of hiPSC-
CM co-cultures at 1.0 Hz pacing (n=6-12), (B) APD80 and (C) APD30 values for 
various hIPSC-CM co-cultures at 1 Hz pacing/ratios at a pacing rate (n=6-12), 
(D) Normalized triangulation of hIPSC-CM co-cultures at 1 Hz pacing (n=6-12) 
(E) Maximum captured rate (n=6-12)  
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Figure 4: Vascular Assembly with hiPSC-ECs co-cultured with hASCs. (A) 
Immunostaining of PECAM-1/CD31 of various ratios of hASC:hiPSC-EC co-
cultures , (B) Total vessel length of ratios of hASC:hiPSC-EC co-cultures (n=3-4), 
(C) Interconnectivity of ratios of hASC:hiPSC-EC co-cultures (n=3-4). 
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Figure 5: Vascular Assembly with hiPSC-ECs co-cultured with hBM-MSCs, 
hNDFs, or hNCF-V. (A) Immunostaining of CD31 of hBM-MSC:hIPSC-EC co-
cultures,  hNDF:hIPSC-EC co-cultures, and hNCF-V:hIPSC-EC co-cultures, (B) 
Total vessel length of ratios of hBM-MSC/hNDF/hNCF-V:hIPSC-EC co-cultures 
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Supplementary Figure 1: hiPSC-CM co-cultured with hASCs at various 
pacing rates. (A) Conduction Velocity, (B) Action potential duration 80% (C) 
Action potential duration 30%, (D) Normalized triangulation  
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Supplementary Figure 2: Effects of hCM:hASC ratios on 
electrophysiological function. (A) Activation maps of cardiomyocyte co-
cultures with hASCs Conduction Velocity of hESC-CM:hASC co-cultures at 1 Hz 
pacing (n=5-11), (B) APD80 and (C) APD30 values for various hESC-CM:hASC 
ratios at a pacing rate of 1 Hz (n=5-11), (D) Normalized triangulation of hESC-
CM:hASC ratios (n=5-11), 
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Supplementary Figure 3: hESC-CM co-cultured with hASCs at various 
pacing rates. (A) Conduction Velocity, (B) Action potential duration 80% (C) 
Action potential duration 30%, (D) Normalized triangulation  
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Supplementary Figure 4: Phenotypic profile of hBM-MSC, hNDFs, hNCF-V, 
and hASCs. 
Mesenchymal markers are CD73 and CD105, vascular markers are CD31, 
CD34, and VEGFR2, and hematopoietic markers CD45 and HLA-DR 
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Supplementary Figure 5: Effects of hESC-CM and hBM-MSC, hNDF, hNCF-
V, or hPSC co-cultures on electrophysiological function. (A) Actiavtion Maps 
(B) Conduction Velocity of hESC-CM co-cultures at 1.0 Hz pacing (n=6-12), (C) 
APD80 and (D) APD30 values for various hESC-CM co-cultures at 1 Hz pacing 
(n=6-12), (E) Normalized triangulation of hESC-CM co-cultures at 1 Hz pacing 
(n=6-12) (F) Maximum captured rate (n=6-12) 
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Supplementary Figure 6: Effects of hESC-CM and hBM-MSC, hNDF, hNCF-
V, or hPSC co-cultures on electrophysiological function at various pacing 
rates. (A) Conduction Velocity of hESC-CM co-cultures (n=6-12), (B) APD80 and 
(C) APD30 values for various hESC-CM co-cultures (n=6-12), (E) Normalized 
triangulation of hESC-CM co-cultures  
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Supplementary Figure 7: DNA quantification of hESC-CMs and hiPSC-CMs 
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Supplementary Figure 8: Fluorescent Recovery After Photobleaching of 
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Supplementary Figure 9: Immunofluorescent staining of vWF in 
















Conclusions and Future Perspectives 
 
 The data presented in this thesis demonstrates that contractile vascularized 
cardiac grafts can be developed utilizing adipose derived stem/stromal cells as the 
vascular mural cell source. The hASCs are able to promote vascular stability and 
networks with the ability to anastomose with host vasculature when implanted in 
vivo while also maintaining the electrophysiological properties of cardiomyocytes.  
5.1 Specific Aim 1 Conclusions: 
 Chapter 2 describes the ability of hASCs to maintain the electrophysioogical 
properties of NRVCMs better than hDFs. After discovering the maximum number 
of hASCs that could be cultured with cardiomyocytes without impeding 
electrophysiological properties, this information was used to establish ratios to 
maximize vessel networks interconnectivity and vessel lengths. We directly 
compared vessel network formation of hASCs to hDFs. We found that hASC co-
cultures resulted in the development of more robust vascular networks compared 
to those formed in hDF co-cultures. By combining the ratios from the NRVCM-
hASC co-cultures with the hASC-HUVEC co-cultures, we developed a 
vascularized tri-culture system consisting of NRCVM-hASC-HUVECs. We found 
that ultimately at the ratio of 500:50:25 we developed robust vessel networks that 
were electrophysiologically similar to the NRVCM only control. This data could be 
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used to develop a vascularized cardiac graft.  This work resulted in the 
development of a first author publication.  
5.2 Specific Aim 2 Conclusions: 
Chapter 3 described the development of vascularized cardiac grafts. The 
initial study characterized the development of fibrin microfiber sheets that served 
as a mechanically tunable scaffold to culture cardiomyocytes. We then assessed 
the viability and morphology of cardiomyocytes on the fibrin microfiber sheets of 
two different stiffnesses. NRVCMs were able to be cultured for up to two months 
on fibrin microfibers and we noticed higher conduction velocities over time on the 
softer matrix compared to the stiffer matrix. We also found that fibrin microfibers 
supported robust vascular assembly. After assessing the cardiomyocytes and 
vascular development independently, we combined all three cell types to develop 
vascularized cardiac grafts. These vascularized cardiac grafts were able to be 
implanted into a rodent infarct model and cardiomyocyte survival was tracked for 
a month. In addition, we were able to assess function of the myocardium through 
echocardiography and optically map the whole heart pacing from the site of the 
patch. This work will result in the submittal of a first-authored publication.  
5.3 Specific Aim 3 Conclusions: 
 
The studies reported in Chapter 4 assessed the ability of human stem cell 
derived cardiomyocytes and endothelial cells, cell-cell interactions with hASCs. 
Initially, pluripotent stem cells derived cardiomyocytes were co-cultured with 
hASCs and electrophysiology was assessed. Using hESC/hiPSC-CMs, we found 
that the presence of hASCs did not impede the electrophysiological parameters of 
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cardiomyocytes but enhanced the conduction velocity of hiPSC-CMs. We 
investigated whether hASCs were superior to commonly used fibroblast-like cells, 
hBM-MSCs, hNDFs, hNCF-Vs, and pluripotent stem cells. We discovered that 
other supporting cell types typically reduced the electrophysiologic potential of both 
hESC-CMs and hiPSC-CMs. We examined the vasculature development of 
HUVECs and hECFCs with similar ratios used in the hCM-hASC co-cultures. This 
data was used to assess the vascular development of hASC-hiPSC-EC co-
cultures. hASCs-hEC co-cultures resulted in dense vessel networks.  Fibroblast-
like cells, hBM-MSCs, hNDFs, hNCF-Vs, and pluripotent stem cells were co-
cultured to determine vascular assembly with hiPSC-ECs.  
5.4 Future Perspectives: 
 
 The studies described in this thesis assessed our ability to form 
vascularized cardiac patches using hASCs as the vascular mural cell. After 
evaluating the cellular interactions independently and in the presence of a 
biomaterial, we assessed the utility of the approach for a completely human cell 
system. The next step to these experiments are implementing this tri-culture 
system using hiPSC-CMs and hiPSC-ECs coupled with hASCs to move toward a 
patient specific therapeutic treatment.  
Initial studies would include the culture of hiPSC-CMs on fibrin microfibers 
to assess the viability, morphology, electrophysiology, and contractility. While 
hiPSC-CMs are a promising cell source, they are fundamentally immature and 
require maturation to integrate with the human myocardium.  By incorporating 
mechanical and electrical stimulation into the system, CMs can undergo 
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maturation. Also, vascular development with hASC-hiPSC-EC co-cultures should 
be assessed on fibrin microfibers. This information can be combined to develop a 
human vascularized cardiac patch that can be assessed an in vivo setting in both 
immunosuppressed and immunocompetent models.  
To investigate developing a thicker graft, we propose stacking multiple fibrin 
microfibers utilizing fibrin hydrogels as the adhesive source. We also propose 
incorporating hASCs and endothelial cells into the hydrogels to promote 
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Appendix 
 
1. Appendix Materials and Methods: 
A2.1 hASC & HUVEC Culture on Fibrin Microfiber Sheets: 
hASCs and HUVECs were mixed together in ratios of 0:100:100, 0:100:50, 
0:100:20, 0:100:10, 0 and seeded in 80L onto fibrin microfiber sheets (1cm2) were 
seeded onto agarose coated culture plates to prevent cells f rom attached to tissue 
culture plastic. The constructs were cultured in vitro for 7 days and fed every other 
day with EGM-2 (Lonza).  
A2.2 Viability Assessment  
To determine cell viability on fibrin fibers, the microfiber sheets were removed 
from frames and placed into 500µL Deoxyribonucleic Acid (DNA) lysing solution 
(10mM Tris, 1mM EDTA, 0.1% Triton X-100, and 0.1 mg/mL proteinase K) and 
frozen at -20°C. Samples were subsequently heated at 50 °C overnight to digest 
proteins and inactivate nucleases. PicoGreen dsDNA quantification assay was 
carried out according to the manufacturer’s instructions. Briefly, the samples were 
combined with PicoGreen reagent (100 µL sample + 100 µL PicoGreen) and 
transferred (200 µL) into a black 96-well plate along with DNA standards. 
Fluorescence was measured at excitation 485nm/ emission 528 nm using a 
fluorescent plate reader. Sampling days included day 0, day 1, day 7, and day 14. 
Live/Dead viability assay assesses cell viability using calcein AM. Calcein AM is a 
cytoplasmic dye cleaved by cytoplasmic esterases ultimately stains the cytoplasm 
green was used at a concentration of 5M. Ethidium Bromide is a nuclear stain 
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that only penetrates dying or dead cells and emits red was used at a concentration 
of 2M. Both dyes were mixed in NRVCM media and incubated at 37C for 20 
minutes and washed with DPBS. Cells were imaged on the LSM-510 confocal.  
A2.3 BLI Imaging Lentiviral Production and NRVM Transduction 
Human embryonic kidney 293T cells were transfected with a CMV-mCherry-
Luciferase plasmid (kindly provided by Dr. Assaf Gilad) using the Pantropic 
ViraSafe Lentiviral Packaging System (Cell Biolabs, Inc.). Cells were transfected 
for 3 hours, and then cultured in stromal medium (High Glucose DMEM with 10% 
FBS and 1% penicillin-streptomycin) for 24 hours to allow for lentiviral production 
to occur. Viral supernatant was collected and filtered through a 0.45 μm membrane 
daily up to 72 hours after transfection. Lentivirus was concentrated by centrifuging 
the supernatant in a SW 28 Ti rotor (Beckman Coulter, Inc.) at 24,000 g for 1.5 
hours. Concentrated virus was resuspended in stromal medium and frozen at -
80°C until transduction. 
NRVCs on fibrin constructs were transduced with CMV-mCherry-Luciferase 
lentivirus in NRVCM medium containing 5 μg/mL polybrene (MOI 6). Transduction 
medium was removed after 48 hours, and constructs were cultured according to 
standard protocol until in vivo transplantation. 
Cell retention in implanted fibrin constructs was monitored using bioluminescence 
imaging. Rats were anesthetized with isoflurane and injected intraperitoneally with 
150 mg/kg of D-Luciferin Potassium Salt (Gold Biotechnology, Inc.) 10 minutes 
prior to imaging. Bioluminescent images of the implanted constructs were acquired 
with an IVIS Spectrum (PerkinElmer Inc.) using 1 min exposure and medium 
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binning. Images were acquired every 5 minutes until peak luminescence was 
observed. Total proton flux of the implant region was quantified using Living Image 
Software (Perkin Elmer Inc.).  
A2.4 Whole Heart Optical Mapping & Analysis:  
Adult rats (Nude) were anesthetized with sodium pentobarbital and sacrificed via 
midline thoracotomy. The hearts were excised, Langendorff-perfused, and stained 
with 10 μM di-4-ANEPPS for 10 minutes. Blebbistatin (10 μM) was used to 
eliminate motion artifacts during optical mapping (MiCAM Ultima Camera, 
SciMedia) of the left ventricular epicardial surface. The patch was positioned in 
half of the field of view to allow imaging of conduction in native and implanted cells. 
Custom platinum plate electrodes outside the left ventricular free wall were used 
for field stimulation, and a stainless steel bipolar electrode was used for point 
stimulation 
AA1.1 hASC-HUVEC Co-Culture Concentration Study:  
ECs (passage 5-6) and ASCs (passage 4) were suspended in 10mg/mL 
fibrinogen solution (dissolved in DPBS). The cell solution was then mixed with 
2U/mL thrombin diluted in DPBS, containing Ca2+/Mg2+, to begin polymerization. 
Fibrin gels (40μL) contained HUVEC and ASC concentrations of 1.25, 2.5, or 5 
million/mL. The fibrin gels were pipetted into 6mm diameter wells and incubated 
at 37°C for 30 minutes to complete polymerization. The constructs were cultured 
in vitro for 7 days and fed every other day with EGM-2 (Lonza).  
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AA1.2 hASC/hDF-HUVEC Co-Culture Ratio Study:  
ECs (passage 5-6) and hASCs (passage 4) were suspended in 10mg/mL 
fibrinogen solution (dissolved in DPBS). The cell solution was then mixed with 
2U/mL thrombin to begin polymerization. Fibrin gels (40μL) contained HUVEC 
concentration constant at 1.25 or 2.5 million/mL, while hASCs were varied at 
ratios of 1:0,1:1,2:1,5:1,10:1, and 0:1 for each concentration of HUVECs. The 
fibrin gels were pipetted into 6mm diameter wells and incubated at 37°C for 30 
minutes to complete polymerization. The constructs were cultured in vitro for 7 
days and fed every other day with EGM-2 (Lonza). 
AA1.3 hDF/hASC-NRVCM Co-Culture System:  
Coverslips were coated with Fibronectin (Sigma Aldrich) and NRVCMs were 
plated at a concentration of 1 million/mL in NRVCM Medium containing 10% 
FBS. Subsequently on the next day, hDFs/hASCs were plated in ratios of 
1:0,1:5,1:10, and 0:1 on top of the NRVCMs. Medium was switched to 2% FBS 
containing medium on the followed day and refreshed other day until day 5 of co-
culture. Cells underwent optical mapping and were fixed for subsequent 
immunocytochemistry.  
AA1.4 NRVCM Gel Formation: 
NRVCMs were suspended in 5mg/mL fibrinogen (Sigma Aldrich) diluted in a (1:1 
ratio of DPBS-NRVCM Media) at concentrations of  5, 10, 20, 40, and 60 million 
cells/mL. Cells were then mixed with 2U/mL thrombin for polymerization at 37°C 
for 30 minutes. Cells were fed daily with NRVCM culture medium containing 10% 
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HI-FBS (Sigma Aldrich/Atlanta Biologicals) and 33μg/mL of Aprotinin(USB 
Affymetrix). 
AA1.5 Whole Mount Immunostaining: 
Samples were fixed with 4% paraformaldehyde for 3 hours at 4°C and then 
washed three times with DPBS for 30 minutes. After fixation, gels were removed 
from wells and placed into microcentrifuge tubes for the remaining steps. Gels 
were then permeabilized and blocked for 4 hours with 5% normal goat serum 
(Sigma Aldrich) in DPBS with 0.1% Tween 20 (0.1% PTween). Gels were stained 
with primary antibodies which included mouse anti-CD31 (Sigma Aldrich), mouse 
anti-Sarcomeric α-Actinin(Sigma Aldrich), rabbit anti-Connexin 43 (Sigma 
Aldrich) at 4°C diluted in 5% normal goat serum and 0.1% PTween overnight. 
Samples were then washed three times with 0.1% PTween for one hour per 
wash. Samples were then incubated overnight with with DyLight 488-conjugated 
goat anti-mouse and DyLight 649-conjugated goat anti-rabbit (Jackson 
ImmunoResearch) secondary antibody in 5% normal goat serum with 0.1% 
PTween. Samples were then washed three times with 0.1% PTween for one hour 
per wash. Samples were then blocked for four hours with 5% normal mouse 
serum. After blocking, samples were incubated with Cy3-conjugated mouse anti-
αSMA (Sigma Aldrich). The samples were washed with 0.1% PTween for one 
hour per wash. Gels were mounted in 70% glycerol in chamber slides and 
imaged using a Zeiss LSM 510 confocal microscope with a 5x and 20x objective. 
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2. Appendix Figures: 
 
 
Appendix Figure 1: Heterogeneous Low Passage hASC vessel 
development. Immunofluorescent staining of CD31/PECAM-1 positive vascular 
structures (green) and cell nuclei (DAPI; blue) on 2.0% fibrin microfibers.  
Increasing the concentration of P2 hASCs resulted in the development of dense 
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Appendix Figure 2: Cardiomyocyte development in fibrin hydrogels. 
Immunofluorescent staining of cardiomyoyctes encapsulated in fibrin hydrogels 
Increasing concentration of cardiomyocytes in fibrin hydrogels results in reduced 
elongation of cardiomyocytes. Immunostaining of cardiomyocytes (green), 
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Appendix Figure 3: Vessel development in fibrin hydrogels with hASC-
HUVEC co-cultures. A) Immunofluorescent staining of CD31 positive vascular 
structures (green) and pericyte-like cells stained with SMA (red). Vessel 
assembly of co-cultured hASCs and endothelial cells encapsulated in fibrin 
hydrogels at a 1:1 ratio. Vessel assembly increases up until a HUVEC 
concentration of 2,500 HUVECs/L and reduces at 5,000 HUVECs/L. B, C) 
Quantification of vessel structure based on length (n=3) (B) and interconnectivity 
(n=3)  (C). Scale Bar is 200 µm p < 0.05; **p < 0.01; ***p < 0.001 
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Appendix Figure 4: Effect of hASC:HUVEC ratios on vessel formation: 
Immunofluorescent staining of CD31 positive vascular structures (green) and 
pericyte-like cells stained with SMA (red) with varying ratios of hASCs and 
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Appendix Figure 5: Effect of hDF:HUVEC compared to hASC:HUVEC ratios 
on vessel formation. Immunofluorescent staining of CD31 positive vascular 
structures (green) and pericyte-like cells stained with SMA (red). A) Vessel 
formation of HUVECs when co-cultured with either hDFs or hASCs at the ratio of 
1-5 and 1-10 (Stromal Cell-HUVEC).  Increased vessel length and junctions were 
obtained with the presence of hASCs compared to hDFs. B, C) Quantification of 
vessel structure based on length (n=3) (B) and interconnectivity (n=3)  (C). Scale 
Bar is 200 µm. 
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Appendix Figure 6: Simultaneous Tri-Culture (NRVCM:hASC:HUVEC) 
Encapsulation in Fibrin Hydrogels. Immunofluorescent staining of 
cardiomyocytes (green) and vasculature development  CD31 positive vascular 
structures (green) and pericyte-like cells stained with SMA (red) with increasing 
concentration of cardiomyocytes with hASC:HUVECs being held constant. Scale 
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